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Abstract
Bone development and repair involve complex processes that include interaction between
cells and their surrounding matrix. In the body, bone sialoprotein (BSP) expression is upregulated at the onset of mineralization. BSP is a multifunctional acidic phosphoprotein with
collagen-binding, hydroxyapatite nucleating, and integrin recognition (RGD sequence, which
is important for cell-attachment and signaling) regions. Mice lacking BSP expression (Bsp-/), exhibit a bone phenotype with reductions in bone mineral density, bone length, osteoclast
activation, and impaired bone healing. This thesis examined the role of BSP in tooth
development and also its potential use as a therapeutic reagent for bone repair. MicroCT and
histological analysis of Bsp-/- mice revealed significant periodontal tissue breakdown marked
by defective acellular cementum formation leading to periodontal ligament detachment,
extensive alveolar bone and tooth root resorption, and tooth malocclusion. Substituting hard
to soft diet, which minimized applied stress during mastication, did not reduce extent of
periodontal tissue breakdown. However, soft diets eliminated the incidence of severe incisor
malocclusion and the Bsp-/- mice featured normal body weight, long-bone length, and serum
alkaline phosphatase activity, suggesting that tooth dysfunction and malnutrition contribute
to growth and skeletal defects previously reported.
In the bone repair studies, the effectiveness of BSP-treated nano-hydroxyapatite/poly(esterurethane) (nHA/PU) scaffolds in promoting bone regeneration was determined using a rat
calvarial defect model. Recombinant human bone morphogenetic protein (rhBMP-2), which
is a potent growth factor was used as the positive control for repair. Addition of BSP to
nHA/PU scaffolds improved cell attachment and differentiation, and the consequent
osteogenic mineralization in vitro. In vivo, at 6 weeks, microCT and histological analysis
indicated that the rhBMP-2 treated nHA/PU scaffolds promoted significant new bone repair,
in which approximately 70% of the defect, based on bone volume to total defect volume,
was filled with new bone. In contrast, both BSP-treated nHA/PU scaffolds and non-treated
scaffolds resulted in approximately 20% new bone formed. These findings suggest that BSP
plays a non-redundant role in cementum formation, likely involved in initiating
mineralization on the root surface. The effectiveness of nHA/PU scaffold as a carrier for
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rhBMP-2 and BSP was verified. However, in our system, BSP by itself was not a potent
promoter of bone regeneration in vivo.

Key words: Bone sialoprotein, cementum, periodontal ligament, bone resorption,
malocclusion, hydroxyapatite, poly(ester-urethane), bone morphogenetic protein 2, bone
repair
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CHAPTER 1

1

Literature Review

2

1.1

INTRODUCTION

Bone is a complex tissue that undergoes a remodeling process involving resorption and
formation of bone. Cell interactions with various hormones and growth factors and the
surrounding extracellular matrix are crucial for bone development and bone regeneration.
The bioactive protein of interest for this study is bone sialoprotein (BSP), whose
expression has been shown to be up-regulated at the onset of mineralization. Various
studies have indicated that BSP plays a role in promoting biomineralization during bone
development. However, the role of BSP in other mineralized tissues such as those
associated with the periodontal tissues is still not fully understood. Furthermore, it has
been suggested that BSP may promote bone repair, however there have only been limited
studies in this area.
This thesis has two main objectives: 1) to determine the role of BSP in periodontal tissue
development and 2) to determine the potential use of BSP as therapeutic agent to enhance
bone repair. The literature review that follows covers these two topics.

1.2

SKELETAL TISSUE DEVELOPMENT

Mineralized tissue formation is an essential development of the human body. All
mammalian skeletal tissues are comprised of inorganic mineral (mainly hydroxyapatite)
that are embedded in an extracellular organic matrix. There are two developmental
processes responsible for bone development and growth: endochondral and
intramembranous ossification (Cohen, 2000; Olsen et al., 2000; Provot and Schipani,
2005). The main difference between the two is that endochondral ossification has the
presence of a cartilaginous intermediate, whereas intramembranous ossification does not.
For both developmental processes, cells such as osteoblasts and osteoclasts are important
in maintaining balance in order to have normal skeletal tissue development.
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1.2.1

Skeletal cell: Osteoblasts

Osteoblasts are cells derived from osteoprogenitor cells within the bone marrow and the
periosteum (Olsen et al., 2000; Wagner and Karsenty, 2001). Osteoblastic differentiation
is regulated by the transcription factors Runx2 and Osterix (Osx) (Aubin, 2001; Chau et
al., 2009). In addition, it can also be induced by various growth factors such as bone
morphogenetic proteins (BMPs) (Long, 2012). Osteoblasts are responsible for the
production of the osteoid matrix, the non-mineralized matrix, and its subsequent
mineralization. During bone formation, osteoblasts have been shown to express a variety
of proteins and enzymes including Type I collagen, alkaline phosphatase (ALP), and noncollagenous proteins such as bone sialoprotein (BSP), osteopontin (OPN), osteonectin,
and osteocalcin. As the osteoblasts mature, they will either become osteocytes, bone
lining cells or undergo apoptosis (Crockett et al., 2011).
Osteocytes are mature osteoblasts trapped within the mineralized bone tissue. These cells
are connected with each other through microscopic canals called canaliculi, which
function as conduits for transport of nutrients and signaling molecules to maintain proper
bone homeostasis. In addition, studies also have shown that the osteocyte network acts as
a mechanosensor that is crucial for the bone-remodeling process (Bonewald, 2006; You
et al., 2008). In contrast, the bone-lining cells are inert reserve cells at the bone surface
that are thought to have a role as osteoprogenitors or involved in coupling of bone
resorption and bone formation (Everts et al., 2002).

1.2.2

Skeletal cell: Osteoclasts

Osteoclasts are cells derived from monocytes (Quinn et al., 1998) or macrophages
(Udagawa et al., 1990) and are usually found in pits on the bone surface called Howship's
lacunae. The differentiation of osteoclasts from hematopoetic lineage cells is regulated
by receptor activator of nuclear factor kappa-B ligand (RANKL) and tumor necrosis
factor (TNF) (Boyle et al., 2003). These multinucleated cells are responsible for the
degradation of both mineral and organic matrix (Blair et al., 1986) in bone during
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development, maintenance and repair. Normal healthy bone requires ongoing bone
resorption and formation. For resorption, osteoclasts bind to mineralized surfaces in bone
where they form a tight seal. Within the sealing zone, due to the activity of the
membrane bound proton pumps, the pH becomes acidic which favors dissolution of bone
mineral (Baron et al., 1985; Schlesinger et al., 1997). In addition, osteoclasts also secrete
enzymes such as tartrate resistant acid phosphatase (TRAP) and cathepsin K that are
involved in the breakdown of the extracellular matrix (Boyle et al., 2003; Crockett et al.,
2011). Various skeletal disorders such as osteopetrosis and Paget's disease are related to
the defective regulation of osteoclast activity or function (Helfrich et al., 2007).

1.2.3

Endochondral and intramembranous ossification

Intramembranous ossification occurs during the formation of flat bones such as the skull,
clavicles and the mandible. In this ossification process, no cartilaginous intermediate is
present. Ossification sites appear within the fibrous connective tissue membrane. During
this stage, mesenchymal stromal cells (MSCs) proliferate and condense to form clusters
which differentiate into osteoblasts. Within the fibrous membrane, osteoblasts secrete
type I collagen matrix and non-collagenous proteins to form the osteoid, which
subsequently is mineralized. The mineralized osteoid is laid down in a random fashion
around the blood vessels to form a bone network that is woven in appearance. At the
same time, mesenchymal cells on the external surface of the woven bone also condense
to become periosteum. The periosteum is a thin non-calcified tissue on the exterior of
bone. The periosteum consists of an exterior layer of fibrous connective tissue and an
internal osteogenic layer. The exterior layer is primarily composed of collagen fibers and
fibroblastic cells. Whereas the inner layer contains the osteoprogenitor cells, which are
critical for bone growth and repair. As the osteoprogenitor cells along the inner surface
of the periosteum differentiate into osteoblasts, they deposit osteoid matrix parallel to the
existing woven bone. These osteogenic cells are responsible for the appositional growth
of woven bone, which eventually is replaced by lamellar bone that is organized in
appearance. As a result, flat bone will have a unique sandwich structure where the outer

5

layers are composed of dense cortical bone and the midsection is filled with trabecular
bone (Cohen, 2000; Olsen et al., 2000).
Endochondral ossification occurs during the formation of long bones and other bone
types. In this process, hyaline cartilage, which is formed first, becomes the platform that
will be remodeled and replaced by bone. Initially, periosteum and blood vessels form
along the diaphysis of the hyaline cartilage. Then periosteum-derived osteoprogenitor
cells proliferate and differentiate into osteoblasts, which secrete osteoid matrix. As the
osteoid matrix mineralizes, bony collars are formed around the diaphysis of the hyaline
cartilage. Then mineralization of the cartilage matrix occurs at the diaphysis of the
hyaline cartilage. The next step involves the formation of a primary ossification site at the
center of the diaphysis. At this stage, the periosteal bud begins to invade the primary
ossification site carrying blood vessels and cells such as osteoblasts and osteoclasts.
Over time, the remaining mineralized cartilage matrix will be broken down by osteoclasts
and replaced by trabecular bone formed by the osteoblasts, which in turn will be
remodeled into mature lamellar bone. In addition, as blood vessels and cells invade the
center of the bone, the diaphysis also starts to elongate. The osteoclasts help to form the
medullar cavity by breaking down the newly formed woven bone.
In addition, the blood vessels also penetrate the hyaline cartilage at the epiphysis of the
long bones to form the secondary ossification centers. The process of secondary
ossification is similar to the primary ossification, except instead of forming lamellar
bone, trabecular bone is maintained. At the end of the process, cartilage that remains at
the ends of the bones is called articular cartilage. In addition, the diaphysis and both
epiphyses of the long bone are separated by epiphyseal plates, the sites responsible for
bone elongation (Cohen, 2000; Olsen et al., 2000; Provot and Schipani, 2005).

1.2.4

Bone repair

Normal bone repair goes through a sequence of stages including inflammation, callus
formation, and remodeling. Damage to bone will result in fairly rapid inflammatory
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response involving coagulation of blood and invasion of hematopoietic cells, which is the
start of the tissue repair process. For example during a repair of non-critical sized long
bone fracture, within days, progenitor cells from the periosteum and bone marrow around
the fracture site differentiate into chondroblasts, which generate new cartilage at the
wound site. At the same time, distal from the fracture site, other progenitor cells
differentiate into osteoblasts, which generate the organic matrix of new osteoid. The two
tissues grow separately and eventually unite to create a bridge composed of a
combination of cartilage and woven bone, which is known as the callus. Eventually, at
the remodeling stage, the callus is resorbed by osteoclasts and replaced with cortical bone
by osteoblasts. The remodeled bone will have a similar shape and strength as the original
bone (Claes et al., 2012; Einhorn and Gerstenfeld, 2015; Marsell and Einhorn, 2011).
However, in severe bone injury such as tumour excision, non-union trauma and criticalsized defect fractures, normal repair is impaired. In this condition, it may require years
for complete healing; in some cases it may never heal completely without intervention.
Therefore, various natural or synthetic biomaterials are used in conjunction with growth
factors or other bioactive proteins to enhance regeneration and improve the functional
state of the damaged tissues.
Various animal models have been used to address the clinical challenge in repairing bone
defects. For our study, the rodent calvarial defect model was chosen since this model
allows for reproducible defects that can be generated quickly. In addition, the calvarial
defect model is more economical compared to the femoral defect models, which require
additional fixation procedures to stabilize the long bone. For calvarial defect model, an 8
mm defect is generally accepted as a critical size defect (Spicer et al., 2012). Critical size
defects are the smallest size defects that will not completely heal, without intervention,
over the lifetime of the animal. Various studies have also used smaller 5 mm defects,
with 2 defects per animal, in order to allow for reduced animal usage for a given study.
However, these non-critical size defects can heal even without intervention. Nevertheless,
this is a good model to determine whether the addition of a specific osteoinductive or
osteoconductive agent can enhance the healing process.
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1.2.5

Mouse tooth development

Mouse tooth development goes through three well-defined stages - the bud, cap, and bell
stages as shown in Figure 1.1 (Caton and Tucker, 2009). Around embryonic day 11.5
(E11.5), at the tooth development site, formation of the dental lamina is observed,
marked by the start of epithelial cell proliferation and thickening of the oral epithelium.
By E12.5, invagination of the dental epithelium becomes apparent. The invagination will
continue further into the underlying neural crest-derived mesenchyme and start to form a
bud. At around E13.5, these underlying neural crest mesenchymal cells start to condense
around the formed bud. By E14.5, tooth development has reached the cap stage, where
the epithelium is further folded and the enamel knot becomes visible. The enamel knot is
a transient structure, which will disappear by the end of the cap stage through apoptosis.
The cells in the enamel knot are regulated by BMP-4 (Jernvall et al., 1998) and the
enamel knot cells have a low proliferation rate. Other studies have shown that these
enamel knot cells act like an anchor constricting the movement of cells in the developing
tooth (Jernvall et al., 1994; Vaahtokari et al., 1996). During the cap stage, the epithelial
cells become the enamel organ and the condensed mesenchyme forms the dental papilla.
As for the surrounding tissue, it will become the dental follicle.
By E16.5, these tissues developed further and form the bell stage. During this stage, cells
begin to differentiate into their respective lineages. The cells in the enamel organ
differentiate into two types of cells - 1) outer enamel cells, which cover the enamel organ
and organize a network for the transport of nutrition, and 2) inner enamel cells, which
become the ameloblasts that form the enamel. The cells in the periphery of the dental
papilla differentiate into odontoblasts that form pre-dentin, the precursor to dentin, which
is mineralized. The central region of the dental papilla, which contains undifferentiated
mesenchymal cells, will become the dental pulp. As for the dental follicle, this tissue
contains progenitor cells that will differentiate into cementoblasts, periodontal ligament
fibroblasts, and osteoblasts to form the cementum-periodontal ligament-alveolar bone
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structure, respectively as shown in a representative diagram of the tooth anatomy in
Figure 1.2.
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Figure 1.1. Schematic of mouse tooth development.
(A) At embryonic day 12.5 (E12.5), thickening and invagination of the dental epithelium
(dark pink) becomes apparent. (B) At around E13.5, the neural crest mesenchymal cells
(black dots) within the underlying mesenchyme (light pink) start to condense around the
formed bud. (C) By E14.5, the epithelium is further folded and the enamel knot becomes
visible (blue oval). During this cap stage, the condensed mesenchyme forms the dental
papilla. (D) At E16.5, the tissue development reaches the early bell stage and cells in the
dental papilla begin to differentiate into their respective lineages. By E20, the
ameloblasts and odontoblasts have started to form enamel (blue) and dentin (yellow)
respectively. The central region of the dental papilla, which contains undifferentiated
mesenchymal cells, will turn into dental pulp (white). Note: This figure is adapted from
(Caton and Tucker, 2009).
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Figure 1.2. A diagram of tooth anatomy.
A cross section of tooth anatomy showing major components of the tooth.
The figure is copied from https://www.nlm.nih.gov/medlineplus/ency/
imagepages/1121.htm
(Permission to use the image was acquired from A.D.A.M. Education)
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1.2.6

Tooth anatomy

The tooth is made up of four major tissues: enamel, dentin, cementum, and dental pulp as
shown in a representative cross section diagram of molar and incisor (Figure 1.2, 1.3 and
1.4). Among the three mineralized tissues, enamel is the hardest and most highly
mineralized. Approximately 96% of enamel by weight consists of hydroxyapatite (HA),
with the remainder water and organic matrix (Deakins and Volker, 1941; LeFevre and
Manly, 1938). Different from dentin, cementum and bone, enamel does not contain
collagen. Enamel contains three major structural proteins called amelogenin,
ameloblastin, and enamelin (Bartlett, 2013).
Dentin, which is found between the pulp chamber and enamel or cementum, is a
mineralized tissue that is formed by odontoblasts. While lower in mineral density than
enamel, dentin is composed of 70% HA, 10% water, and 20% organic matrix. Similar to
bone, dentin's organic matrix is composed of collagen and a variety of non-collagenous
proteins. Within the mineralized matrix of dentin, there are dentinal tubules, which are
microscopic channels that radiate outward from the pulp chamber to either the enamel or
cementum border (Goldberg et al., 2011).
Cementum is a mineralized tissue found adjacent to the dentin and covers the tooth root.
Similar to osteoblasts for bone, cementoblasts are responsible for the formation of the
organic matrix of the cementum, and its subsequent mineralization process. Cementum
consists primarily of 45% HA, 20% water, and 35% organic matrix (Gonçalves et al.,
2005). The main role of the cementum is to act as a medium for the attachment of the
periodontal ligament, which stabilizes and anchors the tooth root to the bone. There are
two types of cementum - acellular and cellular cementum. The acellular extrinsic fiber
cementum is found in the top 40 to 70% of the root surface. This matrix consists of a
dense fringe of short collagenous fibers that are oriented perpendicular to the root surface
(Gonçalves et al., 2005). As the fibers become elongated and become continuous with
the principal PDL fibers, they are called Sharpey's fibers. In addition, two major noncollagenous proteins, bone sialoprotein (BSP) and osteopontin (OPN), are prominently
expressed in acellular cementum. BSP is believed to play a role in cell adhesion,
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progenitor cell differentiation into cementoblasts, and initiating mineralization (Saygin et
al., 2000; Somerman et al., 1990).
The cellular intrinsic fiber cementum contains embedded cementocytes in the mineralized
collagenous matrix. This tissue is found at the apical root portion and it maintains the
root in its proper position. The collagen fibers in the matrix are oriented mostly parallel
to the root surface (Gonçalves et al., 2005). Studies have shown that it also participates
in the repair process, however, there is no direct evidence that it plays a role in tooth
attachment (Bosshardt and Selvig, 1997).
The dental pulp is a soft connective tissue containing blood and nerve supplies to the
tooth, which enters at the apex of the tooth root. Along the boundary of the pulp and
dentin, in the pre-dentin layer, odontoblasts are found. Other cells such as preodontoblasts and fibroblasts are also present in the pulp chamber.
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Figure 1.3. Schematic of a molar tooth cross section.
The image represents a cross section (coronal) of the mice tooth, which are emphasized
by color codes: enamel (blue), dentin (yellow), cementum (green for both acellular and
cellular cementum), alveolar bone (brown), and gingiva (pink). The pulp chamber is
located in the core of the tooth. Whereas the periodontal ligament (PDL) is located
between the alveolar bone and cementum. Note: This figure is adapted from (Foster,
2012).
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Figure 1.4. Schematic of an incisor cross section.
The image represents a cross section (sagittal) of the mice tooth, which are emphasized
by color codes: enamel (blue), dentin (yellow), cementum (green for both acellular and
cellular cementum), alveolar bone (brown), and gingiva (pink). The pulp chamber is
located in the core of the incisor. Whereas the periodontal ligament (PDL) is located
between the alveolar bone and cementum.
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1.3
1.3.1

BONE SIALOPROTEIN (BSP)
BSP structure and function

Bone sialoprotein (BSP), an acidic phosphoprotein, is a member of the Small IntegrinBinding Ligand N-Linked Glycoprotein (SIBLING) family of proteins and a major
component of non-collagenous proteins in bone. BSP is highly conserved and found in
all vertebrate species with mineralized tissue. BSP has been isolated from a wide range
of animals such as bovine (Fisher et al., 1983; Franzen and Heinegard, 1985), pig (Zhang
et al., 1990), rat (Gorski and Shimizu, 1988), rabbit (Kinne and Fisher, 1987), chicken
(Yang et al., 1995), frogs (Shintani et al., 2008), and humans (Fisher et al., 1987). The
calculated molecular weight of human BSP based on mass spectroscopy was determined
to be approximately 49 kDa (Wuttke et al., 2001) and 52.5 kDa (Zaia et al., 2001). The
variability in the average mass of BSP is likely due to its heterogeneous post-translational
modifications. Furthermore, BSP has a flexible structure which is intrinsically disordered
with no secondary or tertiary structure (Fisher et al., 2001; Wuttke et al., 2001). The
flexible nature of BSP is likely important since it may allow for simultaneous interaction
with other proteins, cells and minerals as previously discussed by Fisher et al (Fisher et
al., 2001). On average, BSP contains around 327 amino acid residues including the 16
residue signal sequence and within it, a high concentration of acidic amino acid residues,
glutamic acid and aspartic acid, as well as the negatively charged sialic acid residues
(Zaia et al., 2001), which contributes to the overall negative charge of BSP [isoelectric
point (pI) of 3.9].
BSP has been determined to have three main functional regions: 1) collagen-binding
region, 2) two hydroxyapatite (HA)-nucleating regions, and 3) an integrin recognition
region (Figure 1.5). These functional regions are highly conserved and always found in
BSP regardless of species (Goldberg and Hunter, 2012). The collagen-binding region
(spanning residues 18-45) is a hydrophobic region located near the N-terminus (Tye et
al., 2005). The two nucleating regions (spanning residues 42-100 and 133-205), each
containing a contiguous glutamate sequence, were found to be critical for HA nucleation
(Hunter and Goldberg, 1993) and binding (Goldberg et al., 2001; Stubbs et al., 1997). Of
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the two HA-nucleating regions, the second sequence in rat (BSP 133-205) has been
determined to be more potent than the first one (Harris et al., 2000; Tye et al., 2003).
Previous studies have shown that even the short BSP133-148 sequence containing a polyglutamate sequence and a phosphorylated serine residue, possesses HA-nucleation
activity (Baht et al., 2010). In addition, using a steady state collagen-gel system, it has
been demonstrated that the HA nucleation potency of BSP is enhanced when it is bound
to collagen (Baht et al., 2008). The integrin recognition region (RGD; spanning residues
273-275) is located near the C-terminus (Wuttke et al., 2001). This RGD motif of BSP
has been shown to mediate cell attachment and signaling that contributes to
osteoprogenitor cell differentiation and migration (Gordon et al., 2007). The RGD motif
interacts with the αvβ3 integrin, which is a cell-surface receptor present in osteoblasts
(Oldberg et al., 1988) and osteoclasts (Helfrich et al., 1992). The overexpression of BSP
in MC3T3-E1 osteogenic cells has been shown to increase the level of osteoblast
differentiation signaling markers and formation of matrix mineralization nodules in vitro
(Gordon et al., 2007). However, when the RGD sequence is mutated to KAE, the cellintegrin binding capabilities have been shown to be diminished or abolished in
osteoblasts (Gordon et al., 2007), fibroblasts (Harris et al., 2000), chondrocytes (Gill et
al., 2008) and endothelial cells (Bellahcène et al., 2000). Furthermore, overexpression of
the BSP in rat primary calvarial pre-osteoblasts containing the KAE mutation did not
result in enhanced osteoblastic differentiation in vitro (Gordon et al., 2007).
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Figure 1.5. Linear schematic of BSP functional regions.
BSP contains on average 327 amino acid residues and has three main functional regions.
The first region is the collagen-binding region (red), which is located near the Nterminus. The second region consists of two hydroxyapatite (HA)-nucleating regions,
which are rich in poly-glutamic acid sequences (yellow). The last region is an integrin
recognition region consisting of the RGD sequence that has been shown to promote cell
adhesion and signaling.
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1.3.2

BSP expression and role in biomineralization

BSP appears to be expressed in all mineralized tissues. For example, it is highly
expressed in bone, cementum, and calcified cartilage (Ganss et al., 1999). Other studies
have also suggested that BSP is expressed in dentin at low level (Fujisawa et al., 1993;
Qin et al., 2001). BSP expression has been demonstrated in cells that produce a matrix
that mineralizes such as osteoblasts, hypertrophic chondrocytes, cementoblasts,
ameloblasts, and odontoblasts (Bianco et al., 1991; Chen et al., 1998). This suggests that
BSP may play an important role in osteogenic mineral formation. In the osteoblasts, BSP
is detected in the Golgi apparatus where it is post-translationally modified before being
secreted (Bianco et al., 1993). A potential reason for BSP being a potent nucleator for
HA is likely due to its highly acidic sequences that attract and immobilize calcium ions in
a specific orientation. Therefore when phosphate ions bind, a template for mineral
formation is established. This concept is further supported by a previous study that
demonstrated that the phosphorylation of the Serine-136 residue, but not other potential
serine sites in BSP, enhances HA nucleation potency of the protein (Baht et al., 2010).
Interestingly, the Ser-136 residue is adjacent to a poly-glutamic sequence in BSP. Of
relevance to the potential role of BSP in mineral formation, other studies have shown
BSP is associated with pathological calcification such as the microcalcifications observed
in breast cancer tissue (Bellahcene et al., 1994) and lung cancer tissue (Bellahcene et al.,
1997). Furthermore, various cancer cells, including breast, lung and prostate, express
high levels of BSP (Bellahcene et al., 2008).
A number of in vivo studies have also shown the physiological importance of BSP
including its functional relevance in skeletal development. Mice with the Bsp gene
ablated (Bsp-/-) have impaired bone growth and mineralization. Bsp-/- mice were reported
to have shortened long bones, decreased bone mineral density, delayed mineral
formation, thinner cortical bones, and greater trabecular bone volume as compared to
wild type (WT) mice (Malaval et al., 2008). In addition, studies also indicate that
reduction in osteoclast formation and activities were observed in Bsp-/- mice, which
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resulted in low bone turnover (Boudiffa et al., 2010; Malaval et al., 2008). In a long bone
defect model, Bsp-/- mice also displayed delayed bone repair compared to WT control
(Malaval et al., 2009; Monfoulet et al., 2010). These phenotypes observed in Bsp-/- mice
suggest that BSP plays a crucial role in bone development and mineralization. In
addition, BSP may also be important for maintaining the homeostasis of both osteoblasts
and osteoclasts in number and activities. Of relevance, studies have demonstrated that in
the presence of BSP and RANKL, the differentiation of osteoclast from
monocyte/macrophage cells is greater compared to that without BSP (Valverde et al.,
2005). In addition, previous studies on transgenic mouse line with overexpression of
BSP demonstrated increased osteoclast formation and activity level (Valverde et al.,
2008).
Studies have shown the therapeutic potential for BSP to induce bone repair in vivo (Wang
et al., 2006; Xu et al., 2007). The authors used a bovine BSP treated-collagen scaffold
which was implanted into rat calvarial defects. At 4 days post-surgery, the BSP-collagen
scaffold induced recruitment of osteoblasts and promoted early mineralization. However,
no bone repair was observed when denatured collagen was used as a scaffold (Xu et al.,
2007). Other in vitro studies were also able to confirm that BSP binding affinity to
denatured collagen is less than to native collagen (Baht et al., 2008). The outcomes of
these studies indicate that the collagen-binding region in BSP potentially has an
important role in biomineralization.
On the other hand, there are a couple of studies that indicate BSP was not effective in
promoting bone repair. For example, when recombinant human BSP- (rhBSP) coated
polymeric scaffolds [porous -tricalcium phosphate scaffold (Skelite TM) and synthetic
polymer (Polyactive TM)] were used in an in vivo subcutaneous model in nude mice, the
presence of BSP did not improve the efficiency of bone tissue formation compared to the
control group (Schaeren et al., 2010).
Studies on BSP also look at its potential role in enhancing osteointegration of implants
into biological tissues. BSP coating of a hydroxyapatite-based titanium implant (TICER
®) with rough surface improved its osteoinductive properties and enhanced attachment of

20

bone marrow derived cells in vitro (Graf et al., 2008). Another study on bovine BSP
coating of titanium femoral implants demonstrated enhanced osteoinductive properties
with evidence of abundant osteoid, elongated osteoblasts and neovascularisation around
the implant-bone interface (O'Toole et al., 2004). However, when subjected to
mechanical pullout test, the BSP coating was unable to enhance the strength of the
implant-bone integration.

1.4
1.4.1

BONE MORPHOGENETIC PROTEIN (BMP)
Role of BMP in bone regeneration

Bone morphogenetic proteins (BMPs) are multifunctional cytokines that belong to the
transforming growth factor (TGF)-β superfamily (Abe, 2006). BMPs are potent growth
factors that have been widely investigated for use in the clinical setting for bone repair.
For example, BMP-2, -4, and -7 have been shown to have strong osteogenic properties
(Chen et al., 2012). These BMPs are currently the standard growth factor used in
combination with various carriers for bone tissue regeneration. The BMPs possess the
ability to stimulate osteoblastic differentiation (Canalis et al., 2003; Schmitt et al., 1999).
Previous studies have shown that the growth factors BMP-2,4 and 7 are expressed by the
mesenchymal stromal cells (MSC), osteoprogenitors cells, osteoblasts, endothelial cells,
fibroblasts and chondrocytes at fracture sites and during the inflammatory phase of bone
repair (Bostrom et al., 1995; Canalis et al., 2003; Martinovic et al., 2004; Nakase et al.,
1994; Onishi et al., 1998; Zhang and Li, 2005). After being secreted, the extracellular
matrix temporarily stores the BMPs, which are then released during bone repair and
remodeling. BMPs bind to BMP receptors types I and II, which are important for signal
transduction to activate the transcription factor Smad cytoplasmic proteins. The binding
of BMP catalyzes phosphorylation of Smads 1,5,8, which are also associated with the
activation of Smad-4 which translocates into the cell nucleus. Smad-4 regulates the
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expression of Runx2 and Osx genes, which are gene markers of osteoblastic
differentiation (Chen et al., 2012).
Other studies have also suggested that BMPs play a role in promoting angiogenesis via
the Wnt pathways (de Jesus Perez et al., 2009; Guo and Wang, 2009). During
intramembranous ossification, these BMPs are expressed by the proliferating osteoblasts.
Whereas during chondrogenesis and endochondral ossification, these BMPs are
expressed by both the proliferating chondrocytes and osteoblasts near the ossification
front (Sfeir et al., 2005).
The inactivation of the various BMP genes leads to a variety of phenotypes. For
example, BMP-2-null mice have an embryonic lethal phenotype prior to the formation of
the skeleton. This mutation also caused defects in amnion, chorion, and cardiac
development (Zhang and Bradley, 1996). Similarly, BMP-4-null mice have an early
embryonic lethal phenotype with defects in mesoderm development (Winnier et al.,
1995). As for the elimination of BMP-7 gene, null mice also revealed a lethal phenotype
due to developmental abnormalities in the kidney, eye and skeletal structure (Jena et al.,
1997; Luo et al., 1995). These studies confirmed the important role of BMPs in
development of a variety of tissues, including skeletal tissue.
In addition, the use of BMP as a therapeutic growth factor to enhance bone repair has
been accepted clinically as a standard procedure. Previous studies using various animal
models, including rats (Sawyer et al., 2009), rabbits (Murakami et al., 2002), dogs
(Asamura et al., 2010), sheep (Geiger et al., 2003), and non-human primates (Suh et al.,
2002), have been used to evaluate the addition of BMPs to heal bone defects. All of
these studies have shown that the presence of BMPs accelerates bone formation at the
defect sites.
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1.4.2

Potential side effects of using high dose of BMPs

Currently, there are two FDA-approved recombinant human BMPs (rhBMPs) 2 and 7,
which are obtained by molecular cloning of their respective cDNAs and expressed using
the Chinese hamster ovary cell line, for clinical use in humans (Wozney, 2002). For this
study, we focused on the use of rhBMP-2 since it has been extensively evaluated in
numerous studies for bone repair (Chen et al., 2004). For example, commercialized
rhBMP-2 is delivered with a bovine collagen sponge (INFUSE Bone Graft, Medtronic)
for posterior-lateral spine, tibia and specific craniofacial applications.
Recent studies have reported wound complications in the use of rhBMP-2 for anterior
cervical fusion and non-union fractures (Cahill et al., 2009; Papakostidis et al., 2008;
Williams et al., 2011). These complications include superficial and deep wound
infections, and epidural hematoma or seroma. In addition, there have also been reports of
intense inflammation and bone resorption in children patients treated with BMPs for cleft
lip and palate repair (Neovius et al., 2013) and symptomatic ulnar nonunion repair
(Ritting et al., 2012). However, there are no clear studies that indicate the observed
complication is directly caused by usage of BMP as opposed to normal surgical
complication. Another potential problem is that the commercially available BMP-2 is
also clinically used "off-label".
For in vitro studies, the utilization of BMP-2 is generally at very low dosages (5-20
ng/mL). However, for in vivo or clinical treatments, commercially available rhBMP-2
are usually packaged in large dosage (up to 40 mg), which depend on the size of the
defect. High doses of BMP-2 are usually needed to be clinically effective due to poor
retention of the BMPs to its carrier. In addition, the high cost of rhBMPs for clinical use
is another factor to consider. Of relevance, animals studies have shown that rhBMP-2
has a short half-life of 7-16 minutes systemically (Poynton and Lane, 2002), however if
bound to collagen scaffold, the residence time of rhBMP-2 was determined to be
approximately 8 days; with a half-life of 5.6 days (Sellers et al., 2000). Another main
concern of using rhBMPs at large dosage is that it will pose risks to patients due to its
potential for significant side effects including heterotopic bone formation, significant
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immune responses and potential to be carcinogenic (Carragee et al., 2011; Epstein, 2013).
In spite of all of these controversial results, the use of BMPs is still the best solution for
promoting bone repair in defects that do not respond to normal therapies or procedures.
In orthopedics, the challenge is to use a much lower dose of BMPs without
compromising the overall effectiveness in promoting bone regeneration. Therefore, there
is a necessity of designing a biomaterial scaffold that can retain and systematically
release BMPs over time. Thus, the selection of the carrier for BMPs and the dose used
should be studied carefully in animal models.

1.5

BIOMATERIALS FOR TISSUE ENGINEERING

Large bone defects due to tumour excision, non-union fracture and critical-sized defect
fractures affect millions of people worldwide each year. Normal bone remodeling
requires a number of factors that involve cell migration, adhesion, proliferation, and
differentiation as well as the extracellular matrix and growth factors. In critical sized
defects, normal repair is impeded where in the majority of cases successful healing does
not occur without intervention. Various biomaterials have been developed with the goal
to regenerate and improve the functional state of damaged tissues.

1.5.1

Introduction of biomaterials scaffolds

The use of autogenous and allogenic bone grafts are among the most common clinical
procedures to promote bone regeneration. These bone grafts have their own advantages
and disadvantages. Autograft tissue is the safest and has the fastest healing potential
without dealing with issues such as tissue rejection due to immune response. Clinically,
it is the "gold standard" treatment for bone defects. The source of autograft tissue,
usually from the iliac crest, has the potential to facilitate new bone formation due to the
endogenous presence of growth factors, which can promote angiogenesis and
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osteogenesis (Soucacos et al., 2008). However, additional surgical procedures are
required to harvest the autograft from a secondary site within the patient body, leading to
extended recovery time and potential risk of infection (Younger and Chapman, 1989).
The secondary site (for example iliac crest) could also be uncomfortable and painful for
years after the surgical procedure (Lementowski et al., 2010; Palmer et al., 2008). Lastly,
there is a limited supply of autograft material since over-harvesting can cause
destabilization of the secondary site. In contrast, allografts are obtained from human
donors (cadavers) and do not require additional surgical procedures to the receiving
individuals. However, proper screening for pathogens and risk factors for diseases are
necessary for the use of allografts. Limited supplies and tissue rejection are also
additional concerns for using allografts.
In tissue engineering, the best surgical procedures to treat non-union bone fractures and
spinal fusion involve the use of bone graft substitutes. In addition, these substitutes need
to be osteoconductive, osteoinductive and have mechanical properties allowing them to
withstand normal in vivo loads (Bauer and Muschler, 2000). There has been an emphasis
on the use of synthetic biomaterials that can replace autogeneous and allogenic bone
grafts for large bone defects. Below are brief descriptions of these synthetic biomaterials
for bone grafts, which can be divided into 3 main categories: metals, ceramics, and
polymers.
Metals implants are widely used for load-bearing applications such as fracture fixation
plates or screws. However, in some cases they are required to be removed after the bone
heals, which can be inconvenient and painful for patients. Another potential concern is
that metals can corrode, due to chemical reaction with enzymes and acids in the body,
and the metals ions can be toxic to the body. However, there are medical grade metals
such as titanium, which are naturally resistant to corrosion.
Ceramics are also used for bone implants, in particular those containing calcium
phosphates, the primary inorganic phase of bone minerals. Ceramics are chemically inert
and have high compressive strength.

However, they are also brittle and lack the

toughness needed to bear cyclic loading (Ducheyne, 1987; Yaszemski et al., 1996).
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However, bioceramic scaffolds comprised of porous β-tricalcium phosphate matrix
combined with hydroxyapatite (HA) nano particles show a compressive strength similar
to that of cancellous bone (Lu et al., 2002; Metsger et al., 1993; Ramay and Zhang,
2004).
Various polymers are widely used as biomaterials and they can be easily manufactured
and modified for any application. There are two broad categories of polymers that are
used for biomaterials: 1) natural and 2) synthetic. Natural materials such as type I
collagen are usually derived from animals, which is the main matrix component of many
connective tissues including bone and skin. Natural materials are generally not toxic to
the body and biocompatible. In addition, natural materials may carry specific protein
binding sites and elicit biochemical signals that promote tissue regeneration. However,
occasionally, these materials can also be subject to tissue rejection due to immune
response.

One potential problem with natural materials such as unmodified type I

collagen is their limited mechanical stiffness and strength for load bearing applications;
especially when the scaffold is in aqueous condition.
A variety of synthetic polymers are used in tissue engineering, which include poly(lacticco-glycolic) acid (PLGA), poly(methyl methacrylate) (PMMA), and polyesters. Some
modification can often be done on these synthetic polymers so that they can be
hydrolytically degraded. Unfortunately, in some cases, the degraded particles potentially
may lead to an inflammatory response (Bostman et al., 1990; Vert et al., 1994). Overall,
some advantages of both natural and synthetic polymer scaffolds are the ability of them
to be easily modified, adsorb proteins and retain solutions quite well.
In general, synthetic biomaterials do not possess the three required properties for tissue
engineering applications in bone repair, which includes being osteoconductive,
osteoinductive and load-bearing. Therefore, additional modifications to the synthetic
biomaterials are required to achieve this goal. To improve the osteoinductive property
the most common technique is to combine the biomaterials with growth factors and other
bioactive proteins that are able to promote angiogenesis and osteogenesis (Itoh et al.,
2001; Li et al., 2009; Schliephake et al., 2008). In general the goal is to use the scaffold
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as a carrier for slow release of the growth factors at the defect site. For improvement in
load-bearing properties, composites are used for tissue engineering application. These
composites are usually made up of a combination of polymers and bioceramics. For
example, studies were able to create scaffolds made up of collagen and HA that have the
strength and stiffness comparable to trabecular bone (Itoh et al., 2002; Kikuchi et al.,
2001).

1.5.2

Potential use of nanohydroxyapatite/poly(ester-urethane)
scaffold as a carrier for growth factors and bioactive proteins

Over the years, polyurethane has been shown to be safe, and easily molded into various
shapes. However, for most applications, pure polyurethane is a poor candidate for use in
drug delivery due to its resistance to degradation. The introduction of ester bonds into
the polymer backbone resolves the resistance to degradation issue (Ulery et al., 2011).
In general, polyurethane is composed of hard and soft copolymer segments that can
undergo microphase separation, which allows these polymers to handle physical stress
very well and improves its mechanical strength. Typically, biodegradable poly(esterurethanes) (PU) are synthesized by polycondensation of diisocyanates with polyester diol
or triols, which are composed of either glycilide, lactide or caprolactone, to create the soft
segment of the polymer. For the hard segment, the typical copolymers are composed of
polypeptides or diols or triols of 3-hydroxybutyrate (Guelcher, 2008; Henry et al., 2007).
In the literature, different forms of PU-based scaffolds have been used extensively in
tissue engineering applications such as regeneration of bone (Hofmann et al., 2008;
Kavlock et al., 2007; Li et al., 2009), cartilage (Dresing et al., 2014; Lee et al., 2005), and
other soft tissues (Gogolewski et al., 2008; Guan et al., 2005; Guelcher, 2008; Guelcher
et al., 2008). For bone tissue engineering, another important aspect for a successful
biomaterial is its capability to bind growth factors, such as rhBMP-2, to promote bone
repair. Of relevance, previous in vitro studies have shown that rhBMP-2 binds well to
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PU-based scaffolds (Li et al., 2009). Based on this study, we postulate that the novel PU
scaffolds used in the study may also be an effective carrier for rhBMP-2.
Previous studies have demonstrated that the novel PU scaffolds have porous
interconnected three-dimensional environment for cell and blood vessel infiltration
(Laschke et al., 2009; Laschke et al., 2013). These PU scaffolds are biocompatible and
have viscoelastic properties, which are important for load bearing applications (Hofmann
et al., 2008; Laschke et al., 2009; Laschke et al., 2013; Lee et al., 2005; Pirvu et al.,
2015). In addition, the PU scaffolds were shown to have the capability of supporting the
co-culture of primary human osteoblasts and human umbilical vein endothelial cells
(HUVEC) (Hofmann et al., 2008). Using a novel in vivo subcutaneous model, the
authors showed that the PU scaffolds are osteoconductive and also allow for blood
vessels formation within its 3D matrix.
For our study, modifications were made by incorporating nano-sized hydroxyapatite
(nHA) particles into the PU matrix to make a novel scaffold (nHA/PU). A 10% weight
ratio of nHA to the PU was selected since it gave the best improvement in material
stiffness, increased by 30%, compared to PU scaffold alone (Boissard et al., 2009). The
addition of nHA was also shown to increased the scaffold capacity to bind proteins such
as serum albumin and fibrinogen (Laschke et al., 2010b). The presence of nHA may
potentially enhance binding affinity of growth factors and bioactive proteins to the
nHA/PU scaffold. The incorporation of nHA did not affect its biocompatibility or inhibit
its ability to allow vascularization as previously shown by Laschke et al (Laschke et al.,
2009).

1.6

PURPOSE OF THE THESIS

The role of BSP in skeletal tissue development has been studied using in vitro culture and
transgenic mouse models. BSP has been suggested to promote osteoprogenitor cell
differentiation leading to bone formation. One study has also shown that the addition of
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BSP-treated collagen scaffolds to critical sized defects promoted bone repair. In addition,
BSP is also present in mineralized periodontal tissues, especially in cementum, the
mineralized tissue lining the tooth root. However, the role of BSP in the periodontal
tissues is unknown.
The studies in this thesis are separated into two main objectives. The first objective
focused on the role of BSP in mineralized periodontal tissues. The second objective
focused on the potential use of BSP as a therapeutic agent, with a novel poly(ester)
urethane (PU) scaffold, for bone repair.

Hypothesis 1: The absence of BSP in periodontal tissues, specifically acellular
cementum, will result in a significant periodontal tissue phenotype.
Rationale: Previous studies have shown that the absence of BSP in mice results in
abnormal bone phenotypes indicated by reduced bone growth, mineralization and repair
(Malaval et al., 2008; Malaval et al., 2009; Monfoulet et al., 2010). Other than bone,
BSP has also been shown to be present in the mineralized tissues of the tooth, especially
cementum (McKee et al., 1996; Somerman et al., 1990). It has been postulated that BSP
plays an important, though undefined, role in the formation and mineralization of the
cementum (Somerman et al., 1990).
In chapter 2 of the thesis, characterization of the Bsp-/- mouse periodontium was
conducted to determine whether there were periodontal tissue abnormalities. In brief, the
study confirmed that BSP is present in normal cementum and also demonstrated that the
Bsp-/- mouse has defective acellular cementum, which leads to periodontal tissue
breakdown. Histological, SEM, and microCT analyses were utilized to describe the
observed phenotype.
In chapter 3, the study focused in part on the additional characterization of the
periodontal phenotype and the determination of the potential mechanisms that lead to the
abnormalities observed in the Bsp-/- mouse. Substitution of hard-pellet diet to soft
powdered diet was introduced to verify whether the reduction in occlusal force required
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during mastication of the hard diet prevents or reduces the PDL detachment observed in
the Bsp-/- mouse, which is described in chapter 2. MicroCT and histological analyses
were performed. In addition, detailed morphometric measurements were performed to
characterize the periodontal tissue destabilization and breakdown.

Hypothesis 2: BSP treated poly(ester-urethane) scaffolds promote bone repair.
Rationale: The implantation of BSP treated fibrillar type I collagen scaffolds has been
previously shown to promote bone repair (Wang et al. 2006). Previous studies
(Goldberg's group), however, were not able to reproduce these results using rat BSP and
various types of collagen scaffolds. Based on the efficacy of BSP in promoting
biomineralization in a variety of in vitro studies as well as the published findings of the
Glimcher group (Wang et al., 2006), it was believed that the delivery of BSP to the bone
defect site may be the critical factor.
In a collaborative study (Drs. David Eglin and Mauro Alini, AO Foundation), novel
scaffolds composed of poly(ester) urethane mixed with nano-hydroxyapatite (nHA/PU)
were prepared. Previous studies by our collaborators demonstrated the effectiveness of
the nHA/PU scaffold for tissue engineering applications because of its osteoconductive
property and its ability to bind bioactive proteins (Boissard et al., 2009; Laschke et al.,
2009). The applicability of the nHA/PU scaffold in conjunction with BSP for bone repair
is the focus of our studies.
There were 2 main objectives:
The first goal (chapter 4) was to confirm that nHA/PU scaffolds can safely be used as a
carrier of bioactive growth factors to promote bone repair. The growth factor used was
rhBMP-2, a clinically established therapeutic for bone repair. In brief, using a rat
calvarial defect model, this study indicated that the nHA/PU scaffolds bound rhBMP-2
well, and the treated scaffolds enhanced bone formation. MicroCT and histological
analyses were used to monitor bone repair.
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Based on the enhanced bone repair observed with rhBMP-2 treated nHA/PU scaffolds,
our second goal was to determine the efficacy of BSP-treated nHA/PU scaffolds in
promoting repair (chapter 5). BSP was shown to bind to nHA/PU scaffolds, and the
BSP-treated scaffolds apparently promoted osteoprogenitor cell adhesion, however bone
repair in vivo was not enhanced. MicroCT and histological analyses were used to
monitor the bone repair.
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CHAPTER 2

2

Deficiency in acellular cementum and
periodontal attachment in Bsp-null mice
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2.1

INTRODUCTION

Bone sialoprotein (BSP, or integrin binding sialoprotein) is an extracellular matrix
protein in the Small Integrin Binding Ligand N-linked Glycoprotein (SIBLING) family,
associated with mineralized tissues of the skeleton and dentition (Fisher and Fedarko,
2003; Ganss et al., 1999). Like other SIBLING proteins, BSP is multifunctional, with
roles in cell attachment and migration (through the integrin-binding RGD motif), cell
signaling, collagen binding, and hydroxyapatite nucleation. The ability of BSP to act as a
positive regulator for hydroxyapatite precipitation has been demonstrated in vitro (Hunter
and Goldberg, 1993), and is of particular interest in terms of regulating mineralized tissue
development. Mice null for the Bsp gene (Bsp-/-) feature delayed bone growth and
mineralization (Malaval et al., 2008).
In addition to its inclusion in bone extracellular matrix, BSP is present in both acellular
and cellular cementum (MacNeil et al., 1994; McKee et al., 1996). Acellular cementum
is the thin, mineralized tissue covering the cervical portion of the tooth root, important for
attachment of the periodontal ligament (PDL) to the root surface (Bosshardt, 2005; Foster
et al., 2007). Cellular cementum is a more bone-like tissue covering apical portions of
roots. Developmental factors directing cementogenesis remain poorly defined,
hampering progress towards more effective therapies for cementum regeneration. The
finding that BSP was present in cementum and strongly expressed by cementoblasts led
to speculation that this protein might contribute to cementum formation and
mineralization (MacNeil et al., 1995; Somerman et al., 1990), however this hypothesis
has remained untested in the two decades since these findings. Here, we analyzed the
function of BSP in cementogenesis and periodontal stability by determining effects of
lack of BSP on tooth formation.
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2.2

2.2.1

MATERIALS & METHODS

Animals

Animal procedures were performed in accordance with guidelines of the Canadian
Council on Animal Care and Animal Care and Veterinary Services, University of
Western Ontario. Preparation and genotyping procedures of Bsp-/- and wild-type (WT)
mice were described previously (Malaval et al., 2008). All of the mice were maintained
on a mixed 129/CD1 background and fed a standard mouse diet (2018 Tekland Global
18% protein diet, Harlan Laboratories, USA). Three to six animals were analyzed per
genotype at ages 14, 26, 30, and 60 days postnatal (dpn) to determine abnormal
phenotypes. Serum biochemistry was analyzed using standard assays by NIH Veterinary
Services Clinical Chemistry (Bethesda, MD). For this study, all comparison were made
between Bsp-/- and WT littermate pairs.

2.2.2

Micro-computed tomography (microCT) and scanning
electron microscopy (SEM)

MicroCT of formalin-fixed hemi-mandibles was performed using eXplore Locus SP (GE
Healthcare, Canada). 2D images were acquired at 80 kVp and 80 A, using an
integration time of 1600 ms/frame, 4 frames/view, and a total of 900 views at an
increment of 0.4 degrees. Images were constructed at a spatial resolution of 13 m and
calibrated with a cortical bone phantom (SB3; Gamex RMI, Wisconsin, USA) having a
hydroxyapatite equivalent of 1,100 mg/cc (White, 1978). Data were analyzed using
MicroView ABA version 2.2 (GE Healthcare).
For SEM analysis, extracted and cleansed molars were osmium coated. For fracture
analysis, an ultra-fine diamond burr (Brassfler DET6UF-31) was used to drill through
crowns, and teeth were fractured longitudinally. SEM images were analyzed in
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secondary electron mode at 1-10 kV on a Leo 1540 XB FIB/SEM (Carl Zeiss, Western
Nanofabrication Facility).

2.2.3

Histological procedures

Procedures for histology, in situ hybridization (ISH), and immunohistochemistry (IHC)
were previously described on Bouin’s fixed, decalcified, paraffin-embedded samples
(Foster, 2012; Foster et al., 2012). Histomorphometry was used to quantify cementum,
root-lining cells (cementoblasts) (D'Errico et al., 1997), and epithelial attachment, and
statistical analysis was performed by independent samples t-test.
For the ISH of Bsp mRNA, digoxigenin (DIG)-labeled cRNA probe (Marian Young,
NIDCR, Bethesda, MD) with NBT/BCIP substrate were utilized. As for the IHC,
biotinylated secondary antibodies and peroxidase substrate were utilized. A variety of
primary antibodies were used in the study, which included rabbit anti-BSP (1:200; Renny
Franceschi, University of Michigan, Ann Arbor), rat anti-alkaline phosphatase
(TNAP/ALPL, 1:200; R&D Systems, Minneapolis, MN), LF-175 rabbit anti-osteopontin
(OPN; 1:200) (Larry Fisher, NIDCR), rabbit anti-cytokeratin (Abcam, Cambridge, MA),
goat anti-RANKL (1:50; Santa Cruz Biotechnology, Santa Cruz, CA), and rat antineutrophil antibody (1:200; NIMP-R14; Abcam).
As for undecalcifed, glutaraldehyde/formalin fixed tissues, they were either LR whiteembedded for ultramicrotome sectioning (1 m) for von Kossa staining (Everts et al.,
2012), or processed and methylmethacrylate-embedded for microtome sectioning (6 m)
for Goldner’s trichrome staining (Kacena et al., 2004). For all ISH and IHC sections,
negative and positive controls were always stained to verify no background staining.
The histology sections stained with alcian blue were used to measure the thickness of the
acellular cementum (dark blue in appearance). All of the measurement were done within
the top 2/3 of the root. Three random measurements were conducted and then the
average values were calculated for each mouse.
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2.3

2.3.1

RESULTS

Bsp-/- mice exhibit defective acellular cementum formation

Bsp mRNA is highly expressed by cementoblasts during tooth root formation, as well as
osteoblasts of the alveolar bone (Figure 2.1A). BSP protein is localized to alveolar bone,
and acellular and cellular cementum covering the cervical and apical portions of the
molar, respectively (Figure 2.1B-C). Absence of BSP immunostaining was confirmed in
Bsp-/- mice (Figure 2.1D-E).
Over the course of root development, Bsp-/- mouse molar teeth displayed deficiency in
acellular cementum formation. At 14 days postnatal (dpn), a basophilic layer of acellular
cementum covered the root dentin in WT mice (Figure 2.1F-G), while in Bsp-/- molars,
this layer was thinner (Figure 2.1H-I). At 26 dpn, WT acellular cementum had grown
thicker and inserted PDL fibers radiated from the surface of the cervical root (Figure
2.1J-K). Conversely, Bsp-/- acellular cementum showed no additional growth (Figure
2.1L-M). It was common to find PDL disorganization in Bsp-/- molars, and a structural
defect in the cementum-PDL interface was indicated by detachment in all Bsp-/- samples
(possibly partly due to tissue processing, but not present in WT samples). By 60 dpn,
acellular cementum remained stunted in Bsp-/- mice, and PDL detachment was present in
all Bsp-/-, but not WT, samples (Figure 2.1N vs. P). Histomorphometry confirmed that
the apparent acellular cementum thickness was significantly reduced in Bsp-/- compared
to WT molars (Figure 2.1R). Alcian blue staining supported diminished acellular
cementum and Goldner’s trichrome staining indicated a lack of mineralized cementum
matrix on Bsp-/- molar surfaces (Figure 2.2). The continuously erupting mouse incisor
features acellular cementum on the lingual root analog, and Bsp-/- incisors featured
reduced cementum thickness and PDL disorganization (Figure 2.3), contributing to a high
rate of incisor malocclusion observed in Bsp-/- mice. The quantity of cellular cementum
covering the apical molar root was unaffected at 60 dpn in Bsp-/- compared to WT molars
(Figure 2.1O vs. Q), though at 26 dpn mineralization was delayed in this layer (Figure
2.4).
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Figure 2.1. Bone sialoprotein is required for proper acellular cementum formation.
(A) Bsp mRNA is expressed by cementoblasts (cb) and osteoblasts (ob) during molar
tooth root development at 14 dpn. (B, C) BSP protein is localized to alveolar bone (b),
acellular cementum (ac), and cellular cementum (cc) at 26 dpn. White box in B is shown
at higher magnification in C to highlight acellular cementum. BSP immunolabeling in
(D) WT alveolar bone is absent in (E) Bsp-/- mice. (F, G) Newly formed acellular
cementum anchors periodontal ligament (pdl) attachment in WT molars. (H, I) Acellular
cementum in Bsp-/- molars is thin compared WT. In contrast to the thickened acellular
cementum in (J, K) WT at 26 dpn, (L, M) Bsp-/- molars feature stunted acellular
cementum, and regions of PDL detachment from the tooth (*) were common, indicating
defects in cementum-PDL interface. PDL detachment is observed in all of the Bsp-/mice, whereas in all of the WT mice the PDL attachment appeared normal. The well
organized attachment of the acellular cementum, PDL, and bone in (N) WT molars at 60
dpn is severely degraded in (P) Bsp-/- molars, where stunted acellular cementum is
associated with PDL disorganization. In contrast, cellular cementum in (O) WT and (Q)
Bsp-/- at 60 dpn is not different in size. (R) Both buccal and lingual acellular cementum
are significantly reduced in thickness in Bsp-/- mice compared to WT counterparts (*
indicated significant difference, p < 0.05). Scale bar is 200 µm in panels A, B, F, H, O,
and Q (original 100X), 50 µm in panels C, D, E, G, I, K, M, N, and P (original 400X),
and 400 µm in panels J and L (original 50X). n=6
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Figure 2.2. Decreased thickness and mineralization of acellular cementum in the
Bsp-/- mouse molar.
(A-F) Alcian blue and nuclear fast red (AB-NFR) staining was used to visualize acellular
cementum in WT and Bsp-/- first molars at 14, 26, and 60 dpn because we found it to be a
sensitive stain for cementum (Methods are described in detail in: Foster, 2012). Briefly,
Bouin’s fixed, demineralized, and paraffin-embedded sections were stained with Alcian
blue stain, followed by counter-staining with nuclear fast red, rendering acellular
cementum bright blue. (A, C, E) Compared to the steady appositional growth of
acellular cementum (ac) in the WT from 14 to 60 dpn, (B, D, F) Bsp-/- molars feature thin
cementum that does not increase in size over this time. (G-H) Goldner’s trichrome
(GTC) staining was used to indicate the relative mineralization of dental tissues, where
mineralized tissues (e.g. bone, dentin) stain green and unmineralized fibrous-collagenous
tissues (e.g. osteoid) stain pink to red. Briefly, undecalcified
glutaraldehyde/formaldehyde fixed tissues were methylmethacrylate-embedded, and
sections stained by a standard protocol for Goldner’s trichrome. (G) Whereas WT
mouse molars at 26 dpn feature a mineralized acellular cementum layer (light green,
flanked by white arrows), (H) Bsp-/- molar teeth exhibit no visible layer between root
dentin (d) and periodontal ligament (pdl), suggesting the thin cementum layer identified
by histology is unmineralized. Tears that appear in the tissue are artifacts from
undecalcified sectioning. Scale bar is 20 µm in panels A-H (original 630X). n=6
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Figure 2.3. Loss of BSP compromises mouse incisor cementum development.
(A, B, E, F) Mouse continually erupting incisors feature a layer of acellular cementum
(ac) on the lingual root analogue. (C, D, G, H) In Bsp-/- mice, incisors display a thin
cementum layer, PDL fiber disorganization (#), and PDL detachment from the root
surface (*) indicating cementum-PDL structural defects. PDL detachment is observed in
all of the Bsp-/- mice, whereas in all of the WT mice the PDL attachment appeared
normal. Scale bar is 200 µm in panels A, C, E, and G (original 100X), and 50 µm in
panels B, D, F, and H (original 400X). n=6
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Figure 2.4. Delayed mineralization in Bsp-/- mouse cellular cementum.
Mineralization of the apical cellular cementum (cc) appeared delayed in Bsp-/- compared
to WT at 26 dpn as evaluated by (A, B) H&E stain and (C, D) Alcian blue stain with
nuclear fast red (AB-NFR) stain (see Figure 2.2 caption for description of methods).
(E,F) Goldner’s trichrome (GTC) staining of undecalcified sections at 30 dpn confirmed
increased cementoid (red layer) at the cellular cementum surface in Bsp-/- compared to
WT molars. Tears that appear in the tissue are artifacts from undecalcified sectioning.
Abbreviations: d=dentin; pdl=periodontal ligament. Scale bar is 100 µm for panels E-F
(original 200X) and 50 µm for panels E-F (original 400X). n=6
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2.3.2

Failure of acellular cementum mineralization in Bsp-/- mice

SEM analysis supported histochemical observations that the thin layer of acellular
cementum on Bsp-/- molar roots was not mineralized, as no mineralized cementum
ultrastructure could be identified on the cervical root surfaces of Bsp-/- molars at 60 dpn,
in contrast to the mineralized cementum layer on age-matched WT molars (Figure 2.5).
We considered developmental possibilities predisposing to inhibition of cementum
formation in Bsp-/- mice. Dentin, required as a foundation for cementum deposition,
appeared sound and well-mineralized in Bsp-/- mice by histology (Figure 2.1) and von
Kossa staining (Figure 2.6A-B). Acellular cementum formation requires migration of
dental follicle/cementoblast precursors to the nascent root surface. Root lining cells were
present in similar numbers in Bsp-/- versus WT first molar roots at 14 dpn (Figure 2.6C).
PDL fringe fibers at the root surface suggested that the proper acellular cementum matrix
was present for cementogenesis (Figure 2.6D-E). Immunostaining revealed deposition of
osteopontin (OPN) on the root surface, confirming functional cementoblasts in Bsp-/mice (Figure 2.6F-I). Markers of local and systemic mineral metabolism were assayed.
TNAP immunolabeling in Bsp-/- versus WT molars (Figure 2.6J-M), and serum alkaline
phosphatase, calcium, and phosphorus, were undiminished in Bsp-/- mice (Table 2.1),
ruling out systemic mineral ion disturbance as an underlying cause of the cementum
defect.
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Figure 2.5. Lack of mineralized acellular cementum ultrastructure on Bsp-/- mouse
molar teeth.
Secondary electron SEM analysis on fractured first molars at 60 dpn indicates that,
compared to the mineralized acellular cementum layer visible in WT molars at various
magnifications (A, C, E), no mineralized cementum ultrastructure can be identified on
the roots of Bsp-/- molars (B, D, F). Some cracking is evident as an artifact of sample
preparation. Abbreviations: enam=enamel; ac=acellular cementum; pdl=periodontal
ligament. Scale bar is 50 µm in panels A and B (original 500X), 10 µm in panels C and
D (original 2,000X), and 2 µm in panels C and D (original 10,000X). n=3
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Figure 2.6. Exploration of potential causative factors for lack of acellular cementum
formation in Bsp-/- mice.
Comparison of dentin mineralization, cementoblast number, collagen fringe fiber
distribution, and tissue nonspecific alkaline phosphatase (TNAP) activity were
performed. Von Kossa staining on undecalcified (A) WT and (B) Bsp-/- molars at 14 dpn
indicated Bsp-/- dentin mineralization (black-stained regions) was comparable to WT. (C)
Cell counts for putative cementoblast root-lining cells performed at 14 dpn revealed no
difference in cell numbers of Bsp-/- vs. WT first molar teeth. Picrosirius red staining
under polarized light indicated that fringe fibers (ff) of the PDL (high intensity yellowish
fibers; indicated by white arrows) were similar in density and distribution in (D) WT vs.
(E) Bsp-/- mouse molars. OPN localized to the acellular cementum (ac) of (F, G) WT and
(H, I) Bsp-/- molars at 14 dpn. TNAP was not altered in the periodontia of (J, K) WT vs.
(L, M) Bsp-/- mouse molars at 14 dpn. Abbreviations: pd=predentin; d=dentin;
pdl=periodontal ligament; ac=acellular cementum. Scale bar is 200 µm in panels F, H, J,
and L (original 100X), and 50 µm in panels A, B, G, I, K, and M (original 400X).
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Table 2.1. Serum biochemistry for Bsp-/- and WT mice.
Below are serum calcium, inorganic phosphorus, and alkaline phosphatase activity in
male mice at 3, 4, and 8 weeks postnatal.

Age

3 wks

4 wks

8 wks

Genotype Sample

Calcium,

Phosphorus,

Alkaline

size

mmol/L

mmol/L

phosphatase, U/L

WT

4

2.62 ± 0.09

3.50 ±0.41

257.25 ± 45.09

Bsp-/-

5

2.64 ± 0.12

3.53 ± 0.19

358.20 ± 65.95

WT

3

2.79 ± 0.60

4.50 ± 1.05

290.00 ± 61.02

Bsp-/-

3

2.57 ± 0.33

4.37 ± 0.96

294.67 ± 93.94

WT

6

2.38 ± 0.04

2.52 ± 0.19

119.00 ± 7.21

Bsp-/-

6

2.37 ± 0.06

2.49 ± 0.27

163.67 ± 12.68 *

* indicates p < 0.01 by independent samples (Student’s) t-test
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2.3.3

Periodontal breakdown in Bsp-/- mice

Defective acellular cementum in Bsp-/- mice preceded a progressive breakdown of
periodontal organization at later ages. WT molars at 26 dpn displayed dense and highly
organized collagen fiber insertions in the cervical root, visualized by picrosirius red
staining under polarized light (Figure 2.7A-B). Conversely, Bsp-/- molars lost PDL
organization in the cervical root by this age (Figure 2.7C-D), a condition that degenerated
further over time (Figure 2.8). Defective cementum-PDL attachment in Bsp-/- molars
allowed for significant down-growth of gingival epithelial tissues into the periodontal
region, initiating a long junctional epithelium (Figure 2.7E-F; Figure 2.9). Periodontal
disarray in Bsp-/- mice was accompanied by increased incidence of root resorption by 60
dpn (Figure 2.7G-J), and appearance of osteoclast-like cells, RANKL immunostaining,
and bone resorption in alveolar bone (Figure 2.7K-N). There was no indication that
inflammation played a significant role in the periodontal breakdown, based on histology
and lack of neutrophil infiltration into the periodontia (Figure 2.10).
Tooth and bone resorption were documented further by SEM and microCT. SEM
revealed extensive pitting in Bsp-/- versus WT molars, concentrated in the cervical roots
(Figure 2.11A-F). Lack of acellular cementum was indicated by clearly visible dentinal
tubules on the external surface of Bsp-/- molar roots. MicroCT analysis revealed
extensive reduction in alveolar bone height in Bsp-/- vs. WT mandibles, particularly along
the lingual aspect (Figure 2.11G-J).
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Figure 2.7. Periodontal breakdown in Bsp-/- mice.
(A, B) Picrosirius red stained sections viewed under polarized light reveal a high degree
of organization and directionality (indicated by high intensity yellowish fibers) of
periodontal ligament (pdl) collagen fibrils between acellular cementum (ac) and bone (b)
in WT molars at 26 dpn. The dark space represents either empty space or disorganized
collagen fiber. (C, D) Bsp-/- molars at 26 dpn feature loss of organization of collagen
fibers in cervical PDL region (#) where detachment (*) is also present. (E) Pan-keratin
immunohistochemistry (red-brown color) indicates a well maintained junctional
epithelium (je) in WT molars at 60 dpn, whereas (F) Bsp-/- molars feature down-growth
and establishment of a long junctional epithelium in association with loss of PDL
attachment. Compared to (G, H) WT molars at 60 dpn, (I, J) Bsp-/- molar teeth feature
extensive root resorption (chevrons). Compared to (K, L) WT molars, Bsp-/- molars at 60
dpn showed (M) localization of receptor activator of nuclear factor kappa-B ligand
(RANKL) near tooth and bone surfaces, and (N) numerous osteoclast-like cells (arrow
heads; large, multinucleated, tartrate resistant acid phosphatase (TRAP) positive) on
alveolar bone surfaces. Scale bar is 200 µm in panels A and C (original 100X), 50 µm in
panels B, D, H, J, L, and N (original 400X), 100 µm in panels G, I, K, and M (original
200X), and 100 µm in panels E and F (original 100X). n=3
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Figure 2.8. Progressive loss of PDL organization in Bsp-/- mice.
Picrosirius red staining viewed under polarized light was used to reveal organization and
directionality (indicated by high intensity yellowish fibers) of periodontal ligament (pdl)
collagen fibrils over the course of root development. The same sections photographed
under non-polarized light are shown to illustrate presence of collagen (pink-red)
regardless of organization. At 14 dpn, a similar level of PDL organization is present in
the nascent roots of (A-C) WT and (D-F) Bsp-/- mouse molars. At 26 dpn, cervical PDL
of (G-I) WT molars is highly organized, with directional collagen fibers radiating from
the root surface. The cervical-most PDL of (J-L) Bsp-/- molars at this age is disorganized
and features periodontal detachment (*). At the advanced age of 60 dpn, (M-O) WT
molar PDL is very highly organized, while (P-R) Bsp-/- PDL has become increasingly
disorganized over the cervical portion. Scale bar is 200 µm in panels A, D, G, J, M, and
P (original 100X), and 50 µm in panels B, C, E, F, H, I, K, L, N, O, Q, and R (original
400X). n=6
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Figure 2.9. Progressive epithelial in-growth in Bsp-/- mouse molars and incisors.
Pan-keratin immunohistochemistry was employed to visualize the dental epithelium
(reddish-brown color) over the course of root development. In the (A) unerupted molar
and (B) incisor of WT mice at 14 dpn, ameloblasts (am) of the enamel organ are
positively labeled by pan-keratin antibodies. (C, D) Junctions of epithelium and the
nascent root of Bsp-/- teeth are well maintained at this early time point. Junctional
epithelium (je) is established in erupted (E) WT molars by 26 dpn, and (F) incisors
feature a well maintained labial-lingual epithelial junction. (G) Bsp-/- molars display
abnormal thickening of the junctional epithelium at 26 dpn, in association with
detachment (*) of periodontal ligament (pdl). (H) Bsp-/- incisors at this age display
epithelial in-growth to the periodontal region of the lingual root analogue, in association
with periodontal detachment (*). While WT (I) molars and (J) incisors display well
maintained epithelial junctions at 60 dpn, Bsp-/- (K) molars feature dramatic epithelial
down-growth into regions of periodontal detachment (*), and (L) incisors also display
extensive detachment (*) and epithelial invasion into the periodontal compartment.
Measurement of epithelial attachment at (M) 26 and (N) 60 dpn indicated a significant
and progressive increase in epithelial down growth in Bsp-/- versus WT molars (p<0.05
by ANOVA and post-hoc Tukey test). Abbreviations: d=dentin; b=bone. Scale bar is
200 µm for all panels A-L (original 100X). n=6
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Figure 2.10. Lack of inflammation during periodontal breakdown in Bsp-/- mice.
Immunohistochemistry was used to localize neutrophils (reddish color) in periodontal
tissues. Despite severe bone and tooth resorption (See Figures 2.7 and 2.11), Bsp-/- mice
did not feature greater presence of neutrophils in the periodontal compartment, compared
to WT at ages 26 dpn (B vs. A) and 60 dpn (D vs. C). (E) Neutrophil staining around a
first molar root in a ligature-induced murine model for peridontitis is included as a
positive control for increased neutrophil infiltration associated with bone destruction.
One month old mouse first mandibular molars were tied with a cotton ligature until tissue
harvest 15 days later. Abbreviations: je=junctional epithelium; d=dentin; b=bone. Scale
bar is 200 µm for all panels A-E (original 100X).
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Figure 2.11. Increased tooth root and alveolar bone resorption in Bsp-/- mice.
Compared to the smooth surface of (A, C) 10-week old WT molars viewed by
backscattered SEM, (B, E) Bsp-/- teeth exhibit abundant pitting (white arrows in B and E)
of the root surface consistent with external root resorption, concentrated on the cervical
portion of the root surface. White boxes in A and B indicate regions shown at higher
magnification in C and E, respectively. Compared to the (D) WT molar root surface at
high magnification, (F) Bsp-/- molar roots display exposed dentinal tubules, indicating
absence of cementum in regions of root resorption. MicroCT revealed that compared to
(G, I) WT mandibles, (H, J) Bsp-/- mandibles display extensive reduction in alveolar
bone height, especially on the lingual aspect (black arrows in H and J). Abbreviations:
M1=first molar; M2=second molar; M3=third molar. Scale bar is 100 µm in panels A
and B (original 50X), 20 µm in panels C and E (original 2,00X), and 1 µm in panels D
and F (original 5,000X). n=3
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2.4

DISCUSSION

BSP is an extracellular matrix protein present in bone and cementum. Here we
demonstrate for the first time that lack of BSP inhibited formation and mineralization of
acellular cementum. Further, reduction and loss-of-function of the acellular cementum in
Bsp-/- mice led to structural defects in the cementum-PDL interface, PDL disorganization,
down-growth of epithelium, and increased tooth and bone resorption. Results collected
here demonstrated that BSP plays a non-redundant role in acellular cementum formation,
likely involved in initiating mineralization and/or promoting appositional cementum
growth. Because of its importance to cementum formation, BSP is essential for
formation of a functional periodontium.

2.4.1

Acellular cementum as a mineralization-sensitive tissue

Lack of BSP led to a severe developmental inhibition of acellular cementum formation,
shown here by histology, histochemistry, immunohistochemistry, and SEM. As a late
stage in odontogenesis, cementum formation depends on a number of prior
developmental stages. Our results suggested that the defect did not result from defective
dentin, lack of migration/position of precursor cells, or root surface collagen fringe fibers
[considered the extracellular matrix proper for acellular cementum (Bosshardt and
Schroeder, 1996)]. Local TNAP deficiency (by IHC), hypophosphatemia, and
hypocalcemia were ruled out as causes of cementum inhibition in Bsp-/- mice. It is
notable that acellular cementum formation is similarly inhibited in the Alpl-/- mouse
model featuring loss of TNAP function (Beertsen et al., 1999; Foster et al., 2012; McKee
et al., 2011). Alpl-/- mice harbor increased levels of the mineral inhibitor pyrophosphate
(PPi) and serve as a model of hypophosphatasia (HPP), where lack of acellular cementum
predisposes to tooth loss (van den Bos et al., 2005). We have demonstrated that
reduction of PPi, in turn, promotes increased acellular cementum formation (Foster et al.,
2011; Foster et al., 2012), and hypothesized that acellular cementum represents a tissue
strongly regulated at the physicochemical level of mineralization, i.e. hydroxyapatite
nucleation and growth. Cellular cementum size was undiminished by loss of BSP,
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though mineralization was delayed at earlier ages; functional consequences of this are
under study. Cellular cementum was unaffected in Alpl-/- mice (Beertsen et al., 1999) and
in mice where acellular cementum increased via decreased PPi (Foster et al., 2012),
supporting the view that these tissues are subject to different developmental influences.
Acellular cementum forms as a progressive mineralization of the PDL collagen fiber
bundles inserting into the root surface. We have previously shown BSP binds collagen
with high affinity (Tye et al., 2005), mediates hydroxyapatite formation (Harris et al.,
2000; Hunter and Goldberg, 1993), and that hydroxyapatite nucleation potency is
increased 10-fold when BSP is incubated with collagen (Baht et al., 2010). Considering
BSP is localized across the width of the acellular cementum (Bosshardt et al., 1998;
McKee et al., 1996), and based on our past and present findings, it is likely that BSP is
critical for proper cementum formation and function.
Another SIBLING protein, OPN, was present at Bsp-/- root surfaces, as in WT controls.
OPN functions as an inhibitor of hydroxyapatite crystal growth in vitro and in vivo
(Boskey et al., 2002; Hunter et al., 1994). Presence of OPN in the absence of BSP may
additionally tip the balance toward inhibition of cementum mineralization. It is also
possible that another function of BSP (e.g. cell adhesion, signaling, etc.) may contribute
to the cementum phenotype of the Bsp-/- mouse, and this is currently under study.

2.4.2

Absence of BSP leads to periodontal breakdown

A functional periodontal complex depends on stable insertion of PDL collagen fibers into
the acellular cementum, as well as ability for remodeling on the bone surface of the PDL
space. We propose that lack of acellular cementum in Bsp-/- mice led to a progressive
degradation of periodontal integrity over time. Lack of PDL-tooth anchorage was
followed by PDL disorganization, epithelial down-growth, and tooth and alveolar bone
resorption. These are hallmarks of periodontal breakdown associated with periodontal
disease, however this phenotype developed without an apparent inflammatory response in
the periodontal compartment, suggesting failure of function/adaptation of the
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periodontium. Similar examples of periodontal degradation have resulted in transgenic
mouse models with compromised periodontal function, e.g. Dmp1 null (Ye et al., 2008)
and periostin null (Rios et al., 2008) mice. Substitution of a soft diet for pelletized chow
is currently being studied to determine the contribution of occlusal stress to incidence of
periodontal breakdown and incisor malocclusion.
An unexpected finding was the increased incidence of tooth and alveolar bone resorption
in Bsp-/- mice. Previous studies employing Bsp-/- mice showed that BSP deficiency
impairs osteoclastogenesis and bone resorption in vivo and in vitro (Boudiffa et al., 2010;
Malaval et al., 2008). Conversely, BSP over-expression increased osteoclastic activity
(Valverde et al., 2008). We propose that increased resorption in the periodontal
compartment of Bsp-/- mice is the result of local loss of integrity and function in a tissue
that functions under high mechanical stress and depends on rapid remodeling for proper
maintenance. While increased presence of RANKL and TRAP-positive osteoclast-like
cells was noted in periodontia of Bsp-/- mice, the cause for increased tooth and bone
resorption is being explored further in this model.
In summary, results from these studies show for the first time that BSP is critical for
acellular cementum formation and periodontal attachment. The role of BSP in acellular
cementogenesis is likely to be in promoting mineralization at the root surface, to anchor
PDL fibers and provide strong attachment of the tooth to the alveolar bone. Loss-offunction of BSP may predispose to periodontal disease through defective cementum-PDL
attachment. Ongoing studies will further elucidate potential roles of BSP in cementum
formation and regeneration, and in wider periodontal biology.
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CHAPTER 3

3

Mechanical Forces Exacerbate Periodontal
Defects in Bsp-null Mice
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3.1

INTRODUCTION

Bone sialoprotein (BSP) is a multifunctional phosphoprotein belonging to the Small
Integrin Binding Ligand N-Linked Glycoprotein (SIBLING) family (Fisher and Fedarko,
2003). BSP localizes primarily to mineralized tissues, including bone, calcified cartilage,
dentin and cementum, where its expression is up-regulated at the onset of mineralization
(Macneil et al., 1994; McKee et al., 1996). In vitro studies have demonstrated that the
integrin-binding RGD sequence in BSP promotes cell attachment, signaling, and
migration (Ganss et al., 1999; Goldberg and Hunter, 2012). In addition, BSP binds
collagen (Baht et al., 2008; Tye et al., 2005) and hydroxyapatite with high affinity
(Goldberg et al., 2001) and promotes mineral formation (Hunter and Goldberg, 1993).
Analysis of the Bsp-/- mouse, during development and repair, revealed decreased growth
and mineralization of long-bones (Holm et al., 2015; Malaval et al., 2008; Malaval et al.,
2009). Lack of BSP also affected osteoclast formation and recruitment negatively,
leading to reduced long-bone turnover (Boudiffa et al., 2010; Malaval et al., 2008).
Previously, we reported that loss of BSP causes inhibition of functional acellular
cementum on molar and incisor tooth roots, hypomineralization of cellular cementum,
and detachment and disorganization of the periodontal ligament (PDL) (Foster et al.,
2013b). In contrast to reduced bone turnover reported in femurs and tibias (Malaval et
al., 2008), we reported increased osteoclastic resorption in alveolar bone of Bsp-/- mice,
associated with increased presence of receptor activator of nuclear factor kappa-B ligand
(RANKL) in the periodontium, increased numbers of TRAP-positive osteoclast-like cells,
cervical resorption of molars, substantial alveolar bone loss, and increased incidence of
incisor malocclusion (Foster et al., 2013b). Collectively, these data support the
interpretation that lack of acellular cementum is the primary defect, leading to PDL
detachment, epithelial downgrowth, and alveolar bone destruction. We hypothesized that
defective periodontal attachment due to lack of acellular cementum played a central role
in the periodontal breakdown observed in Bsp-/- mice, and forces generated by occlusion
contributed to these pathological changes in dentoalveolar tissues. In this study, we
aimed to determine whether reducing masticatory forces through use of soft diet would
ameliorate periodontal dysfunction and malocclusion in Bsp-/- mice. To elucidate the
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pathological mechanisms involved, changes in molar and incisor teeth were analyzed by
micro-computed tomography (microCT) and histology over time.

3.2
3.2.1

MATERIALS AND METHODS
Animals

Animal care followed guidelines of the Canadian Council on Animal Care and Veterinary
Services at the University of Western Ontario. Preparation and genotyping of Bsp-/- and
wild-type (WT) mice, maintained on a mixed 129/CD1 background, were performed as
described previously (Malaval et al., 2008). At 3 weeks of age, Bsp-/- and WT littermates,
offspring from heterozygous mice mating, were randomly assigned to groups fed a diet
(2018 Tekland Global 18% protein, Harlan Laboratories, Indianapolis, IN) either in the
form of hard pellets (hard diet; HD) or soft powder (soft diet; SD) and had access to
water ad libitum. Mice were weighed weekly (3-9 weeks). Experimental endpoints for
histological and radiographic analysis were 4, 8, and 20 weeks.
The mice were observed on a weekly basis to determine onset of malocclusion. Any
form of incisor misalignment was considered a malocclusion. For classification of a
severe malocclusion phenotype, both incisor misalignment and overgrowth need to be
present.

3.2.2

Blood chemistry

Animals were anesthetized with isoflurane gas and whole blood collected by cardiac
puncture. Blood samples were transferred to BD Vacutainer® SST™ tubes and allowed
to coagulate at room temperature for 20 min. After centrifugation at 3,000g for 10 min at
4°C, sera supernatants were collected and stored at -20°C. Serum biochemistry was
analyzed at the NIH Veterinary Services Clinical Chemistry (Bethesda, MD).
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3.2.3

Histology

Long-bones and mandibles used for microCT were harvested, fixed in 10% neutralbuffered formalin solution overnight and stored in calcium-free Hanks' buffered saline
solution. Procedures for histology and analysis of hemi-mandibles were previously
described (Foster, 2012).

3.2.4

Micro-computed tomography

MicroCT analysis of hemi-mandibles was performed using eXplore Locus SP at 80 kVp,
80 µA, with 0.508mm Al filter and exposure time of 1600 msec/frame at 4 frames/view
to obtain 900 views. These images were reconstructed at 13 μm spatial resolution with
calibration and data analysis as described previously (Foster et al., 2013b). Long-bone
images were acquired with eXplore Locus Ultra to obtain 1000 views at 120 kVp, 20 µA,
and 16 msec/view exposure time. Data were reconstructed at 154 μm spatial resolution.
Long-bone lengths were measured between the tips of the medial condyle and greater
trochanter (femurs) or medial malleolus (tibias).
For analysis of hemi-mandibles, regions of interest (ROIs) were identified at three
anatomical positions along the length incisor: alveolar crest, first molar (mesial root),
and third molar. These anatomical positions are relative position of the mandible to the
length of the incisor as shown in Figure 3.3A. Coronal sections at these positions were
used to measure the mineral density, thickness, and areas of incisor enamel, labial dentin
and lingual dentin. For the first molar analysis, ROIs were determined at three positions:
crown enamel and dentin, and root dentin. For all mineral density measurements, 3D
cubical volumes of interest (VOIs; 10 isotropic voxel size) were defined within the ROIs.
Three separate measurements were obtained and averaged for each ROI. The 2D area of
interest was defined by manually drawn contours along the boundaries of the incisors.
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For mandibular molars, mesial root exposure was determined by comparing the distance
between buccal/lingual alveolar ridge crest and cemento-enamel junction to the total root
length. All measurements were performed at the midline of mesial root of first and
second molars. As an indicator of bone loss, the PDL width in the furcation region of
first and second molars was measured.

3.2.5

Measurement of incisor eruption rate

At 8 weeks, WT and Bsp-/- mice (3 mice per group) were anesthetized by isoflurane gas.
Lingual surfaces of mandibular incisors were etched with phosphoric acid gel etchant
(Kerr Corporation, Orange, CA) for 30 sec, then cleaned by wiping with moist gauze.
Incisors were dried completely using gauze, then bonding agent (OptiBond Solo Plus;
Kerr Corporation) was applied to the etched surface and light cured for 20 sec. Dental
composite resin (Premise Flowable; Kerr Corporation) was applied to the incisors and a
small (1-2 mm) piece of stainless steel wire was fixed to the incisors near the socket
margin. Composite was polymerized by UV light. The affixed stainless steel wires are
monitored for 9 days to determine the incisor eruption rate; based on the change in
distance from the fixed wire to the socket margin. A cabinet X-ray (Faxitron X-ray
Corp., Chicago, IL, USA) was used for radiographic analysis of skulls, and a dissecting
stereomicroscope (StereoDiscovery.V8) and digital camera (MRc5, Carl Zeiss
Microscopy Gmbh, Jena, Germany) were used to capture images and make
measurements.

3.2.6

Statistical analyses

Quantitative data are expressed as mean ± standard error. Statistical analyses between
experimental groups were performed using two-way analysis of variance and Bonferroni
post-tests with Prism 5 version 5.03 (GraphPad, La Jolla, CA).
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3.3
3.3.1

RESULTS
Soft diet normalized body weight, long-bone length, and
incisor malocclusion of Bsp-/- mice

In order to analyze the role of masticatory forces on the periodontal phenotype of Bsp-/mice, WT and Bsp-/- mice were assigned to hard (HD) or soft (SD) diet groups. From 3-9
weeks of age, Bsp-/-(HD) mice weighed significantly less than WT(HD) (Figure 3.1A),
consistent with studies on 8-week-old (Bouleftour et al., 2014) and 4-month-old mice
(Malaval et al., 2008). However, WT(SD) and Bsp-/-(SD) groups were not statistically
different in weight. While weight of WT mice fed either diet were not significantly
different, weight of Bsp-/-(SD) was significantly greater than Bsp-/-(HD) at 3-5 weeks, but
not in older mice, suggesting differences become less pronounced with age. These data
suggest that soft diet, at least partially, rescues the reduced body weight phenotype of
Bsp-/- mice. Bsp-/- mice did not exhibit any abnormalities in behavior, fertility, breeding,
and nursing capabilities.
Bsp-/- mandibular incisors featured chalky white enamel, in contrast to the normal yellowbrown coloration in WT and heterozygous mice (Figure 3.1C). Regardless of diet, Bsp-/mice developed malocclusion, with mandibular incisors rotated in a lingual-to-labial
direction compared to WT (Figure 3.1C insets). Over the course of 8 weeks, ~30% of
Bsp-/-(HD) but only ~3% of Bsp-/-(SD) developed severe malocclusion affecting maxillary
and mandibular incisors, causing overgrowth and resulting in dysfunction (Figure
3.1C,D). The onset of these severe malocclusion occurs within the first 5 weeks post
weaning (Table 3.1). WT and heterozygous mice fed either diet did not develop
malocclusion (data not shown). Bsp-/-(HD) mice with severe incisor malocclusion
weighed significantly less than Bsp-/-(HD) with milder incisor malocclusion (Figure
3.1B), suggesting that severe malocclusion, with corresponding malnutrition, may
contribute to the observed bone phenotype.
Previous studies reported shortening of long-bones in Bsp-/- mice fed normal hard pellet
diet at 4 and 16 months of age (Malaval et al., 2008), consistent with our findings at 8
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weeks (Figure 3.1E). However, when fed SD, femur and tibia lengths of Bsp-/- and WT
mice were not significantly different. Further, increased serum alkaline phosphatase
(ALP) activity, a marker of skeletal activity, in Bsp-/- mice (Foster et al., 2013b), was also
normalized with SD (Figure 3.1F). Other blood-chemistry markers, including calcium,
phosphorus, magnesium, sodium, chloride, glucose, albumin, and protein triglycerides
were similar for all groups (Table 3.2). Thus, SD normalized body weight, long-bone
length, serum ALP, and reduced severe malocclusion in Bsp-/- mice.
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Figure 3.1. Soft diet normalizes body weight, bone length, and incisor malocclusion
in Bsp-/- mice.
(A) Between 3 and 9 weeks, Bsp-/- mice fed with hard diet (Bsp-/-(HD)) weigh
significantly less (*) than the WT counterpart (WT(HD)) (n=35-58 for week 3-8; n=27 at
week 9). However, WT and Bsp-/- mice fed soft diet (WT(SD) and Bsp-/-(SD)) are not
statistically different in weight. Between 3 and 5 weeks, Bsp-/-(SD) weigh significantly
greater (#) than Bsp-/-(HD), but not in older mice. (B) Bsp-/-(HD) with severe
malocclusion weigh significantly less (‡) than Bsp-/-(HD) with milder malocclusion,
suggesting this phenotype might be caused by dental dysfunction and malnutrition. (C)
Bsp-/- mice, regardless of diet, developed some degree of malocclusion that is associated
with labial rotation of the incisors, observed by altered location of the cemento-enamel
junction (black arrow in insets). Severe malocclusion of maxillary and mandibular
incisors is prominent in Bsp-/- mice fed hard diet. (D) Over 8 weeks, 10 out of 35
(~30%) Bsp-/-(HD) mice develop severe incisor malocclusion, a feature evident in only 1
out of 35 (~3%) Bsp-/-(SD) mice. (E) In the HD groups, femurs and tibias are
significantly shorter in 8-week old Bsp-/- mice compared to WT, however no differences
were apparent between the two SD groups (n=6). (F) The increased serum alkaline
phosphatase (ALP) activity in Bsp-/- vs. WT is normalized in the SD groups (n=5). For
A, B, E and F, values shown represent means ± SEM; *p < 0.05, **p<0.01, ***p<0.001.
Note: (A) The average body mass for Bsp-/-(HD) mice includes all mice regardless of
degree of malocclusion.
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Table 3.1. The effect of diet on the onset of severe malocclusion in Bsp-/- mice.
Bsp-/- and wild type littermates were fed either a hard or soft diet from the time of
weaning. Each week animals were examined for evidence of severe malocclusion of the
incisors. The onset of malocclusion for Bsp-/- mice were observed within 5 week post
weaning. For each Bsp-/- mouse, the first observation of severe malocclusion was
recorded. No malocclusion was observed in any of the wild type mice.

Number of mice that have first indication of
malocclusion per week
Bsp-/Mice

Week 4

Week 5

Week 6

Week 7

Week 8

Total

35

0

7

2

1

0

10

28.6

35

0

1

0

0

0

1

2.9

Diet
Hard
Diet
Soft
Diet

Malocclusion

N

Rate (%)
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Table 3.2. Serum biochemistry for Bsp-/- and WT mice.
Below are various chemical activity analysis of 8-week-old, which include calcium,
phosphorus, magnesium, sodium, chloride, glucose, albumin, alkaline phosphatase, and
protein triglycerides. n = 4 mice per group.

Genotype

Sodium,

Chloride,

Calcium,

Magnesium,

and Diet

mmol/L

mmol/L

mmol/L

mmol/L

WT (HD)

462.00 ± 4.24

409.50 ± 5.20

2.03 ± 0.14

0.85 ± 0.04

WT (SD)

464.25 ± 1.50

413.25 ± 2.87

2.18 ± 0.08

0.87 ± 0.05

Bsp-/- (HD)

463.50 ± 5.20

413.5 ± 4.50

2.17 ± 0.07

0.83 ± 0.11

Bsp-/- (SD)

465.00 ± 4.90

412.50 ± 1.73

2.27 ± 0.15

0.83 ± 0.09

Genotype

Phosphorous,

Glucose,

Blood Urea

Uric acid,

and Diet

mg/dL

mg/dL

Nitrogen

mg/dL

(BUN), mg/dL
WT (HD)

7.88 ± 0.62

253.50 ± 7.55

2.03 ± 0.14

1.20 ± 0.24

WT (SD)

7.95 ± 0.39

212.25 ± 17.73

2.18 ± 0.08

1.28 ± 0.29

Bsp-/- (HD)

8.10 ± 1.49

240.75 ± 40.50

2.17 ± 0.07

1.13 ± 0.29

Bsp-/- (SD)

8.18 ± 1.28

237.75 ± 16.68

2.27 ± 0.15

1.73 ± 0.51
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Genotype

Albumin,

Cholestrol,

Triglycerides,

Alkaline

and Diet

g/dL

mg/dL

mg/dL

Phosphatase,
U/L

WT (HD)

2.85 ± 0.39

147.00 ± 11.75

144.00 ± 61.73

108.00 ± 5.48

WT (SD)

2.93 ± 0.15

138.00 ± 9.49

138.75 ± 23.03

96.75 ± 7.89

Bsp-/- (HD)

2.93 ± 0.15

135.75 ± 19.81

120.00 ± 57.60

138.75 ± 17.73 *

Bsp-/- (SD)

2.70 ± 0.24

141.75 ± 17.56

151.50 ± 41.10

111.75 ± 18.87

Genotype

Aspartate

Amylase, U/L

Total Protein,

and Diet

Trans, U/L

WT (HD)

63.00 ± 19.44

2347.50 ± 223.41

4.65 ± 0.17

WT (SD)

60.75 ± 35.53

2415.75 ± 262.32

4.58 ± 0.15

Bsp-/- (HD)

45.00 ± 10.68

2386.50 ± 255.60

4.65 ± 0.17

Bsp-/- (SD)

57.00 ± 17.83

2680.50 ± 447.30

4.58 ± 0.15

mg/dL

* indicates p < 0.05 by two-way analysis of variance and Bonferroni post-tests.
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3.3.2

Altered dentin and enamel formation in incisors of Bsp-/- mice

At 4 weeks of age, Bsp-/- incisors appeared similar to WT (Figure 3.2A). However, by 8
weeks, microCT and histology revealed increased dentin thickness and decreased pulp
volume in Bsp-/- mouse incisors compared to WT (Figure 3.2B,C,E,G,I, and Figure
3.3A,B). Incisor dentin thickness measured at the first and third molar increased by 85%
in Bsp-/- mice (Figure 3.3B), whereas enamel thickness was normal at all positions
(Figure 3.4). At first, the incisors appeared to have enhanced mineralization of both
dentin and enamel in the unerupted portion compared to WT incisors (Figure 3.2B, 3.3CD). At the site of eruption (at the alveolar crest), dentin and enamel mineral densities
were equivalent in Bsp-/- and WT. Mineral density of Bsp-/- molar crown and root dentin
were comparable to WT, however, enamel mineral density was elevated by 12.4%
(Figure 3.3E).
Due to these alterations in dentinogenesis and enamel mineralization in Bsp-/- mice,
irrespective of diet type, we analyzed the incisor rate of eruption. Bsp-/- mouse incisors
erupted at a significantly reduced rate compared to WT, 141 vs. 323 m/day, respectively
(Figure 3.5). Therefore, relative alterations in dentin and enamel mineral densities near
incisor apices are likely due to reduced rate of eruption in Bsp-/- mice.
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Figure 3.2. Altered incisor dentin and enamel formation in Bsp-/- mice.
For microCT analysis, 4 different landmarks were chosen: (1) alveolar crest, (2) mental
foramen, (3) first molar, and (4) third molar.

The WT images in (A and B) are

representative of both WT(HD) and WT(SD) since no apparent differences in phenotype
were observed between these WT groups. (A) At 4 weeks of age, microCT analysis
indicates no striking difference in incisors of Bsp-/- mice compared to WT. (B) By 8
weeks of age, microCT images reveal increased dentin thickness (red arrow) and
decreased pulp volume towards the apical end of the incisors in Bsp-/- mice compared to
WT, regardless of diet. In addition, regardless of diet, resorption of enamel and dentin
(green arrow) and incisor-associated bone (white arrowhead) can be seen in Bsp-/- mice.
(C, E, G, I) Histology (H&E stain) confirms increased dentin (DE) thickness and
decreased dental pulp (DP) space in Bsp-/- mouse incisors compared to WT. (D, F, H, J)
Detachment (*) and disorganization of periodontal ligament (PDL) collagen-fiber
bundles in Bsp-/- mouse incisors with Picrosirius red (PR) staining under polarized light.
Soft diet does not normalize dentinogenesis, or PDL attachment in Bsp-/- mouse incisors.
The histological tissues were sectioned at a position relative to the mental foramen
(position 2).
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Figure 3.3. Increased incisor dentinogenesis and enamel mineralization in Bsp-/mice.
(A) Using microCT incisor dentin thickness, area, and mineral density were analyzed at:
(1) alveolar crest, (2) mental foramen, (3) first molar and (4) third molar. Linear
measurements were also performed to determine thickness of incisor enamel, labial and
lingual dentin, as well as cross-sectional area of the dentin and enamel. By 8 weeks of
age, microCT analysis reveals significantly increased dentin thickness (B) and mineral
density (C) in the apical end of the Bsp-/- mouse incisors (incisor position 3 and 4)
compared to WT, regardless of diet. (D) Similar to dentin, the enamel mineral density is
increased significantly at both incisor positions 3 and 4 of the Bsp-/- mice, regardless of
diet. Interestingly, both enamel and dentin mineral density at position 3 and 4 are
equivalent to the erupted incisor tissue densities (position 1) in both WT and Bsp-/- mice,
regardless of diet. (E) First molar crown and root dentin densities are not different in
Bsp-/- compared to WT mice; however, the enamel mineral density is significantly
increased in Bsp-/- molars compared to WT, regardless of diet. For B-E, values shown
represent means ± SEM; n=5; *p < 0.05, **p<0.01, ***p<0.001. Note: Measurements of
thickness and mineral density determined at positions 1 and 2 were similar to each other,
and showed no significant difference between WT and Bsp-/- groups, thus only
measurements at position 1 are shown.
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Figure 3.4. Similar enamel thickness was observed between experimental groups.
Using microCT incisor dentin thickness, area, and mineral density were analyzed at: (1)
alveolar crest, (2) mental foramen, (3) first molar and (4) third molar. Linear
measurements were also performed to determine thickness of incisor enamel. No
significant difference in enamel thickness were observed between the mice groups.
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Figure 3.5. Bsp-/- mice feature reduced rates of incisor eruption.
WT and Bsp-/- mice at 8 weeks old were fixed with dental composite to affix a small
length of stainless steel wire to the labial surface of the mandibular incisors near the
socket margin. (A-D) Radiographs of skulls taken after 9 days indicate the placement of
the composite (COMP) on the incisors. (E, F) Stereomicroscope images show the labial
incisor (INC) surfaces, including the mass of composite, the embedded wire (outlined in
red), and the socket margin (outlined in yellow). Measurements made between the socket
margin and middle of the wire were used to calculate incisor eruption distance and rate.
(G) Bsp-/- mice featured a significantly reduced incisor eruption distance over 9 days, (H)
corresponding to a more than 2-fold significantly reduced rate of eruption, compared to
WT incisors. Graph in (G) shows mean ± SD and graph in (H) shows individual
measurements and mean ± SD. ** indicates p < 0.01 for unpaired t-test (n=3 for each
group).
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3.3.3

Soft diet does not rescue periodontal defects in Bsp-/- mice

Defects noted in acellular cementum, PDL and alveolar bone in Bsp-/- mice prompted us
to determine the role of masticatory forces on these periodontal manifestations. SD did
not rescue PDL detachment and disorganization, and resorption of incisor enamel, dentin,
or associated bone in Bsp-/- mice (Figure 3.2C,E,G,I). Furthermore, between 4 and 20
weeks of age, Bsp-/- mice in both diet groups exhibited similar dramatic loss of alveolar
bone, extensive cervical root resorption (Figure 3.6A), PDL detachment, and epithelial
downgrowth (Figure 3.6B-I). The reduced periodontal structure contributed to premature
loss of teeth, especially third molars, as the Bsp-/- mice aged.
Periodontal structures were analyzed quantitatively at 8 and 20 weeks, including
exposure of molar roots (an indicator of alveolar bone reduction) and width of PDL in the
interradicular region (Figure 3.7A). MicroCT analysis confirmed increased root exposure
for all Bsp-/- molars compared to WT, regardless of diet type (Figure 3.7B). At 20 weeks,
additional loss of alveolar bone in Bsp-/- mice was apparent, especially on the lingual side
(Figure 3.8). At both 8 and 20 weeks, Bsp-/- mice exhibited significantly wider PDL in
the interradicular regions of first and second molars (Figure 3.7C), reflecting bone loss in
that region as well. However, at 8 weeks, Bsp-/-(SD) featured significantly less of a width
increase in PDL than Bsp-/-(HD), indicating diet-associated amelioration of bone loss in
this region. The altered periodontal structure, evidenced by reduced alveolar bone and
wider PDL space (Figure 3.7D), is likely responsible for the observed molar
malocclusion by 8 weeks of age (Figure 3.7E).
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Figure 3.6. Soft diet does not rescue periodontal phenotype in Bsp-/- mice.
(A) MicroCT images demonstrate progressive tooth root resorption (green arrow) and
alveolar bone (AB) loss (red arrow) in both Bsp-/- diet groups at 8 and 20 weeks. (B, D,
F, H) H&E stained first-molar sections in 8-week-old mice reveal that Bsp-/- mice in both
diet groups feature identical phenotypes marked by lack of acellular cementum (white
arrowhead), PDL detachment (*), and epithelial (EP) downgrowth (yellow arrow). (C, E,
G, I) Picrosirius red (PR) stained sections under polarized light microscopy demonstrate
loss of PDL collagen organization in both Bsp-/- diet groups.
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Figure 3.7. Progressive periodontal breakdown in mandibles of Bsp-/- mice.
(A) MicroCT cross-sectional images reveal alveolar bone loss around molar roots (green
arrows). For all three molars (M1-M3), root exposure on buccal (blue arrow) and lingual
(orange arrow) aspects, and PDL width in the interradicular region (yellow line) were
determined. (B) MicroCT analysis confirms significantly increased molar root exposure
in all three molars in 8-week-old Bsp-/- mice, with no difference in root exposure
observed between both Bsp-/- diet groups. (C) At both 8 and 20 weeks, Bsp-/- mice
exhibited significantly wider PDL in the interradicular regions of first and second molars
compared to WT, regardless of diet. At 8 weeks, Bsp-/- mice in the SD group exhibit
significantly less increase in PDL width than the HD group, indicating diet-associated
amelioration of bone loss in this region.

As expected, Bsp-/-(SD) showed further

widening of PDL width at 20 weeks compared to 8 weeks due to progressive alveolar
bone loss. At 8 weeks, (D) extensive alveolar bone loss around the molar roots (green
arrows) contributes to loss of periodontal support that lead to (E) molar malocclusion
(red arrows). For B and C, values represent means ± SEM; n=5; *p < 0.05.**p<0.01,
***p<0.001. Abbreviations: M1 = first molar; M2 = second molar; M3 = third molar.
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Figure 3.8. Further extensive alveolar bone resorption is seen in older Bsp-/- mice.
Quantitative microCT analysis of 20-week-old Bsp-/-(SD) mice revealed continuing progressive loss of alveolar bone, with more profound bone loss on the lingual aspects of
M1-M3. Values represent means ± SEM; n=5; *p<0.05, **p<0.01, *** p<0.001.
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3.4

DISCUSSION

We hypothesized that the periodontal manifestations in Bsp-/- mice resulted from absence
of acellular cementum, with the resulting loss of PDL attachment and associated
abnormal mechanical forces leading to tooth dysfunction and periodontal tissue
destruction. We tested this hypothesis using a diet designed to reduce masticatory forces,
thus reducing mechanical stress on the periodontal apparatus. Soft diet was unable to
diminish periodontal breakdown associated with Bsp-/- mouse molars, including PDL
detachment and disorganization, severe and progressive alveolar bone loss, and
resorption of tooth root surfaces, indicating that masticatory forces are not primary
factors in those pathological changes. However, SD almost eliminated severe incisor
malocclusion in Bsp-/- mice, supporting the hypothesis that occlusal loading contributed
to the malocclusion phenotype. Surprisingly, SD normalized body weight, long-bone
length, and serum ALP activity in Bsp-/- mice, suggesting that tooth dysfunctions
predispose Bsp-/- mice to feeding problems and nutritional deficits that affect body and
skeletal growth, and that provision of SD improves post-weaning nutrition. Another
surprising finding was Bsp-/- incisor phenotype of enhanced dentinogenesis and enamel
mineralization that is likely due to a slower eruption rate. This study demonstrates the
importance of BSP in maintaining proper periodontal function and alveolar bone
remodeling, and points to dental dysfunction as causative factor of skeletal defects
observed in Bsp-/- mice.

3.4.1

Role of altered mechanotransduction in Bsp-/- mice periodontal
breakdown

In this study, we demonstrated a progressive and severe alveolar bone loss in Bsp-/- mice,
in contrast to reduced long-bone turnover in vivo and reduced osteoclast activation in
vitro reported previously (Malaval et al., 2008). We propose two potential causal factors
to account for the discrepancy in turnover between long-bone and alveolar bone in Bsp-/-
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mice: (1) excessive traumatic forces, or (2) unloading of alveolar bone resulting in altered
mechanotransduction.
In normal function, alveolar bone undergoes frequent loading during mastication and is
subject to continuous remodeling to accommodate tooth function (Sodek and McKee,
2000). The PDL is a mechanosensitive tissue that provides connection between tooth
root and supportive alveolar bone acting as a pool of progenitor cells, a source of
vascularity and innervation, and, importantly, as a shock-absorber helping to prevent
tissue damage under the forces generated by tooth use (Beertsen et al., 1997). Alveolar
bone operates as a functional unit with the non-mineralized PDL, and proper mechanical
and biological signals between PDL and alveolar bone are critical to maintain functional
homeostasis of the periodontal apparatus (Ho et al., 2013; Wise and King, 2008).
Masticatory forces are transmitted through the PDL generally in an occlusal-apical
direction before being distributed to the surrounding alveolar bone (Meikle, 2006; Milne
et al., 2009), including buccal and lingual alveolar ridges, interdental bone, and
interradicular bone in multi-rooted teeth.
Alveolar bone resorption can result from excessive compression forces or occlusal stress
by stimulation of osteoclastogenesis through local up-regulation of RANKL, such as
directed resorption on the compression side during orthodontic tooth movement (Kook et
al., 2011; Sanuki et al., 2010; Walker et al., 2008; Wise and King, 2008). Up-regulation
of RANKL, often associated with inflammatory-mediated bone resorption (Yoshinaga et
al., 2007), was evident in the PDL region of Bsp-/- mice, although inflammatory cells
were not observed (Foster et al., 2013b). Furthermore, loss of PDL attachment and
epithelial downgrowth in Bsp-/- mice compromises the shock-absorbing function of the
PDL, disturbing the stress-distribution function of the periodontium, and subjecting the
bony socket to increased and possibly traumatic compression forces during mastication.
Extensive resorption of alveolar bone in Bsp-/- mice was most evident in the cervical root,
where load-bearing horizontal and oblique PDL fibers enter bone as Sharpey’s fibers. In
contrast, traumatic hyperocclusion in mouse molars is more associated with bone and
tooth resorption near the apex and in the interradicular bone (Walker et al., 2008).
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Secondly, alveolar bone resorption can also result from absence of mechanotransduction
from the PDL. Alveolar bone formation occurs as the tooth root forms and remodels in
response to changes in tooth use (e.g. orthodontics), and disappears in the absence of
teeth (e.g. edentulous ridges) (Hansson and Halldin, 2012; Wise and King, 2008). These
processes are regulated by the PDL, as both a mechanotransductor supplying mechanical
stimuli to bone, and as cellular source of biological signals including regulators of bone
homeostasis (e.g. RANKL and osteoprotegerin (OPG)). The tooth-PDL-alveolar bone
functional unit can be understood through application of the mechanostat theory
introduced by Harold Frost (Frost, 1987), which proposes that proper functional loading
is necessary to maintain structural integrity in bone through balanced resorption and
formation. Similar to edentulous ridges, where lack of mechanical stimuli leads to
osteopenia and alveolar ridge resorption (Hansson and Halldin, 2012), Bsp-/- mice may
experience alveolar bone loss as a result of disturbance of tooth attachment and reduced
functional loading.
The inability of SD to ameliorate periodontal breakdown in Bsp-/- mice supports the
hypothesis that loss of PDL attachment and altered mechanotransduction are contributors
to reduction in alveolar bone in Bsp-/- mice. Limitations of the study include inability to
measure true mechanical forces in mouse periodontia, and inability to control chewing of
other hard materials (e.g. cage wires, bedding) that could introduce unrecognized occlusal
trauma into the SD group.

3.4.2

Malocclusion and altered incisor formation in Bsp-/- mice

While SD did not alter periodontal breakdown around molar teeth, it almost completely
rescued the severe incisor malocclusion in Bsp-/- mice. This finding strongly supports
non-physiological distribution of occlusal forces as a causative factor for incisor
malocclusion. We also demonstrate, for the first time, evidence of molar misalignment
and malocclusion in Bsp-/- mice, likely due to PDL detachment coupled with occlusal
stress, similar to the incisor.
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These data favor dental dysfunction and malnutrition as factors contributing to low body
weight, reduced long-bone length, and elevated serum ALP in Bsp-/- mice. Previous
studies have demonstrated Bsp-/- mice fed on normal hard pellet diet were smaller with
shorter long-bones (Bouleftour et al., 2014; Malaval et al., 2008), and increased serum
ALP (Foster et al., 2013b). These parameters were normalized with provision of SD to
Bsp-/- mice. Studies on periostin-null mice, which exhibit a similar periodontal
breakdown and incisor malocclusion, also report similar rescue with SD in body weight
and long-bone length (Rios et al., 2005). Additionally, pain associated with tooth
dysfunction in enamelin-null mice resulted in malnutrition and reduced body weight,
which was rescued by SD (Chan et al., 2013). These parallel observations support the
interpretation that post-weaning malnutrition from malocclusion contributes to the bone
and weight phenotype in Bsp-/- mice. However, all bone changes in Bsp-/- mice, do not
necessarily stem from tooth dysfunction and malnutrition. We and others have shown
early delays in long-bone ossification in Bsp-/- mice (Bouleftour et al., 2014; Holm et al.,
2015). Serum ALP is a commonly used biomarker for bone formation and mineralization
(Yadav et al., 2012). In the Bsp-/- mice, elevation of ALP activity may serve as a
compensatory mechanism for the demonstrated skeletal hypomineralization described in
(Bouleftour et al., 2014). SD helps to reduce the severe malocclusion in Bsp-/- mice,
ameliorating the skeletal defect, which in turn is reflected by normalized serum ALP.
Another surprising insight is related to the rapid incisor dentin and enamel mineralization
in Bsp-/- mice. Dentin is reported to include BSP (Fujisawa et al., 1993; Qin et al., 2001),
yet Bsp-/- molar dentin appeared normal (Foster et al., 2013b), and confirmed by microCT
analysis in this report. Enamel is formed from dental epithelium and suspected to include
BSP (Chen et al., 1998). The question arises as to why the incisor is so dramatically
affected by loss of BSP. We determined that Bsp-/- incisors erupt at a slower rate than
WT, causing the appearance of enhanced or accelerated dentinogenesis and enamel
mineralization towards the apex. Alterations in Bsp-/- incisor eruption could result from
periodontal dysfunction due to lack of cementum and also, indirectly, chronic occlusal
trauma. Previous studies indicate that migration of PDL fibroblasts contributes to the
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continuously erupting rodent incisor (Beertsen et al., 1997). Several other mouse models
have similar incisor enamel and/or dentin phenotype including periostin-null mice (Rios
et al., 2005; Rios et al., 2008), OPG-null mice (Sheng et al., 2010), Vitamin D receptornull mice (Zhang et al., 2009), and integrin α11β1-null mice (Popova et al., 2007). We
propose that periodontal dysfunction and resulting lower rates of incisor eruption may
underlie dentin and enamel changes in all of these models.

3.4.3

Limiting factors of the studies

The use of SD reduces the occlusal forces during mastication in comparison to hard diet.
However, to address the role of occlusal forces on acellular cementum in the Bsp-/- mice
we can incorporate a similar strategy used in the periostin null mice. This method
requires weekly trimming of one side of the mandibular incisors using surgical clippers.
The other side of the mandibular incisors will be used for comparison (Rios et al., 2008).
Using this model they demonstrated that occlusal hypofunction was achieved. In the
study, the reduced incisors were able to rescue the enamel and dentin resorption observed
in the incisors of periostin-null mice. However, for our study, the surgical trimming of
the incisors will introduces additional forces, which may have an effect on the integrity of
the cementum-pdl interface of the Bsp-/- incisor.

3.5

CONCLUSION

This study provides new insights into the role of BSP in the formation and maintenance
of the periodontium, confirming the importance of BSP for acellular cementum formation
that cannot be corrected by diet.
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CHAPTER 4

4

Healing of rat calvarial defects with nanohydroxyapatite/ poly(ester-urethane) scaffolds
loaded with low dose rhBMP-2
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4.1 INTRODUCTION
Large bone defect repair generally requires surgical intervention and the use of
biomaterials, combined with growth factors, as a temporary filler to promote de novo
bone formation. Various biomaterials such as autologous bone, allogeneic devitalized
bone, resorbable ceramics, polymers, and ceramic/polymer composite have been used in
clinical and research settings to enhance bone repair. In general, biomaterials need to
provide structure, rigidity, and a medium that enables cell and blood vessel infiltration.
Due to the lack of osteoinductive property of most synthetic biomaterials, recombinant
human bone morphogenetic protein-2 (rhBMP-2), which is one of the most prevalent
growth factor used clinically due to its high potency to induce bone formation, are
commonly added to scaffolds to promote tissue regeneration. Of relevance, various
studies have shown that the addition rhBMP-2 is effective in promoting the in-growth of
cells and bone tissue regeneration (Brown et al., 2011; Fricain et al., 2013; Kim and
Hollinger, 2012; Li et al., 2009). Since rhBMP-2 has been shown to be primarily
activated during fracture healing (Yu et al., 2010), it is important to maintain the presence
of rhBMP-2 at the defect site during the bone repair process. For clinical application, in
2002, the Federal Drug Administration approved the InFUSETM bone graft, which is a
porous collagen sponge that acts as a vehicle to deliver 12 mg of rhBMP-2. However,
this high dose of rhBMP-2 is required to be clinically effective due to the poor retention
of the growth factor in the collagen sponge. Not only is rhBMP-2 costly, but at high
doses, patients would be at potential risks of adverse side effects that includes heterotopic
bone formation, unnecessary immune response and even cancer (Carragee et al., 2011;
Epstein, 2013). Since retention and slow release from scaffolds would be optimum, it is
important to develop a strategy that utilizes appropriate biomaterials with the right
properties as a carrier of low dose rhBMP-2, without compromising its effectiveness.
Here, for the first time, we investigate the effectiveness of a novel poly(ester-urethane)
(PU) scaffolds incorporated with nano-sized hydroxyapatite (nHA) as the carrier of
rhBMP-2, and mediator of bone repair.
In recent years, PU-based scaffolds have been extensively developed and shown to have
potential applications for the tissue regeneration. Various studies have demonstrated
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success using PU-based scaffold for tissue repairs in bone (Hofmann et al., 2008;
Kavlock et al., 2007; Li et al., 2009), cartilage (Dresing et al., 2014; Lee et al., 2005), and
other soft tissues (Gogolewski et al., 2008; Guan et al., 2005; Guelcher, 2008; Guelcher
et al., 2008). The PU-based scaffolds used in this study were designed to have porous
interconnected network that allows for cell and blood vessel infiltration (Laschke et al.,
2009; Laschke et al., 2013). In addition, the scaffolds are biocompatible and have
viscoelastic property for easy physical fitting into the bone defects, as shown in previous
studies (Hofmann et al., 2008; Laschke et al., 2009; Laschke et al., 2013; Lee et al., 2005;
Pirvu et al., 2015). Furthermore, the incorporation of nHA particles into the PU matrix
was able to improve its material stiffness (Boissard et al., 2009) and increased its capacity
to bind proteins such as serum albumin and fibrinogen (Laschke et al., 2010b). The
incorporation of nHA particles did not appear to affect the scaffolds' biocompatibility and
ability to allow for angiogenesis to proceed within its porous network (Laschke et al.,
2009).
In this study, in vitro experiments were done on the novel nano-sized hydroxyapatiteincorporated poly(ester-urethane) (nHA/PU) scaffolds to determine the ability of the
biomaterial to support osteoblastic cell culture. In addition, a well-established rat
calvarial defect model (Cacciafesta et al., 2001; Kim et al., 2008; Mardas et al., 2008;
Sawyer et al., 2009) was also utilized to validate the effectiveness of the nHA/PU
scaffolds in delivering low-dose rhBMP-2 for guided bone regeneration. The bone repair
were assessed using micro-computed tomography (microCT), histology and mechanical
testing.

4.2
4.2.1

MATERIALS AND METHODS
Scaffold preparation

The biodegradable PU solution was synthesized in a one-step solution polycondensation
as previously described in detail (Laschke et al., 2010b). The process involved the use of
1,6-hexamethylene diisocyanate (Sigma-Aldrich, Milwaukee, WI), poly(-caprolactone)
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diol (MW = 530 g mol-1, Sigma-Aldrich, Milwaukee, WI), and 1,4,3,6-dianhydro-Dsorbitol as reactants. Dibutyltin dilaurate (Fluka, Buchs, CH) was used a catalyst for the
reaction and N,N-dimethylformaide (Fluka, Buchs, CH) was used as a solvent. To create
nHA/PU solution, nHA (Biomaterials US, Ltd., USA) particles, ranging in size from 50
to 200 nm, were dispersed into a PU solution. The nHA mass fraction added was 10
wt.% of the PU solution. Prior to usage, the nHA particles were washed with ethanol and
dried at 100°C under vacuum (Laschke et al., 2010b). The nHA/PU scaffolds were
prepared using a salt leaching-phase inverse process as previously described (Boissard et
al., 2009; Gorna and Gogolewski, 2006; Laschke et al., 2010b). This method involved a
vigorous mixing of nHA/PU solution with porogen (sodium phosphate heptahydrate
dibasic salt; Fluka, Buchs, CH) until a homogeneous paste was obtained. The paste was
then poured into a cylindrical mould and left in air to allow for slow evaporation of the
solvents. The salt was leached out by extensive washing in water, which created porous
nHA/PU sponges. In order to produce scaffolds of consistent thickness, the sponges were
cut using a water jet system. In this study, the scaffolds were prepared with a circular
dimension of 5.5 mm and 1 mm thickness with pore sizes ranging from 90 to 300 m.
The scaffolds were washed in ethanol, dried under vacuum, and sterilized in ethylene
oxide prior to use in the studies.

4.2.2

In vitro rhBMP-2 release kinetics

Three nHA/PU scaffolds were each incubated with 1 g of rhBMP-2 (R&D systems,
Minneapolis, MN) diluted into 25 l of saline solution for 24 h at 4°C. Control scaffolds
were incubated in an equal volume of saline. After 24 h incubation, each scaffold was
immersed and agitated in 1 ml of phosphate buffered saline (PBS) to remove unbound
rhBMP-2. To determine the release kinetics of the bound rhBMP-2 from the nHA/PU
scaffolds, the samples were further incubated at 37°C in 1 ml PBS in microcentrifuge
tubes. At 3, 24 and 72 h, the PBS solutions were replaced with fresh PBS and 100 l of
the supernatant used to quantify the concentration of the rhBMP-2 using a Human BMP2 Quantikine ELISA kit (R&D systems, Minneapolis, MN) according to the
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manufacturer's instructions. The accumulated rhBMP-2 release kinetics were expressed
as percentage of the rhBMP-2 bound to the nHA/PU scaffold.

4.2.3

Cell isolation, culture conditions and cell viability

Bone marrow was isolated from male Sprague-Dawley rats (Charles River Laboratories
International, Wilmington, MA) aged 11-12 weeks (325-375 g) by flushing the tibia and
femur marrow canal with culture medium consisting of Iscove's Modified Dulbecco's
Medium (IMDM) supplemented with 10% fetal bovine serum (FBS), 1% penicillinstreptomycin and 1% L-glutamine (Life Technologies, Carlsbad, CA). The recovered
cells enriched in mesenchymal stromal cells (MSC) were cultured in culture medium in
75 mm2 flasks (NUNC) at 37°C in 5% CO2 for 3 days, and then sub-cultured using
0.05% Trypsin-EDTA solution. Cells at passage 2 were used for subsequent studies.
Prior to cell seeding, the nHA/PU scaffolds (n=3 for each group; experiment conducted in
triplicate) were incubated for 24 h at 4°C with either 25 l saline solution or 1 g of
rhBMP-2 in 25 µl saline solution. In addition, nHA/PU scaffolds that were pretreated
with 1 µg rhBMP-2 and used in the 72 h rhBMP2 release kinetics study were also used in
the studies outlined below. Rat MSC were seeded onto the control and rhBMP2pretreated nHA/PU scaffolds at a density of 3.5 x 105 cells/scaffold and incubated in 24well plates (NUNC). After 1 h incubation, the MSC-seeded scaffolds were placed
between a sandwich construct consisting of 2 Teflon-rings in a clean 24-well plate in
order to fully immerse the scaffolds in culture medium. The MSC-seeded scaffolds were
then cultured in osteoblast differentiating medium consisting of culture medium
supplemented with 50 µg/ml ascorbic acid and 2 mM -glycerophosphate. The
mineralizing medium was changed every 2 days for the duration of the culture. For a
control group, nHA/PU scaffolds with no cells were also incubated with differential
media.
After 4 weeks of culture, the scaffolds were washed with Hank's Balanced Salt Solution
(HBSS) three times, fixed with 4% paraformaldehyde for 20 min, and processed for cryo-
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section. In order to determine the relative level of matrix mineralization, the
cryosectioned scaffolds were stained for calcium mineral deposition with Alizarin red
staining solution (1% w/v, Ricca Chemical company, Arlington, TX) for 20 min at room
temperature. To remove excess dye, the sections were washed with deionized water three
times (5 min incubation time for each wash).

4.2.4

Scanning Electron Microscopy (SEM) analysis

nHA/PU scaffolds cultured with MSC for up to 4 weeks were fixed with 4%
glutaraldehyde solution (Sigma-Aldrich, Oakville, ON) for 15 min, after which the
scaffolds were gently rinsed three times with Phosphate Buffered Saline (PBS) solution.
Samples were dehydrated in a series of ethanol dilutions (25%, 50%, 75%, 90% and
100%) for 5 min at each concentration and then air-dried. The samples were osmiumcoated, and imaged with a Leo 1540 XB FIB/SEM using secondary electron mode at 120 kV (Carl Zeiss, Western Nanofabrication Facility, University of Western Ontario,
London, ON).

4.2.5

Animals and surgery

Male Sprague-Dawley rats aged 11-12 weeks (325-375 g) were maintained on a standard
rat diet (5P00-Prolab RMH 3000; LabDiet, St. Louis, MO). Animal experiments were
conducted in accordance with guidelines of the Canadian Council on Animal Care
(CCAC) and Animal Care and Veterinary Services (ACVS), University of Western
Ontario.
Animals were anaesthetized with isoflurane gas and the heads positioned in a stereotaxic
frame. The dorsal part of the cranium was shaved, aseptically prepared, and a midline
incision of approximately 20 mm created. The skin flaps were kept opened using a
retractor and the underlying periosteum was removed. A 5-mm stainless steel trephine
drill (Salvin Dental Specialties, Charlotte, NC) was used to create circular defects on

122

each of the parietal bones, thus creating 2 defects in each rat. The diameter of the wound
is usually slightly larger at approximately between 5.1 to 5.3 mm. Caution was exercised
to prevent damage to the dura membrane by adding a custom-made stainless steel sleeve
(1.5 mm depth shorter) around the trephine drill. In addition, in order to prevent heat
damage of the host bone, irrigation with saline solution was done throughout the
procedure. The nHA/PU or rhBMP-2 (1 g) treated nHA/PU (nHA/PU/rhBMP-2)
scaffolds without any cells were then implanted and secured in place by double crossing
4-0 Vicryl suture attached to the temporalis muscles. The amount of rhBMP-2 used per
scaffold in the study was determined by previous studies that used low dose of rhBMP-2
(La et al., 2010; Schofer et al., 2011b). For the negative control group, the defect holes
were left empty without any double crossing suture. In order to prevent any
contamination, both defects in each rat were implanted with scaffolds of the same
treatment group. The skin was closed using 4-0 Silk sutures. Antibiotics and analgesic
were administered to the animals and they were allowed to recover for up to 12 weeks
post surgery, after which they were euthanized with CO2 gas inhalation according to
CCAC and ACVS guidelines. At 6 and 12 weeks post-op, the implants and surrounding
bone were recovered, fixed with 10% buffered formalin overnight at 4°C and prepared
for histology. Samples for mechanical testing were not fixed but stored in HBSS
containing 0.10% sodium azide.

4.2.6

In vivo micro-computed tomography analysis

At 0, 2, 6, 12 weeks post-op, animals were anaesthetized with isoflurane gas and placed
in a microCT scanner (eXplore speCZT; GE Healthcare, London, ON). The scans were
performed using a standardized live-animal protocol (90 kVp, 40 µA, 900 views, 16 ms
per view). Images were reconstructed at a spatial resolution of 50 m and calibrated with
a cortical bone phantom (SB3; Gammex RMI, Middleton, WI) having a hydroxyapatite
equivalent of 1,100 mg/cc (White, 1978). Data were analyzed with MicroView ABA
version 2.2 (GE Healthcare).

123

In order to visually determine the new bone formation, the 2D Maximum Intensity
Projection (MIP) and 3D isosurface images of the rat calvarial bones defect sites were
constructed. As for the quantification of the newly formed bone, a cylindrical region of
interest (ROI, 5 mm x 1.5 mm) was positioned within the center of each defect site. The
bone mineral content (BMC) within the ROI was determined linearly by assigning a
value threshold for air (-1000 Hounsfield unit (HU)), water (0 HU), soft tissues (below
700 HU), trabecular bone (above 700 HU), cortical bone (above 1700 HU) and SB3
phantom (2700 HU). The total new bone volume (BV) formation was determined by
adding all the voxels with HU value above 700 within the ROI. Bone-to-total tissue
volume ratio (BV/TV) was determined by calculating the ratio of total voxels with HU
value above 700 over the total voxels of the ROI. As for the cortical bone volume
(CBV), only voxels with HU above 1700 were considered for calculation. Twenty
calvarial defects were measured at 2 and 6 weeks and twelve calvarial defects were
measured at 12 weeks for each group (nHA/PU and nHA/PU/rhBMP-2 up to 12 weeks;
empty control only up to 6 weeks).

4.2.7

Histological Analysis

The parietal bones were fixed with 10% formalin for 24 h and then decalcified in 0.65 M
ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate, pH 7.4, at 37°C for 2
weeks. After dehydration, the samples were embedded in paraffin, and sectioned at 5 m
thickness. The sagittal sections were stained with hematoxylin and eosin (H&E) and
Masson's Trichrome (MT). The percentage of new bone area in the defect was quantified
for each treatment group by comparing pixel quantities using image J. Color threshold
tools in Image J were used to differentiate pixels correspond to new bone or other nonmineralized soft tissue.
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4.2.8

Mechanical Testing

The implants with surrounding parietal bones were recovered (undecalcified) , stored in
HBSS containing 0.10% sodium azide overnight and then tested on an Instron machine
(ElectroPuls E1000, Instron, Norwood, MA). Native bone samples were also used for
comparison. For the mechanical testing, a custom-made stainless steel push-out test jig
was made. The base and cap had a 5.5-mm hole in the center to allow for the penetration
of the cylindrical punch during testing. Each specimen was then mounted with
cyanoacrylate adhesive onto the base and adjusted to make sure that the center of the
implant was aligned with the center of the hole. The cap was then placed and tightened
in order to prevent bowing of the specimen during testing.
Indentation tests on the center of implants were performed using the Instron machine
with a 100-N load cell and 1-mm diameter indenter in order to assess the quality of the
newly formed bone within the defects. The rate of indentation was 1 mm/min to a
maximum load of 2N (± 0.003N). The load and displacement data were recorded during
the testing procedure and the elastic modulus was calculated with the following formula
used in previous studies. (McKee et al., 2011a; McKoy et al., 1999):
E = S(1 - v2)/d
Where S is the indentation stiffness or the slope of the load-displacement in its linear
region (N/mm) and d (mm) is the diameter of the indenter. The Poisson's ratio (v) of
bone was assumed to be 0.3 (Busa et al., 2005). Five to eight specimens were used for
each group.
Push-out tests were conducted to evaluate the osteointegration of the implant with the
surrounding host calvarial bone using the Instron machine with a 2-kN load cell and 1
mm/min rate. An indenter probe of 5-mm diameter with a flat polished end was
fabricated for the test. Load and displacement data were recorded during the testing
procedure and all specimens were tested to failure. Five to seven specimens were used
for each group.
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For both mechanical test, intact native rat parietal bones of the same age were used as
controls.

4.2.9

Statistical Analyses

Quantitative data were expressed as means ± standard error. Statistical analyses among
groups were performed using two-way analysis of variance (ANOVA) and Bonferroni
post-tests with Prism 5 version 5.03 (GraphPad Software, La Jolla, CA). p<0.05 was
considered to be statistically significant.

4.3
4.3.1

RESULTS
Cells adhesion and nHA/PU scaffold properties

The sponge-like nHA/PU scaffolds are comprised of a network of multi inter-connected
channels with pore sizes that varied from 90-300 m (Figure 4.1 A1-E1). To determine
whether cells attach, spread out and thrive in the scaffold, rat long bone MSC cells at
passage 2 were seeded onto the scaffold and cultured for 2 or 4 weeks, fixed and
observed by SEM. The images demonstrate cells adhering to the wall of the internal
pores in the scaffolds (Figure 4.1 C2 and C3). In addition, collagen fibrils are also
evident (Figure 4.1 E2 and E3). These data showed that the nHA/PU scaffold is a
biocompatible surface that permits MSC attachment and secretion of extracellular matrix.

4.3.2

In vitro bioactivity of bound rhBMP-2

In order to determine whether the nHA/PU scaffolds binds rhBMP-2 and releases it over
time, the release profiles of rhBMP-2 from the scaffolds were determined (Figure 4.2).
Of the 1 µg added to the scaffold, approximately 8.77 ± 1.25% of the rhBMP-2 was not
bound. After a 3 h incubation period, approximately 5% of the originally bound rhBMP-
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2 was released into the incubation medium. At 24 and 72 h incubation period, only very
low levels (a total of less than 2%) of the growth factor were released. These results
imply that the nHA/PU scaffolds were able to retain the bound rhBMP-2 very well.
After the 72 h incubation period, no direct measurement of bound rhBMP-2 was
attempted due to the harsh demineralizing and denaturing solutions that would be
required to recover the rhBMP-2 from the scaffold. However, to confirm the presence of
bioactivity of the growth factor, these nHA/PU/rhBMP-2 scaffolds, after the 72 h
incubation and buffer exchanges, were seeded with MSC and cultured in differentiation
media for 4 weeks. The control groups included untreated scaffolds and scaffolds treated
with fresh 1 µg rhBMP-2 incubated overnight at 4°C without washing, prior to MSC
seeding. Both rhBMP-2 treated scaffold groups appeared to have enhanced
mineralization based on Alizarin Red staining, compared to the control untreated scaffold
group with or without cells (Figure 4.3 A and B). Minimal red staining were observed in
groups without any cells seeded after 4 weeks cultured with differential media. These
results suggest that even after incubation for 72 h, with buffer exchanges, the rhBMP-2
treated scaffolds still retained activity consistent with the presence of rhBMP-2.
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Figure 4.1. SEM images of nHA/PU scaffolds incubated with mesenchymal stromal
cells (MSC).
Panels A1-3 are representative images of the surface and cross-sectional area of the
nHA/PU scaffold with or without cell culture. Panels B1-3 and D1-3 are 200X
magnification of the area marked by white boxes as shown in panel A. At higher
magnification (C1, E1), inter-connected pores can be seen in the nHA/PU scaffolds.
Macro (white star) and micro (white triangle) pores ranging from 90 to 300 µm and
aggregates of hydroxyapatite nanoparticles (white circle) are evident in the nHA/PU
scaffold. By 2 weeks, extracellular matrix made by the cells can be observed covering
the surface of the scaffold (B2,B3). At 2 (C2, E2) and 4 weeks (C3, E3), cells (white
arrow head) were seen adhering on the walls of the nHA/PU scaffolds. Collagen fibrils
(white arrow) secreted by the cells and aggregates of hydroxyapatite (red arrow head)
were observed on the walls and across the pores of the nHA/PU scaffolds.
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Figure 4.2. In vitro cumulative release of rhBMP-2 from nHA/PU scaffolds.
At 72 h, only approximately 7% of the originally bound rhBMP-2 was released from the
scaffold. n=3
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Figure 4.3A. Control nHA/PU scaffolds show minimal alizarin red staining.
The images in panel A1-2 and B1-2 represent transverse and cross-sectional sections,
respectively, of control nHA/PU scaffolds without cells stained with alizarin red. The
nHA/PU scaffolds were incubated with differential media for 0 day and 4 weeks. At
both time point, minimal red staining was observed.
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Figure 4.3B. The presence of rhBMP-2 in nHA/PU scaffold increased matrix
mineralization when cultured with MSC cells.
The images in panel A1-3 and B1-3 represent transverse and cross-sectional sections,
respectively, of treated and control nHA/PU scaffolds stained with alizarin red. The
histology sections of nHA/PU/rhBMP-2_72h group appears to have similar quantity of
alizarin red staining compared to nHA/PU/rhBMP-2 group, which confirms that a
significant proportion of the rhBMP-2 remains associated with the nHA/PU scaffolds
even after 72 h of incubation and 3 washes. Both nHA/PU groups treated with rhBMP-2
qualitatively appear to have elevated alizarin red staining compared to nHA/PU control
group.

133

4.3.3

rhBMP-2 treated nHA/PU scaffolds promote bone repair

An established rat calvarial defect model was used to determine whether the rhBMP-2
treated nHA/PU scaffolds (nHA/PU/rhBMP-2) promotes in vivo bone repair. At 2 weeks
post-op, bone in-growth into the defects from host bone and some island-like bone
spicules were observed in the nHA/PU/rhBMP-2 group, indicated by faint grey coloring
in the MIP images that filled the defects (Figure 4.4). This was not observed in the
untreated nHA/PU control group. At 6 weeks, the defect sites of the rhBMP-2 treated
group were filled with apparent bone, whereas minimal bone formation was observed in
the untreated nHA/PU control group. Even after 6 weeks, for the group with empty hole,
no new bone formation was observed in the middle of the defects (data not shown). Most
of the very limited bone in growth was from the periphery of the defects. Therefore no
further measurement was conducted for this group.
The bone mineral content (BMC), new total bone volume (BV), percentage of bone-totissue volume (BV/TV) and cortical bone volume (CBV) of the nHA/PU/rhBMP-2 group
were significantly higher compared to nHA/PU group at all three time points (Figure
4.5A to D). Interestingly, between 6 and 12 weeks, no significant increase in new bone
formation was observed in either group as shown in Figure 5B and C. However, the
BMC values at 12 weeks were significantly higher compared to values at 6 weeks, which
was likely due to the continuous process of remodeling and densification of the newly
formed bone. This was confirmed by the observed significant increase in percentage of
CBV between the three time points for both nHA/PU/rhBMP-2 and control groups
(Figure 4.5D).
Detailed histological analysis confirmed that rhBMP-2 treated nHA/PU scaffolds
enhanced bone formation in vivo compared to the control scaffolds (Figure 4.6). At 6
weeks, compared to the control group, the nHA/PU/rhBMP-2 group demonstrated
significantly more new bone formation. This is indicated by union bone formation
adjacent to the dura-membrane and island-like bone spicules throughout the defect sites.
At higher resolution, fibrous tissue and individual island-like bone spicules, of which
some appeared to contain osteons, can be seen forming in the defects of both groups.
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However, the amount of fibrous tissue appears to be greater in the control group
compared to the nHA/PU/rhBMP-2 group (Figure 4.6, panels C and D). Quantitative
measurements on histological sections were also done to determine the amount of new
bone formed in the defects. At both 6 and 12 weeks, nHA/PU/rhBMP-2 group showed
significantly more new bone area compared to nHA/PU group (Figure 4.7). However,
similar to microCT analysis, the histological analysis demonstrated that similar amount of
total bone formation was observed for both groups. This result confirmed that, after 6
weeks post-op, minimal increase of new bone formation was observed for both groups.
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Figure 4.4. MicroCT images of bone repair for nHA/PU and nHA/PU/rhBMP-2
groups.
Maximum Intensity Projection (MIP) and 3D isosurface images of rat calvarial defects
indicate that the presence of rhBMP-2 enhanced bone formation in the calvarial defect
sites. By 6 weeks, new bone fills most of the defect site in the nHA/PU/rhBMP-2
scaffold group and the radiodensity of the newly formed bones also appeared to be more
dense over time, which is an indication of increasing mineral content. The image on the
left describes the cylindrical region of interest (ROI), coloured yellow to highlight area
that was analyzed. (n=12 for 2 and 6 weeks, n=20 for 12 weeks)
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Figure 4.5. Quantitative microCT analysis of bone repair.
MicroCT analysis showed that (A) bone mineral content (BMC); (B) new bone volume
(BV); (C) percentage of bone-to-tissue volume (BV/TV) and (D) percentage of cortical
bone volume, were enhanced in nHA/PU/rhBMP-2 scaffold group compared to nHA/PU
scaffold group at 6 and 12 weeks. Data represents mean ± standard error (n=20 for 2 and
6 weeks, n=12 for 12 weeks, *p<0.05, **p<0.01, ***p<0.001).
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Figure 4.6. Histology and microCT analysis of rat calvaria at 6 and 12 weeks.
Both microCT and histology analyses confirmed that the presence of rhBMP-2 in
nHA/PU scaffolds enhanced bone formation in vivo. (Panel A and B) Sagittal sections of
nHA/PU/rhBMP-2 group showed extensive bone healing compared to nHA/PU group.
Staining consists of H&E (Panel A and C; dark pink – mineralized bone) and Masson’s
Trichrome (Panel B and D; teal – collagen and less mineralized bone, dark purple red –
mature bone). Arrows indicate edge of the bone defect adjacent to host bone (HB).
Arrowheads indicate island-like new bone formation in the defect sites. Triangle
indicates continuous in-growth of new bone formation from the host bone adjacent to the
dura membrane. (Panel C and D) At a higher magnification, defects containing nHA/PU
scaffolds are predominately filled with fibrous tissue (#); however, mineralized bone (*)
can also be observed. For the nHA/PU/rhBMP-2 scaffold group, island-like bone
formation can be seen throughout the defect; especially at 12 weeks post-implantation.
MicroCT images of coronal (Panel E) and sagittal (Panel F) sections confirm the
demonstration of new bone formation indicated by histology.
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Figure 4.7. Quantitative histological analysis of explanted tissues at 6 and 12 week.
For both time points, nHA/PU/rhBMP-2 group have significantly higher amount of new
bone area within the original defect compared to nHA/PU group. Data represents mean
± standard error (n=8 for both 6 and 12 weeks, ***p<0.001).
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4.3.4

Mechanical test analysis

To test the mechanical property of the newly formed bone and degree of osteointegration
of implant-host bone, push-out and indentation tests were performed on the bone repair
sites. Based on the indentation experiments, at 6 weeks, the elastic modulus was
significantly higher (15-fold) for the nHA/PU/rhBMP-2 group compared to the untreated
nHA/PU control group; however, the value was still significantly lower compared to
native bone (Figure 4.8A). By 12 weeks, the elastic modulus of the nHA/PU/rhBMP-2
had doubled, and interestingly, the level was statistically similar to native bone modulus
at 6 weeks but not at 12 weeks. The modulus for the untreated nHA/PU group remained
unchanged over time (Figure 8A). The push-out tests indicates that at 6 weeks,
approximately 50% more load was required to fracture the bone-implant osteointegration
region of the nHA/PU/rhBMP-2 group compared to the untreated control and no scaffold
groups (Figure 4.8B). This suggests that the new bone in-growth from the host bone
integrated well with the scaffold within the defect site. Interestingly, the no scaffold
group also registered similar fracture load compared to untreated control group, which
was likely due to the in-growth of new bone from the host bone around the defect. The
similarity in fracture load for the nHA/PU control and no scaffold group indicates that the
presence of the nHA/PU scaffold did not hinder the bone in-growth from the host tissue.
This result suggests that the nHA/PU scaffold is biocompatible and well tolerated in vivo.
Unexpectedly, at 12 weeks, the required load to fracture the bone of the untreated
nHA/PU control and nHA/PU/rhBMP-2 groups were similar to those at 6 weeks, which
indicates that the bone-implant osteointegration region strength had potentially peaked
(Figure 4.8B). This value was approximately 30% lower compared to native bone
strength.
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Figure 4.8. Mechanical testing of rat calvarias at 6 and 12 weeks.
(A) Micro-indentation tests indicated that the stiffness of newly formed bone in
nHA/PU/rhBMP-2 group was significantly higher compared to nHA/PU group at both
time points. (B) Push-out tests showed a significant difference in load of fracture for
nHA/PU/rhBMP-2 group compared to the nHA/PU group. The bone-control was done
on undamaged calvarial bone. Data represents mean ± standard error (micro-indentation
test: n = 6 for bone groups and n= 8 and 5 for all other groups at 6 and 12 weeks,
respectively; push-out test: n = 5 for no scaffold group and n=7 for all other groups;
*p<0.05, **p<0.01, ***p<0.001).
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4.4

DISCUSSION

In tissue engineering, biocompatibility, degradation rate, osteoconductive, and
osteoinductive are important properties of effective biomaterials for bone repair.
However, most biomaterials are not osteoinductive in nature; thus, the addition of various
growth factors or bioactive proteins is a common practice. Clinically, rhBMP-2 is the
most prevalent growth factor for bone tissue regeneration due to its high potency in
driving osteoprogenitor cell differentiation to osteoblastic cells, which leads to de novo
bone formation. A high dose of rhBMP-2 is usually required in the clinical setting to
ensure the enhancement of bone repair. Bone repair studies in small animals have also
demonstrated that increasing the dose of rhBMP-2 enhances the rate and amount of bone
formed (Angle et al., 2012; Ben-David et al., 2013; Murakami et al., 2002). However,
there are potential side effects due to the high levels of growth factor that include
excessive bone formation, adverse immune responses, and cancer (Carragee et al., 2011;
Epstein, 2013). Therefore, delivery strategies that utilize low levels of rhBMP-2 and still
achieve sufficient bone formation are required. In this study, we demonstrate that the
novel nHA/PU scaffold loaded with low-dose rhBMP-2 is effective in promoting bone
regeneration. In addition, rhBMP-2 appeared to bind well onto the nHA/PU scaffold as
indicated by the low concentration of rhBMP-2 released from the scaffold after 72 hr
incubation.

4.4.1

nHA/PU scaffold supports cell attachment and binding of
rhBMP-2

Previous studies have shown that the inter-connective pore networks in PU scaffolds
allow for the in-growth of cells and blood vessels (REF). Furthermore, these scaffolds
have an inherent mechanical stiffness and viscoelastic properties, which are important for
bone tissue engineering applications (Boissard et al., 2009; Gogolewski et al., 2008). In
addition, the PU scaffolds have good angiogenic properties and are effective in
supporting cell attachment, growth, and differentiation (Hofmann et al., 2008; Laschke et
al., 2010a; Laschke et al., 2012; Laschke et al., 2013). The addition of nHA to PU
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scaffolds allow for improved mechanical stiffness and enhanced binding of proteins
(Laschke et al., 2010b). SEM images demonstrated that even though most of the mineral
crystals appear to be embedded, some are found on the surface including the walls of the
pores as shown in Figure 1.
Hydroxyapatite has been shown to effectively bind proteins as demonstrated in its use as
a chromatography resin (Matsumoto et al., 2004; Shen et al., 2008; Xie et al., 2010).
Thus, this property of HA likely contributes to the binding of rhBMP-2 to the nHA/PU
scaffold. Of relevance, rhBMP-2 was shown to have higher binding to HA-coated
ceramic surfaces than uncoated surfaces and, more importantly, be released at a slower
rate (Autefage et al., 2009). Our in vitro study indicates that approximately 7% of the
initial bound rhBMP-2 to the HA/PU scaffold was released by 72 hrs, which is a similar
release rate described in previous studies that utilized methods of rhBMP-2 entrapment
within nano/micro-particle vehicles for controlled release (Li et al., 2009; Li et al., 2015;
Xie et al., 2010).
rhBMP-2 has been shown to promote differentiation of osteoprogenitor cells to
osteoblastic cells which in turn leads to increased matrix formation with subsequent
calcification. This osteoinductive property of the rhBMP-2 is crucial for promoting bone
repair, including the parietal bones which undergo intramembranous ossification.
Previous studies have indicated that intramembranous ossification begins within the first
few days of fracture and BMP expression is up-regulated in the proliferating
osteoprogenitors during this process (Sfeir et al., 2005). Therefore, the presence of
rhBMP-2 within the interconnected porous network of the scaffold may promote
osteogenic differentiation, which in turn will speed up the bone repair process.
In order to confirm the bioactivity of the bound rhBMP-2, the treated nHA/PU scaffolds
were seeded with MSC and cultured. Based on alizarin red staining, the rhBMP-2 treated
nHA/PU scaffolds qualitatively appeared to have higher amount of matrix mineralization
compared to untreated nHA/PU scaffolds. Interestingly, nHA/PU/rhBMP-2 that were
incubated and washed in media for 72 h prior to the addition of the MSC, also appeared
to have similar levels of mineralization compared to the nHA/PU scaffolds treated with
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fresh rhBMP-2. This result confirmed that rhBMP-2 was present and active even after
the 72 h incubation period that included multiple washes.
A limitation of our study was the difficulty to quantify certain metrics from the 3D cell
cultures in the porous scaffolds. Analysis using microscopic techniques quantifying cell
numbers or mineral content require reproducible and representative sections of the 3D
scaffolds with equivalent cell numbers spread evenly through the structure. Staining of
the polymers for cells, for example, showed an uneven distribution, with few cells found
at or near the surface of the polymers. Furthermore, histological sections through the
scaffold show inconsistent pore sizes and distribution.
In order to determine cell numbers in the scaffold, we tried to quantify DNA content.
Unfortunately, no reliable data was obtained. For example, using TRIzol reagent,
inadequate levels of DNA was extracted from the scaffolds, whereas measureable levels
were extracted from cultures in the absence of scaffolds.

4.4.2

nHA/PU scaffold treated with low dose rhBMP-2 enhanced
repair of calvarial bone defects

MicroCT analyses have been reliably used to quantify level of mineralization with
regards to the spatial distribution of new bone within the calvarial defects (Cowan et al.,
2007; Sawyer et al., 2009; Umoh et al., 2009). In agreement with these studies, our CT
bone volume measurements and histological analyses both demonstrated increased
formation of new bone in the nHA/PU/rhBMP-2 scaffolds compared to untreated
scaffolds. A number of studies have shown that the addition of rhBMP-2 to various
scaffold materials promotes bone repair. In studies that used the rat calvarial defect
model, large doses (5 µg or more) of rhBMP-2 were loaded into each scaffold of various
compositions, which includes synthetic materials such as β-tricalcium phosphate,
polylactic and polyglycolic acid gel, and poly ε-caprolactone/tricalcium phosphate, as
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well as natural materials such as collagen and autogenous bone chips (Luvizuto et al.,
2011; Sawyer et al., 2009; Schwarz et al., 2009). In comparison, our nHA/PU scaffold
was only loaded with 1 µg of rhBMP-2 and was shown to be as good if not better in
generating new bone. In our study, the percentage of bone covering the defect volume
(BV/TV) for the rhBMP-2 treated group was 75.48 ± 8.36 % at 12 weeks, which is
greater than the findings reported by Sawyer et al and Luvizuto et al (Luvizuto et al.,
2011; Sawyer et al., 2009). Of relevance, other studies using the calvarial defect model
have also demonstrated that lower doses (174 - 500 ng) of rhBMP-2 per scaffold
(polylactic acid based) can achieve relatively moderate bone formation covering
approximately 20-45% of the defect volume (La et al., 2010; Schofer et al., 2011b). The
length of time in which rhBMP-2 is present in the scaffold during bone repair has been
noted to be crucial for bone formation. Previous studies have demonstrated that longterm delivery of rhBMP-2 (1 µg or greater) promoted greater amount of bone formation
compared to a short-term delivery method. However at a very low dose of rhBMP-2 (500
ng of less), both delivery methods resulted in the same amount of bone formation (La et
al., 2010). In our system, the effectiveness of nHA/PU/rhBMP-2 scaffold in bone repair
is likely attributed to its porous interconnected network that allows for in-growth of cells
and vascularization system, and also its ability to absorb and bind growth factors and
other bioactive proteins. The slow release of rhBMP-2 from nHA/PU scaffold
contributed to the high percentage of new bone volume seen in this study. Of relevance,
most studies that used high dose of rhBMP-2 usually have a fast rhBMP-2 release profile
from the scaffold. For example, Sawyer et al. indicated that almost all of the bound
rhBMP-2 was released from the poly ε-caprolactone/tricalcium phosphate/collagen
scaffold within 10 hours of incubation (Sawyer et al., 2009).
No adverse inflammatory response was observed in any of the treatment groups,
supporting that the nHA/PU scaffold is biocompatible as previously shown (Dresing et
al., 2014; Laschke et al., 2010b). The mode of healing between the rhBMP-2 treated
scaffolds appears to differ compared to the control scaffold group. In the control group,
containing only the untreated scaffold, minimal new bone formation was observed, with
most observed at the edge of the defect and some island-like bone formation in the
interior of the scaffold. In contrast, use of the rhBMP-2 treated scaffold resulted in
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widespread healing throughout the defect site. This result also confirmed our in vitro
study, which showed that the rhBMP-2 treated nHA/PU scaffold was effective in
promoting cell migration and differentiation within the scaffold.
At all three time points, we found that BMC, BV, BV/TV of rhBMP-2 treated nHA/PU
scaffolds were significantly higher compared to those of the control scaffold group. By 6
weeks, the BV/TV analyses indicated that approximately 70% of the defects were filled
with bone. However, this BV/TV value was statistically similar to that at 12 weeks,
which suggests that the rate of bone formation was significantly reduced after 6 weeks
and likely approaching the limits of bone growth. Other studies have also shown that
new bone growth was significantly reduced after 8 weeks. (Schofer et al., 2011a). In
comparison, the average BMC and the percentage of cortical bone volume in the defect
were significantly higher at 12 weeks compared to 6 weeks. Together with the BV/TV
values, these data indicate that bone remodeling was likely the main process during this
post 6-week repair period. Thus, this data highlights the importance of promoting and
maximizing new bone growth at early stages of the bone repair.
Of relevance, previous in vivo studies using a subcutaneous model demonstrated that
BMPs induced both chondrogenesis and osteogenesis (Kuboki et al., 2001; Wang et al.,
1990). Similarly, in vitro studies also have shown that BMP induces cartilage formation
using muscle-derived cells (Sampath and Reddi, 1983; Sato and Urist, 1984). However,
it is possible that the type of ossification during bone repair depends on location and type
of bone. For example, the parietal bones are known to be formed via intramembranous
ossification and during the bone repair, however in this study we did not analyze for
markers of cartilage formation within the calvarial defects.
Mechanical testing on the repaired bone defects was also performed in this study since it
is another parameter that is crucial in evaluating the quality of new bone. Two types of
mechanical test models were utilized: micro-indentation and push-out test. The microindentation test has previously been shown to be useful in determining the elastic
modulus of newly formed bone (Sawyer et al., 2009). At both 6 and 12 weeks, the elastic
modulus of the newly formed bone at the center of the defect were significantly higher
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for the nHA/PU/rhBMP-2 group compared to the control scaffold group, though it is still
lower than that of native bone. The latter was expected since histological and microCT
analyses suggest that the newly formed bone had not been fully remodeled even by 12
weeks. In order to determine the quality and strength of the osteointegration, the load of
fracture at the implant-bone boundary was obtained using the push-out test. The results
indicate that significant higher load of fracture was required for the nHA/PU/rhBMP-2
group compared to control group; but this value was still lower compared to that of native
bone. Interestingly, the control group has a similar load of fracture value compared to the
no-scaffold group, which indicates that the mechanical strength at the osteointegration
boundary is mainly due to the normal bone in-growth at the periphery of the defect.
In conclusion, this study demonstrated that the nHA/PU scaffold has a high binding
affinity with rhBMP-2. Combined with low dose rhBMP-2, the nHA/PU scaffold was
able to effectively promote bone repair by 6 weeks. This data indicates that nHA/PU is
an ideal scaffold for bone tissue engineering.
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CHAPTER 5

5

Effect of bone sialoprotein treated nanohydroxyapatite/ poly(ester-urethane) scaffolds
on bone formation
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5.1

INTRODUCTION

BSP is an acidic phosphoprotein highly expressed in mineralized tissues such as skeleton
and dentition (Fisher and Fedarko, 2003; Ganss et al., 1999). It is also a member of
Small Integrin-Binding Ligand, N-Linked Glycoprotein (SIBLING) group and a major
component of non-collagenous proteins in bone. Similar to other SIBLING proteins,
BSP contains several highly conserved functional domains. These included a collagenbinding domain, two hydroxyapatite nucleation regions and an integrin recognition site
(RGD motif, which is involved in cell attachment, migration and signaling) (Goldberg
and Hunter, 2012). BSP has been previously shown to be a potent nucleator of
hydroxyapatite (HA) (Hunter and Goldberg, 1993). In addition, the attached phosphate
has been demonstrated to be an important modification that regulates the HA nucleation
potency, in particular at the Serine-136 position (Baht et al., 2010).
Mice with Bsp gene ablated (Bsp-/-) have impaired bone growth and mineralization.
Early studies by the Malaval group have shown Bsp-/- mice to have shortened long bones,
decreased bone mineral density, delayed mineral formation, thinner cortical bone
thickness, and greater trabecular bone volume, as well as reduction in osteoclast
formation and activity, which resulted in low bone turnover compared to wild type (WT)
mice (Boudiffa et al., 2010; Malaval et al., 2008). In femoral defect model, Bsp-/- mice
also displayed delayed bone repair compared to WT control (Malaval et al., 2009;
Monfoulet et al., 2010). All these defects seen in Bsp-/- mice suggest that BSP plays a
crucial role in bone development and mineralization. Furthermore, studies reported by
Wang and Glimcher indicate that BSP promoted new bone formation in vivo (Wang et
al., 2006; Xu et al., 2007). In these studies, the collagen-BSP scaffolds were able to
induce some mineral formation along the dura membrane within 4 days of implantation
in rat calvarial defect. In addition, by day 7, cell proliferation, matrix mineralization, and
angiogenesis were found within the BSP-treated implant.
The physiological importance of BSP and its functional importance in skeletal
development has been the main focus of research on BSP. However, minimal research
has been done testing BSP as a potential therapeutic reagent for promoting bone repair.
In this study, we investigate the effectiveness of BSP-treated poly(ester-urethane) (PU)
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scaffolds in promoting bone repair. PU based scaffolds have been extensively studied
and shown to have potential tissue engineering applications in tissues such as bone
(Hofmann et al., 2008; Kavlock et al., 2007; Li et al., 2009), cartilage (Dresing et al.,
2014; Lee et al., 2005), and other soft tissue (Gogolewski et al., 2008; Guan et al., 2005;
Guelcher, 2008; Guelcher et al., 2008) regeneration. The PU scaffolds are
biocompatible, biodegradable and have viscoelastic properties for easy physical fitting
into the bone defects (Hofmann et al., 2008; Laschke et al., 2009; Laschke et al., 2013;
Lee et al., 2005; Pirvu et al., 2015). For bone tissue engineering application, nano-sized
hydroxyapatite (nHA) particles were incorporated into the PU-based (nHA/PU) scaffolds
to improve the material stiffness (Boissard et al., 2009) and also to increase its capacity to
bind proteins such as albumin and fibrinogen (Laschke et al., 2010b).
In this study, in vitro experiments were conducted to determine the amount of BSP that
can bind onto the nHA/PU scaffolds. Furthermore, the BSP-treated nHA/PU scaffolds
were cultured with MSC to validate whether the presence of BSP can improved cells
attachment. In addition, rat calvarial defect model will be utilized to validate the
effectiveness of BSP-treated nHA/PU scaffolds in promoting bone repair. Microcomputed tomography (microCT) and histological analysis will be used to monitor the
rate of bone repair.

5.2
5.2.1

MATERIALS AND METHODS
Scaffold preparation

The biodegradable PU solution was synthesized in a one-step solution polycondensation
as previously described in detail (Laschke et al., 2010b). The process involved the use of
1,6-hexamethylene diisocyanate (Sigma-Aldrich, Milwaukee, WI), poly(-caprolactone)
diol (MW = 530 g mol-1, Sigma-Aldrich, Milwaukee, WI), and 1,4,3,6-dianhydro-Dsorbitol as reactants. Dibutyltin dilaurate (Fluka, Buchs, CH) was used a catalyst for the
reaction and N,N-dimethylformaide (Fluka, Buchs, CH) was used as a solvent. To create
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nHA/PU solution, nHA (Biomaterials US, Ltd., USA) particles, ranging in size from 50
to 200 nm, were dispersed into a PU solution. The nHA mass fraction added was 20
wt.% of the PU solution. Prior to usage, the nHA particles were washed with ethanol and
dried at 100°C under vacuum (Laschke et al., 2010b). Both PU and nHA/PU scaffolds
were prepared using a salt leaching-phase inverse process as previously described
(Boissard et al., 2009; Gorna and Gogolewski, 2006; Laschke et al., 2010b). This method
involved a vigorous mixing of PU or nHA/PU solution with porogen (sodium phosphate
heptahydrate dibasic salt; Fluka, Buchs, CH) until a homogeneous paste was obtained.
The paste was then poured into a cylindrical mould and left exposed to air to allow for
slow evaporation of the solvents. The salt was leached out by extensive washing in
water, which created porous PU or nHA/PU sponges. In order to produce consistent
thickness scaffolds, the sponges were cut using water jet system. In this study, the
scaffolds were prepared with a circular dimension of 5.5 mm and 1 mm thickness with
pore sizes ranging from 90 to 300 m. The scaffolds were washed in ethanol, dried
under vacuum, and sterilized in ethylene oxide prior to use in the studies.

5.2.2

BSP expression and purification

Recombinant rat BSP (rBSP) was expressed in Escherichia coli strain BL21(DE3) cells
and purified by fast protein liquid chromatography (FPLC) as described previously (Baht
et al., 2010; Tye et al., 2003). To phosphorylate the protein, rBSP was treated with
casein kinase 2 (CK2) in reaction buffer [150 mM sodium chloride (NaCl), 10 mM
magnesium chloride (MgCl2), 1 mM dithiothreitol (DTT), 0.1 mM adenosine
triphosphate (ATP) and 50 mM tris(hydroxymethyl)aminomethane-hydrochloride (TrisHCl); pH 7.4] as described previously (Baht et al., 2010). Phosphate content was
determined by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry
(Department of Biochemistry, UWO, London, ON).
Native bovine BSP (bBSP) was purified from the long bones of a still-born calf. The
procedure followed methods previously described in detail for purification of native rat
BSP (ratBSP) (Goldberg and Sodek, 1994). In brief, bone chips were first washed 3
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times with phosphate buffered saline (PBS) containing proteinase inhibitor (PI) [100 mM
amino caproic acid, 5 mM benzamidine HCl, 5 mM N-ethyl maleimide, and 1 mM
phenylmethylsulfonyl fluoride (PMSF)] solutions followed by a series (3-4 times) of
freeze-thaw cycles for 24 h in order to fracture the bone to allow for removal of inner
blood and cells from bone cavities. Then the bone chips were incubated in chloroformmethanol solution overnight in order to dissolve and remove fats and lipids. The next
step involved the extraction of the bone chips with 4.0 M guanidine hydrochloride/TrisHCl buffer containing PI (4 x 24 h incubations) to remove unwanted proteins not
associated with bone mineral. Finally, the mineral-associated proteins were extracted
with 0.5M ethylenediaminetetraacetic acid (EDTA)/Tris-HCl buffer containing PI
solutions (4 x 24 h incubations).
The extracted protein solution was concentrated using an Amicon ultrafiltration cell and
YM10 membranes (cut-off, 10 KDa) (EMD Millipore, Etobicoke, ON) with at least 2
buffer exchanges with Q-buffer A (50 mM Tris-HCl, 7 M urea, pH7.4) chromatography
solution. The concentrated protein solution was diluted with Q-buffer A solution and
then passed through Q Sepharose Fast Flow (Fast Q) column (1 x 10 cm; Pharmacia
Biotech, GE Healthcare Life Sciences, Mississauga, ON) connected to an FPLC system
to separate the proteins based on charge. The proteins were eluted with a linear gradient
of NaCl (0 - 1.2 M) at a flow rate of 2.5 ml/min. The fractions containing the proteins of
interest were then collected and pooled together. Aliquots of the fractions were also run
on 12.5% polyacrylamide gels using the Phastgel system (Amersham Biosciences, GE
Healthcare Life Sciences, Mississauga, ON) to confirm the presence of the protein. After
electrophoresis, the gels were stained with Stains-All and silver nitrate (Goldberg and
Warner, 1997). The proteins were re-chromatographed on Fast Q column and then
finally by gel filtration using a Superdex 200 PG column (1.6 x 60 cm; Pharmacia
Biotech, GE Healthcare Life Sciences, Mississauga, ON) with S-buffer [50 mM
Tris/HCl, 0.2 M NaCl, and 4 M urea; pH 7.4] to separate proteins based on molecular
size, as described previously (Goldberg and Sodek, 1994). The fractions enriched with
BSP were pooled and dialyzed with 10 mM ammonium bicarbonate for 72 h at 4°C using
Spectra/Por dialysis membrane (cut-off, 12-14 kDa) (Spectrum Laboratories, Rancho
Dominguez, CA). After dialysis, the final solutions were aliquoted and lyophilized. The
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purity and quantity of the protein samples were determined using Bicinchoninic acid
(BCA) assay (ThermoFisher Scientific, Burlington, ON), amino acid analysis
(Macromolecular Crystallography Facility, Department of Biochemistry, UWO, London,
ON), and MALDI mass spectrometry (Bruker® Reflex IV MALDI TOF MS, MALDI
Mass Spectrometry Facility, Department of Biochemistry, UWO, London, ON).

5.2.3

In vitro prBSP binding experiment

PU and nHA/PU scaffolds were first incubated in 500 l of phosphate buffered saline
(PBS) solution for 1 h. The scaffolds were then transferred and incubated with either 5,
10 or 20 g of phosphorylated rBSP (prBSP) diluted into 60 l of PBS solution for 24 h
at 4°C. After 24 h of incubation, the scaffolds were centrifuged and the supernatants
collected to determine (by sodium dodecyl sulfate - polyacrylamide gel electrophoresis
(SDS-PAGE) analysis) the amount of unbound prBSP. The scaffolds were then washed
with 60 l of PBS solution (4 times, 5 min each time) and 60 l of 0.5 M NaCl solution
(for 5 min) to remove loosely bound prBSP. Finally, the prBSP scaffolds were eluted
from the scaffolds using 60 l of SDS loading buffer. For SDS-PAGE analysis, 10 l of
the 60 l supernatants from each step were collected and mixed with 10 l of 2 times
concentrated SDS loading buffer. The solutions were denatured at 95°C for 5 min prior
to loading onto the gels. The amount of bound prBSP (that were eluted with SDS-PAGE
loading buffer) was estimated by comparing the relative pixel-to-intensity ratio of the
stained protein bands with the total of unbound, washed, and eluted bands on the
acrylamide gels after electrophoresis.

5.2.4

Cell isolation, culture conditions and cell viability

As previously mentioned, BSP has a RGD motif which plays a role in cell signaling and
attachment. In this study, we would like to verify that the presence of BSP on the
nHA/PU scaffolds may increased the amount of cells bind onto the scaffolds.
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Three in vitro experiments were done in the study. In the first experiment, C3H10T1/2
cells were used to determine the effect of prBSP on cell attachment. Each nHA/PU
scaffold was incubated for 24 h at 4°C with either 150 l of PBS solution or 150 µl of
prBSP-PBS solution (containing 20 g of prBSP). Approximately 1.2 x 106 of
C3H10T1/2 cells were seeded onto the scaffold and incubated for 1 h in culture media.
The scaffolds were then fixed with 4% paraformaldehyde, sectioned (10 m) and imaged
using confocal microscopy to determine the number of attached cells. Three sections
from each scaffold were assessed for cell numbers with the field of view being
approximately 1.16 mm2. The total surface area for the scaffold was estimated to be
approximately 23.76 mm2. Therefore, in order to determine the total numbers of cells,
the average cells per section was multiplied with the number of sections (in this case
equal to 100 since the thickness of the scaffold is 1 mm). A limitation of the technique is
that the polymer scaffolds are porous and have irregular pore size, which are factors that
we are unable to include in our total surface area or volume calculation.
The second experiment involved the use of mesenchymal stromal cells (MSC). Bone
marrow was isolated from male Sprague-Dawley rats (Charles River Laboratories
International, Wilmington, MA) aged 11-12 weeks (325-375 g) by flushing the tibia and
femur marrow canal with culture medium consisting of Iscove's Modified Dulbecco's
Medium (IMDM) supplemented with 10% fetal bovine serum (FBS), 1% penicillinstreptomycin and 1% L-glutamine (Life Technologies, Carlsbad, CA). The MSC were
cultured in culture medium in 75 mm2 (NUNC) flasks at 37°C in 5% CO2 for 3 days, and
then sub-cultured using 0.05% trypsin-EDTA solution. Cells at passage 2 were used for
subsequent studies.
Prior to cell seeding, the nHA/PU scaffolds were incubated for 24 h at 4 °C with either 25
l of saline solution or 25 µl of prBSP-saline solution (containing 20 g of prBSP). Rat
MSC were seeded onto the control and pretreated nHA/PU scaffolds at a density of 3.5 x
105 cells/scaffold and incubated in 24-well plates (NUNC). After 1 h incubation, the
MSC-seeded scaffolds were placed between a sandwich construct consisting of 2 Teflonrings in a clean 24-well plate in order to fully immerse the scaffolds in culture medium.
The MSC-seeded scaffolds were then cultured in differentiating medium consisting of
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culture medium supplemented with 50 µg/ml ascorbic acid and 2 mM glycerophosphate. The mineralizing media were changed every 2 days for the duration of
the culture.
After 4 weeks of culture, the scaffolds were washed with Hank's Balanced Salt Solution
(HBSS) three times, fixed with 4% paraformaldehyde for 20 min, and processed for
cryosectioning. In order to determine the relative level of matrix mineralization, the
cryosectioned samples were stained for calcium mineral deposition with Alizarin red
staining solution (1% w/v, Ricca Chemical company, Arlington, TX) for 20 min at room
temperature. To remove excess dye, the samples were washed with deionized water for
three times (5 min incubation time for each wash).
The third experiment used the same method as the second experiment; however, instead
of prBSP, bBSP was used.

5.2.5

Animals and surgery

Male Sprague-Dawley rats (Charles River Laboratories International, Wilmington, MA)
aged 11-12 weeks (325-375 g) were maintained on a standard rat diet (5P00-Prolab RMH
3000; LabDiet, St. Louis, MO, USA). Animal experiments were conducted in
accordance with guidelines of the Canadian Council on Animal Care (CCAC) and
Animal Care and Veterinary Services (ACVS), University of Western Ontario.
Animals were anaesthetized with isoflurane gas and the heads positioned in a stereotaxic
frame. The dorsal part of the cranium was shaved, aseptically prepared, and a midline
incision of approximately 20 mm created. The skin flaps were kept opened using a
retractor and the underlying periosteum was removed. A 5-mm stainless steel trephine
drill (Salvin Dental Specialties, Charlotte, NC) was used to create circular defects on
each of the parietal bones, thus creating 2 defects in each rat. Caution was exercised to
prevent damage to the dura membrane by adding a custom-made stainless steel sleeve
(1.5 mm depth shorter) around the trephine drill. In addition, in order to prevent heat
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damage of the host bone, irrigation with saline solution was done throughout the
procedure. The nHA/PU or bBSP treated nHA/PU (nHA/PU/bBSP) scaffolds without
cells were then implanted and secured in place by double crossing 4-0 Vicryl suture
attached to the temporalis muscles. In order to prevent any contamination, both defects
in each rat were implanted with scaffolds of the same treatment group. The skin was
closed using 4-0 Silk suture. Antibiotics and analgesic were administered to the animals
and they were allowed to recover for up to 12 weeks post surgery, after which they were
euthanized with CO2 gas inhalation according to CCAC and ACVS guidelines. At 0, 2, 6
and 12 weeks, in vivo microCT analysis was performed, as described below. In addition,
at 6 and 12 weeks, the rats were euthanized with CO2 and then the implants with
surrounding bone were collected, fixed with 10% buffered formalin overnight at 4°C, and
prepared for histology.

5.2.6

In vivo micro-computed tomography analysis

At intervals of 2 weeks, animals were anaesthetized with isoflurane gas and placed in a
microCT scanner (eXplore speCZT; GE Healthcare, London, ON). The scans were
performed using a standardized live-animal protocol (90 kVp, 40 µA, 900 views, 16 ms
per view). Images were reconstructed at a spatial resolution of 50 m and calibrated with
a cortical bone phantom (SB3; Gammex RMI, Middleton, WI) having a hydroxyapatite
equivalent of 1,100 mg/cc (White, 1978). Data were analyzed with MicroView ABA
version 2.2 (GE Healthcare).
In order to visually determine new bone formation, the 2D Maximum Intensity Projection
(MIP) and 3D isosurface images of the rat calvarial bones defect sites were constructed.
As for the quantification of the newly formed bone, a cylindrical region of interest (ROI,
5 mm x 1.5 mm) was positioned within the center of each defect site. The bone mineral
content (BMC) within the ROI was determined linearly by assigning a value threshold for
air (-1000 Hounsfield unit (HU)), water (0 HU), soft tissues (below 700 HU), trabecular
bone (above 700 HU), cortical bone (above 1700 HU) and SB3 phantom (2700 HU). The
total new bone volume (BV) formation was determined by adding all the voxels with HU
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value above 700 within the ROI. Bone-to-total tissue volume ratio (BV/TV) was
determined by calculating the ratio of total voxels with HU value above 700 over the total
voxels of the ROI. As for the cortical bone volume (CBV), only voxels with HU above
1700 were considered for calculation. Twenty calvarial defects were measured at 2 and 6
weeks and twelve calvarial defects were measured at 12 weeks for each group.

5.2.7

Histological Analysis

The parietal bones were fixed with 10% formalin for 24 h and then decalcified in 0.65 M
ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate, pH 7.4, at 37°C for 2
weeks. After dehydration, the samples were embedded in paraffin, and sectioned at 5 m
thickness. The sagittal sections were stained with hematoxylin and eosin (H&E). The
amount of bone formation was quantified at the center sections of the implants.

5.2.8

Statistical Analyses

Quantitative data were expressed as mean ± standard error. Statistical analyses among
groups were performed using two-way analysis of variance (ANOVA) and Bonferroni
post-tests with Prism 5 version 5.03 (GraphPad Software, La Jolla, CA). p<0.05 was
considered to be statistically significant.

5.3
5.3.1

RESULTS
bBSP expression and purification

The extracted protein solution from the bovine bone was first passed through Fast Q
column and eluted with a linear NaCl gradient in order to separate the proteins based on
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charge. At pH 7.0, bovine osteopontin (bOPN) and bBSP enriched fractions (proteins are
eluted in overlapping peaks) were collected (Figure 5.1). PhastGel electrophoresis was
performed to confirm the presence of bOPN and bBSP in the fractions (data not shown).
The collected fractions, with the highest concentration of bBSP, were pooled,
concentrated, and re-chromatographed on Fast Q Sepharose column to further purify the
protein (data not shown). The bBSP enriched fractions were pooled, concentrated, and
applied to a Superdex gel filtration column to separate proteins based on molecular size
(Figure 5.2). Based on the SDS-PAGE analysis, fractions (14-19) with the highest
concentration of bBSP were pooled, concentrated and re-chromatographed on the
Superdex 200 PG column to increase the purity of bBSP (Figure 5.3). Fractions 14-18
from the second Superdex run were combined, dialyzed and lyophilized. Aliquots were
analyzed by amino acid analysis to determine protein content, and relative purity.
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Figure 5.1. Separation of bone proteins by ion exchange chromatography.
Extracted solution containing various bone proteins were passed through Q Sepharose
Fast Flow column connected to the FPLC system. The proteins were eluted with a
linear gradient of NaCl (0-1.2M). Fractions containing bBSP and bOPN were collected,
pooled, and re-chromatographed on the Q-Sepharose column. The bBSP and bOPN
were eluted when the concentration of the NaCl at approximately 0.40-0.45M.
Absorbance at 230 and 280 nm were determined.
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Figure 5.2. Separation of bBSP using Superdex 200 PG gel filtration column.
The fractions from Q-Sepharose chromatography enriched in bBSP were pooled and run
on a Superdex gel filtration column. Fractions enriched in bBSP (Fractions 14-19;
~75KDa) were pooled, concentrated and rechromatographed on the gel filtration column
(Fig.2.3) Absorbances at 230 and 280 nm were measured.
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Figure 5.3. Re-purification of bBSP using Superdex 200 PG gel filtration column.
The pooled fractions, which contain mainly bBSP were re-chromatographed on Superdex
200 PG column, and samples analyzed by SDS-PAGE (inset). Fractions 14-18
representing the ‘cleanest’ fractions enriched in bBSP were pooled and used for future
study.
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5.3.2

Addition of nHA improved prBSP binding to the PU-based
scaffold

To be generally effective in tissue regeneration, scaffolds should demonstrate a
propensity to bind and slowly release the added factors. Our binding experiments
demonstrated that prBSP are able to bind well to PU-based scaffolds. The PU scaffolds
were incubated with prBSP, followed by elution with 0.5 M NaCl which was unable to
elute the bound prBSP (Figure 5.4). Based on the relative intensity for both 5 and 10 µg
prBSP loading onto scaffold, it was estimated that maximum binding to the PU scaffold
was approximately 2.5 g of prBSP (Table 5.1 and Figure 5.4). The addition of nHA to
the PU scaffold was able to increase the binding capacity. Approximately 7 g of bound
prBSP appears to be the limit for nHA/PU scaffolds since loading 10 or 20 g of prBSP
gave similar binding capacity (Table 5.1 and Figure 5.5).
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Figure 5.4. SDS-PAGE analysis of prBSP binding to PU scaffold.
The binding capacity of the prBSP on the PU scaffold was determined using a SDSPAGE based assay. During the assay, a series of washes as indicated was done on the
prBSP-treated PU scaffold to remove unbound or weakly bound prBSP. Two concentrations of prBSP - 5 g (Left image) and 10 g (Right image) were used. The amount
of bound prBSP was estimated by comparing the relative pixel to intensity ratio of the
SDS-eluted prBSP band with the total of unbound and from washes, and the intensity to
the control 0.5µg of prBSP.
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Figure 5.5. SDS-PAGE analysis of prBSP binding to nHA/PU scaffold.
The binding capacity of the prBSP on the nHA/PU scaffold was determined using a
SDS-PAGE-based assay. During the assay, a series of washes was done on the prBSP
treated nHA/PU scaffold to remove unbound or weakly bound prBSP. Two
concentrations of prBSP - 5 g (Left image) and 10 g (Right image) were used. The
amount of bound prBSP was estimated by comparing the relative pixel to intensity ratio
of the SDS-eluted prBSP band with the total of unbound and washes and the intensity to
the control 0.167µg of prBSP.
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Table 5.1. Estimation of bound prBSP for each treatment group.
The amount of bound prBSP was estimated by comparing the relative pixel to intensity
ratio of the SDS eluted prBSP band with the total of unbound, washed, and the control
prBSP sample. The assumption was that the total amount of prBSP loaded equaled the
combined pixels to intensity ratio of unbound, washed, and eluted prBSP.

Number of pixels

Sample

PU + 5 µg
prBSP
PU + 10 µg
prBSP
nHA/PU +
5 µg prBSP

Intensity (Mean)

Pixels to intensity
ratio

Unbound Washed Eluted Unbound Washed Eluted Unbound Washed Eluted
prBSP

prBSP prBSP

prBSP

prBSP prBSP

prBSP

prBSP prBSP

Bound
prBSP
(µg)

4245

1731

4156

30.22

134.05

29.14

140.47

12.91

142.62

2.41

5911

1451

3889

15.28

24.58

25.38

386.85

59.03

187.84

2.56

1535

-

5341

66.48

-

45.56

23.09

-

117.23

4.18

4914

-

8075

79.86

-

48.4

61.53

-

166.84

7.31

9775

4670

8389

105.54

154.28

117.95

92.62

30.27

71.12

7.33

nHA/PU +
10 µg
prBSP
nHA/PU +
20 µg
prBSP
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5.3.3

The addition of BSP improved cell attachment and appeared to
have increased mineral formation

The C3H10T11/2 mouse cell line was used to study cell attachment and mineral
formation in the HA/PU scaffolds. After only 1 h of incubation, the presence of prBSP
increased the number of cells attached to the scaffold by a factor of 5 (Figure 5.6, Table
5.2). Other in vitro studies have shown that the addition of recombinant human BSP
(rhBSP) to MSC, in the presence of osteogenic media, drive osteogenic differentiation
into osteoblasts (Xia et al., 2011). Our experiments with MSC culture demonstrated that
the presence of prBSP or bBSP on nHA/PU scaffold appeared to have enhanced mineral
formation compared to their respective control groups (Figure 5.7 and 5.8). In addition,
these result also indicate that due to the highly conserved nature of BSP, its functional
properties are similar regardless of the species source.
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Figure 5.6. The effect of prBSP treated nHA/PU scaffold cultured with C3H10T1/2
cells.
nHA/PU scaffolds were either untreated or treated with 150 μl of prBSP-PBS solution
(containing 20 µg of prBSP). Approximately, 1.2 x 106 C3H10T1/2 cells were seeded
onto the scaffold and then incubated for 1 hr and fixed with 4% PFA. Confocal image
of the sectioned scaffold suggests that prBSP treated nHA/PU scaffolds had higher cell
attachment compared to control group. Blue is DAPI staining of cell nuclei.
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Table 5.2. The effect of BSP on cell attachment to the nHA/PU scaffold.
The presence of BSP increased the number of attached cell to the nHA/PU scaffold.

Treatment group

Total number of cell in
the polymer (105)

Percentage of cell
attached (%)

nHA/PU

0.70

5.80

nHA/PU/prBSP

3.42

28.50
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Figure 5.7. Effect of prBSP on nHA/PU cultured with MSC for 4 weeks.
After 4 weeks, the scaffolds were fixed, cryosectioned, and stained with alizarin red.
Compared to the control group, the nHA/PU/prBSP group appeared to demonstrate more
alizarin red staining, which suggest an increased in mineral formation. Note: The three
images in each group are from different scaffolds.
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Figure 5.8. Effect of bBSP on nHA/PU cultured with MSC for 4 weeks.
The images in panel A1-2 and B1-2 represent transverse and cross-sectional sections,
respectively, of control and bBSP treated nHA/PU scaffolds stained with alizarin red.
After 4 weeks, the scaffolds were fixed, cryosectioned, and stained with alizarin red.
Compared to the control group, the nHA/PU/bBSP cryosections qualitatively appeared
to have more alizarin red staining, which may be due to an increase in osteogenic
mineralization.
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5.3.4

bBSP treated nHA/PU scaffolds are not effective in promoting
bone repair

An established calvarial defect model was used to determine the effectiveness of the
bBSP treated nHA/PU scaffolds in promoting in vivo bone repair. At 2, 6, and 12 weeks
after implantation, the nHA/PU/bBSP group showed similar bone mineral content
(BMC), new total bone volume (BV), percentage of bone-to-tissue volume (BV/TV), and
percentage of cortical bone volume compared to the control group (Figure 5.9). In both
groups, minimal bone in-growth into the defects from host bone and some island-like
bone spicules were observed (Figure 5.10). Occasionally, higher bone formation was
observed in nHA/PU/bBSP group; however, this was also observed in the control group
(Figure 5.11). In agreement with the microCT data, the histological analysis of
nHA/PU/bBSP groups also indicated a similar observation compared to control group
(Figure 5.12). In contrast, the rhBMP-2 treated nHA/PU group, which is the positive
control group was able to promote bone repair as indicated in Chapter 4.
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Figure 5.9. Quantitative microCT analysis of bone repair.
The microCT analysis of (A) bone mineral content (BMC); (B) new bone volume; (C)
percentage of bone-to-tissue volume and (D) percentage of cortical bone volume were
similar for both nHA/PU/bBSP group and nHA/PU group at 2, 6, and 12 weeks. The data
suggest that bBSP are not effective in promoting bone repair. Data represents mean ±
standard error (n=20 for 2 and 6 weeks, n=12 for 12 weeks)
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Figure 5.10. MicroCT images of bone repair in rat calvarial defects from 0 to 12
weeks post-op.
Maximum intensity projection (MIP) images of both nHA/PU and nHA/PU/bBSP
demonstrated a similar healing pattern. Both groups often demonstrated variable results
as presented in the two representative images for each group. The white arrowheads
referred to the island-like bone formation seen in the defect.
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Figure 5.11. MicroCT images of bone repair in rat calvarial defects after 12 weeks
post-op.
Maximum intensity projection images of both nHA/PU and nHA/PU/bBSP demonstrated
a similar healing pattern. These are additional images from 2 different pair of rats. Both
groups demonstrated variable results in bone formation.
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Figure 5.12. Histological analysis of rat calvaria at 12 weeks.
H&E stained sectioned of nHA/PU/bBSP and nHA/PU groups demonstrated similar
bone repair response even after 12 weeks post-op. Minimal island-like new bone
formation are observed in the defect site as marked by black arrows. No apparent major
inflammation can be seen in any of the groups. These results suggest that BSP is not a
potent promoter of bone repair.
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5.4

DISCUSSION

In tissue engineering, prevalent strategies to enhance bone repair utilize osteoconductive
biomaterials in combination with osteoinductive growth factors or bioactive proteins.
This study was designed to evaluate the effectiveness of BSP-treated nHA/PU scaffolds
for guided bone regeneration using a rat calvarial defect model. BSP is an extracellular
matrix protein present in mineralized tissue such as bone and dentition. The expression
of BSP in mineralized tissues is upregulated at the onset of mineralization. Previous
studies have shown that the presence of BSP enhances osteoblast differentiation and HA
nucleation in vitro (Cooper et al., 1998; Zhou et al., 1995). In addition, other studies
have also provided evidence for the role of BSP in bone formation, in which the authors
demonstrate that the presence of BSP enhanced bone repair in vivo (Wang et al., 2006;
Xu et al., 2007).
The presence of BSP in the PU based scaffold is able to promote cell attachment and
differentiation, which in turn led to the improved overall osteogenic mineralization in
vitro. The addition of nHA was able to significantly improve the PU-based scaffold
capability to bind BSP. These results confirmed the effectiveness of nHA/PU scaffold as
a carrier for bioactive proteins. Unfortunately, in spite of the promising in vitro results,
our data indicated that, in our model, the presence of BSP was not effective in promoting
bone regeneration in vivo; suggesting that BSP is not a potent promoter of bone repair.

5.4.1

The presence of BSP enhanced mineral formation in vitro;
however, BSP is not effective for bone repair in our in vivo
model.

In the literature, there are few studies on the potential role of BSP as a therapeutic reagent
to promote bone repair. However, over the years, various in vitro studies have postulated
for an important role of BSP in biomineralization and bone development. Previous
studies including from our group were able to identify the three functional regions of BSP
[collagen binding, HA nucleation, and integrin recognition (RGD)] that play important
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roles in biomineralization as described in (Goldberg and Hunter, 2012). In addition,
various in vitro studies were able to demonstrate that BSP promotes cell proliferation and
differentiation to osteoblasts, which led to increase osteogenic mineralization in culture
(Cooper et al., 1998; Gordon et al., 2007; Xia et al., 2011; Zhou et al., 1995). In vivo
studies demonstrated that Bsp-/- mice have a bone phenotype, which include lower bone
density, shorter long bone length, thinner femoral cortical bone (Malaval et al., 2008),
and slower bone repair process (Malaval et al., 2009; Monfoulet et al., 2010).
Furthermore, the use of BSP bound to native but not denatured collagen in an in vivo
bone repair model was effective in promoting bone repair (Wang et al., 2006; Xu et al.,
2007). These latter authors indicated that bovine BSP-treated collagen scaffold in rat
calvarial defects was able to promote early mineral deposition within the first 4 days,
followed by new bone formation over time. These findings led us to believe that BSP
can be a good therapeutic reagent for bone repair since it plays an important role in
mineralization and maintains homeostasis during bone remodeling (Ganss et al., 1999;
Goldberg and Hunter, 2012).
In our study, we investigated the potential use of BSP-treated nHA/PU scaffolds in bone
repair. Previous studies indicated that long term delivery of growth factors such as bone
morphogenetic-2 (BMP-2) has resulted in greater amount of bone formation compared to
a shorter term delivery (La et al., 2010). The authors showed the importance of
continuous presence of the BMP-2 in the system during bone repair. For this study, we
believed that the presence of BSP throughout the bone repair was also crucial; therefore
increasing the BSP binding capability of the PU scaffold was determined to be a
necessity. Previous studies had shown that the addition of nHA improved the adsorption
of bovine serum albumin, fibrinogen, and other proteins derived from fetal calf serum to
the scaffold (Laschke et al., 2010b). Our results confirmed that the addition of nHA
particles also increased the level of BSP bound to the nHA/PU scaffold. Furthermore,
our binding studies demonstrated that the elution step with high salt was unable to
remove the additional BSP from the nHA modified PU scaffolds, suggesting that the BSP
was tightly bound to the exposed hydroxyapatite. Of relevance, hydroxyapatite is a wellestablished material used in chromatographical purification since it has significant protein
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binding properties (Matsumoto et al., 2004; Shen et al., 2008; Xie et al., 2010). The data
from the binding studies suggest that nHA/PU scaffold is an effective carrier for BSP.
The addition of either prBSP or bBSP to the scaffolds was able to enhance cell
attachment and mineral formation in our in vitro cultures compared to the control group.
The integrin recognition region (RGD sequence) near the C-terminus of BSP likely
contributed to the recruitment and attachment of cells onto the scaffold. RGD motifs are
known to mediate cell attachment and signaling for differentiation and migration since it
interacts with the αvβ3 integrin, a cell-surface receptor present in both osteoblasts
(Oldberg et al., 1988) and osteoclasts (Helfrich et al., 1992). Furthermore, other in vitro
studies also indicated that the addition of BSP was found to improve the overall
osteoconductivity of implants made from various materials such as titanium, ceramic, and
synthetic polymer and enhanced cell attachment (Graf et al., 2008; O'Toole et al., 2004).
These in vitro results were promising and together with previous demonstration of BSP
promoting in vivo bone repair (Wang et al., 2006), led us to perform in vivo experiments
using rat calvarial defect model to monitor the effect of BSP in bone repair.
Analysis of the implanted BSP-treated nHA/PU scaffolds in rat calvarial defects resulted
in no significant differences in new bone formation compared to the control group. The
results of both prBSP and bBSP-treated scaffold were variable, in which moderate
amount of island-like bone formation were observed on occasion in the defect site;
however, most of the time only minimal bone formation were observed. These surprising
results prompted us to look at the use of collagen scaffold instead of nHA/PU scaffold to
re-confirm the positive result from previous published studies (Wang et al., 2006; Xu et
al., 2007). However, similar to BSP-treated nHA/PU scaffold, BSP-treated collagen
scaffold did not enhance bone formation compared to the respective control group (data
not shown, n=4). Of relevance, other in vivo studies also indicate that the presence of
BSP did not significantly enhanced the efficiency of bone formation (Schaeren et al.,
2010) or improved the strength of implant-bone integration (O'Toole et al., 2004).
Similar to our study, the authors demonstrated that in the in vitro setting the presence of
BSP induced cell differentiation and osteogenic mineralization. However, in their in vivo
system, BSP was not effective in enhancing bone repair.
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In order to understand how the Glimcher group (Wang et al., 2006; Xu et al., 2007) was
able to show that BSP promoted bone repair in vivo, we contacted the authors responsible
for the study (Glimcher is deceased). In contrast to what was indicated in their
manuscripts (Wang et al., 2006; Xu et al., 2007), succinimide was added to the BSPcollagen incubation solution, which immobilized the BSP through covalent linkage to the
collagen (E. Salih, personal communication). The use of succinimide, which is a potent
cross-linking agent was not indicated in the relevant manuscripts. Confirmation of this
knowledge, as well as additional information regarding the relatively poor potency of
BSP and collagen mixtures to promote bone repair in vivo was also obtained (J. Wang,
personal communication). It has been documented that immobilization of anionic
peptides or proteins to a surface promotes nucleation since the overall negative charges of
the protein will attract and bind calcium, which will initiate mineral formation by itself.
For example, phosphorylated acidic peptides have been demonstrated to act as nucleators
of HA when immobilized on a surface (Saito et al., 1997). It is well known that the
implantation of mineral in bone defects, either hydroxyapatite or calcium carbonate, is
relatively effective in initiating bone repair (Fu et al., 2013; Parizi et al., 2013). Thus the
initiation of mineral deposition in the calvarial defects that was evident in the Wang et al.
study, may have been the required prerequisite to initiate the remodeling sequence that
would ultimately drive the bone repair that was observed in their study. While BSP binds
tightly to collagen, it is quite possible that the HA nucleating regions in BSP are less
susceptible to blood derived enzymatic activity if crosslinked to collagen. Enzymatic
activity would normally be elevated during the initial stages of repair.
Our recent studies have shown that some of the Bsp-/- mice bone defects reported by the
Malaval group are related to malnourishment (Soenjaya et al., 2015). The absence of
BSP resulted in defective acellular cementum formation (Foster et al., 2013b), which in
turn destabilized the periodontium, causing periodontal breakdown and tooth
malocclusion. As a result the Bsp-/- mice were not able to feed properly. When given a
soft food diet, many of the bone phenotypes were reversible. These results suggested that
Bsp-/- mice do not have a major bone phenotype as described in the previous studies done
by the Malaval's group. In spite of the ineffectiveness of BSP in enhancing bone repair in
our study, BSP has still been shown to be relevant for bone development since delayed
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mineralization were observed in fetal or young long bones (Holm et al., 2015) and
craniofacial bones (Foster et al., 2015) of Bsp-/- mice. In addition, absence of BSP was
also shown to negatively affect the rate of bone repair and cause reduced osteoclast
activity (Malaval et al., 2008; Monfoulet et al., 2010). Therefore, there is a possibility
that BSP may be more relevant in promoting osteoclast formation and maintaining
osteoclast activity. If this process is delayed, then bone turnover will also be delayed.
In summary, this study showed that BSP can bind effectively onto the nHA/PU scaffold
and the presence of BSP resulted in improved cell attachment and osteogenic
mineralization in vitro. These results confirmed that nHA/PU scaffold is an effective
carrier for bioactive proteins. However, in spite of the encouraging observation in the in
vitro experiments, our in vivo studies using the calvarial defect model indicate that BSP
by itself is not an effective therapeutic reagent for enhancing bone repair.
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6.1

DISCUSSION

Development and repair of skeletal tissue and its subsequent mineralization involve
complex processes and cell-cell interaction. During the onset of mineralization, the
expression of bone sialoprotein (BSP) is up-regulated in mineralized tissues such as the
bones and teeth (Fisher and Fedarko, 2003; Ganss et al., 1999). Our previous studies
have been focused on determining the functional roles of BSP in biomineralization.
These include the demonstration that BSP has three highly conserved functional regions:
1) collagen-binding region, 2) two HA-nucleation regions, and 3) an integrin recognition
region (Goldberg and Hunter, 2012). However, we still have yet to determine which one
or combination of the three functional regions is the most critical for biomineralization
and bone formation. The nucleating regions of BSP were found to not only contribute as
HA nucleation sites (Hunter and Goldberg, 1993) but also allow for binding to HA
(Goldberg et al., 2001; Stubbs et al., 1997). The phosphorylation of BSP was verified to
be a very important modification of BSP since this regulated the HA nucleation potency,
especially at the Serine-136 position (Baht et al., 2010). Additional studies demonstrated
that the HA nucleation potency of BSP is further enhanced when it is bound to collagen
(Baht et al., 2008). This suggests that the combination of collagen binding and HA
nucleation regions might potentially be important for bone formation. The integrin
binding region (RGD motif) of BSP has been previously shown to mediate cell
attachment to the matrix and cell signaling as well as contributing to differentiation of
osteoprogenitor cells to osteoblasts and their migration (Gordon et al., 2007). The RGD
motif is recognized by cell-surface receptors, in particular the αvβ3 integrin, which are
present in both osteoblasts (Oldberg et al., 1988) and osteoclasts (Helfrich et al., 1992).
In recent years, the physiological relevance of BSP in skeletal development has also been
investigated by other research groups using the Bsp-/- mouse model. In various in vivo
studies, Bsp-/- mice were found to have impaired bone growth and mineralization. The
observed bone phenotype includes: shortened long bone, delayed mineral formation,
reduced bone mineral density, and thinner cortical bone thickness compared to WT mice
(Malaval et al., 2008). The absence of BSP was also found to negatively affect osteoclast
formation and activities (Boudiffa et al., 2010; Malaval et al., 2008), which in turn
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reduced bone turnover. As a result, Bsp-/- mice also displayed delayed bone repair
compared to WT mice (Malaval et al., 2009; Monfoulet et al., 2010). Furthermore,
previous studies had indicated that BSP is a promising therapeutic reagent for bone
repair. Using a rat calvarial model, the authors were able to induce osteoprogenitor cell
recruitment and early mineralization at the defect site when it was implanted with BSPtreated collagen scaffold (Wang et al., 2006; Xu et al., 2007). All of these studies
provided strong evidence for BSP playing an important role in bone development and
mineralization.
Bone is not the only mineralized tissue that expresses BSP. Studies have shown that BSP
is also present in both acellular and cellular cementum (Macneil et al., 1994; McKee et
al., 1996), however the role of BSP in cementum development is undefined. The
acellular cementum is a thin layer of mineralized tissue that covers the cervical portion of
the tooth root. This tissue layer has been shown to be important in maintaining the
attachment of the periodontal ligament (PDL) to the tooth root surface (Bosshardt, 2005;
Foster et al., 2007). In contrast, the cellular cementum is a bone-like tissue covering the
apical portions of the tooth root. During normal root formation, cementoblasts express
and secrete BSP which led us to postulate that it likely contributes to cementum
formation and mineralization (Macneil et al., 1995; Somerman et al., 1990).
The purpose of this thesis project was to further understand the role of BSP in the
periodontal development and its potential as a therapeutic reagent for bone repair. The
information gained from these studies will allow us to potentially design a new novel
therapeutic peptide, based on BSP functional regions, for use in enhancing periodontal
and bone repair.

Role of BSP in mineralized tissue development
In the absence of BSP, we demonstrated that acellular cementum formation is severely
affected (chapters 2 and 3). Bsp-/- mice have severe periodontal tissue breakdown,
marked by defective acellular cementum on both of the molar and incisor roots. The
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acellular cementum appeared hypomineralized and detachment was observed at the
acellular cementum-PDL interface (Foster et al., 2013b). The PDL detachment from the
cementum likely contributed to the observed disorganization of PDL Sharpey's fibers,
increased epithelial down-growth into the detached space, and tooth malocclusion. The
destabilization of the periodontium eventually resulted in extensive root and alveolar
bone resorption (Foster et al., 2013b). In comparison, under normal conditions, PDL
fibers inserted into the cementum, anchor and stabilize the tooth. Previously, our group
demonstrated that BSP has a high binding affinity site to collagen (Tye et al., 2005), and
its HA nucleation potency is significantly increased (10-fold) when bound to collagen
(Baht et al., 2010). Thus, BSP may function as a glue at the cementum-PDL interface
while promoting proper mineralization of the tissue, which in turn, provides stabilization
of the tissue. Histological analyses indicated that the structural defect only occurs at the
acellular cementum-PDL interface. The alveolar bone-PDL interface appears to be
unaffected by the absence of BSP (Foster et al., 2015); which may be due to the cellular
nature of bone and presence of possible compensatory mechanisms in bone but not in
acellular cementum. Of relevance, the phenotype of the Alpl-/- mouse was also that of
deficient acellular cementum formation due to the loss of TNAP function that led to
increased levels of pyrophosphate, which is a potent inhibitor of mineralization (Beertsen
et al., 1999; Foster et al., 2013a; McKee et al., 2011b). In addition, other studies have
demonstrated that the reduction in the level of pyrophosphate promotes acellular
formation (Foster et al., 2011; Foster et al., 2013a). Similar to that in bone matrix, the
presence of various growth factors such as transforming growth factor-β, bone
morphogenetic proteins (BMPs), and fibroblast growth factor were also observed in the
cementum matrix. However, the acellular cementum, which lacks cementocytes, does
not have a similar distribution of these growth factors compared to cellular cementum
and bone (Bosshardt, 2005). These findings suggest that the acellular cementum is
strongly regulated by the physicochemical level of mineralization. Thus, the absence of
BSP, which binds well with collagen and is involved in hydroxyapatite nucleation and
growth, likely has directly weakened the acellular cementum that led to PDL detachment
observed in Bsp-/- mice.
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Periodontal tissue breakdown is usually associated with periodontal disease due to
infection. However, in the Bsp-/- mice no apparent inflammatory response was observed
in the periodontal ligament or adjacent tissues, suggesting that the defect was likely due
to failure in the function of the periodontium. These findings prompted us to investigate
whether occlusal stress contributes to the periodontal breakdown and tooth malocclusion
observed in Bsp-/- mice.
All of the mice in this study were fed either the standard hard diet (HD) or powdered soft
diet (SD), which should reduce the stress applied to the periodontium during mastication.
As expected, similar to previous study (chapter 2), Bsp-/- mice fed with HD were found to
have higher incident of tooth malocclusion, were smaller in size [long bone length and
body weight], and had elevated serum alkaline phosphatase (ALP) activity compared to
WT mice. The substitution of SD was able to reduce the severe incisor malocclusion rate
by a factor of 10-fold, suggesting that excessive occlusal loading contributed to the
malocclusion phenotype of Bsp-/- mice. In addition, the Bsp-/- mice fed with SD appeared
to have normal body weight, long bone length, and serum ALP activity compared to WT
mice. These results indicated that Bsp-/- mice do not have a major bone phenotype as
previously described by Malaval's group. These bone phenotypes are likely related to
malnourishment due to difficulty of the mice to consume standard HD (Soenjaya et al.,
2015). Another factor to consider is that litter mate controls were used in all of our
studies; in contrast, Malaval's group did not, as indicated by different color mice
(between groups) used in their recent study (Bouleftour et al., 2014), but also evident in
their other publications. Other studies have demonstrated that undernutrition negatively
influences immune function (Chan et al., 1996), growth (Lifshitz, 2009) and offspring
neurodevelopment (Akitake et al., 2015), behavior and fertility (Rios et al., 2005), and
intuitively breeding and nursing capabilities. We did not observe any significant issues
with these characteristics in our Bsp-/- mouse colony. However, in contrast, Malaval's
group have reported uncharacteristic nesting behavior of their Bsp-/- mice colony
compared to WT mice (Bouleftour et al., 2014), presumably due to malnutrition.
Changing the diet was not able to prevent PDL detachment, tooth malocclusion, and
periodontal breakdown in Bsp-/- mice. Furthermore, regardless of diet group, Bsp-/- mice
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have lower rates of incisor eruption compared to WT mice, which is likely due to lack of
acellular cementum formation and the associated periodontal detachment. In addition, a
small preliminary study on older Bsp-/- mice (above 1 yr old), indicate that odontoma-like
nodules are present at the apical end of the incisors (data not shown). These unusual
features are not yet fully understood, however, we postulate that it is caused by the
inability of the mouse incisor to properly erupt due to the defects at the PDL-acellular
cementum interface. Over time, the cumulative occlusal stress from mastication possibly
has caused the cementum-PDL interface to become progressively weaker, and thus less
resistant to the forces. This might have pushed the continually developing incisor inward
or into the socket, which resulted in the continuously forming dentin and enamel to be
deposited around the apical end of the incisor. These results demonstrate the importance
of BSP in maintaining proper periodontal structure and function and alveolar bone
remodeling, and point to dental dysfunction as causative factor of skeletal defects
observed in Bsp-/- mice.

Potential use of nHA/PU scaffold and BSP for bone regeneration therapy
The second half of the thesis [Chapter 4 and 5] focused on the role of BSP as a
therapeutic reagent to enhance bone repair. As mentioned before, previous studies done
by the Glimcher's group indicated that the addition of BSP in a collagen scaffold was able
to promote early mineralization in rat calvarial defect model and promoted bone repair
that was evident after a month (Wang et al., 2006; Xu et al., 2007). For our study, a
similar rat calvarial defect model was used. However, novel PU and nHA/PU scaffolds
developed by our collaborators, David Eglin and Mauro Alini (AO Foundation) were
used instead of collagen scaffolds. The first step of the study was to determine whether
the scaffolds could be effective carriers for growth factor and bioactive proteins. Both
the PU and the nHA/PU scaffolds have previously been demonstrated to be
biocompatible and effective for tissue regeneration (Hofmann et al., 2008; Laschke et al.,
2009; Laschke et al., 2010b). The PU-based scaffold has been shown to be
osteoconductive and also able to bind bioactive proteins. The addition of nHA particles
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was found to be have additional capacity to bind serum proteins (Boissard et al., 2009).
Our in vitro experiments verified that nHA/PU scaffolds had a threefold higher binding
capacity for BSP than PU scaffolds alone. Of relevance, other studies have shown that
during bone repair, long term delivery of growth factor resulted in a greater amount of
bone formation than a scaffold that would release the factor over a shorter time period
(La et al., 2010). Thus, the use of a scaffold with higher binding capacity, and potentially
with increased affinity, was relevant in our bone repair model. Furthermore, previous
studies have also demonstrated that the PU scaffolds were able to promote angiogenesis
in vivo (Hofmann et al., 2008; Laschke et al., 2010b), which is critical in the normal bone
remodeling sequence that occurs in bone repair.
In this study, recombinant human morphogenetic protein-2 (rhBMP-2) was used as a
positive control group. rhBMP-2 is the most common growth factor used in the clinical
setting due to its high potency to drive osteoprogenitor cell differentiation to osteoblasts
which subsequently leads to increased new bone formation. However, a main concern is
that clinically high doses of rhBMP-2 are usually required to ensure successful bone
repair. Various studies have demonstrated that there are potential side effects when high
levels of BMPs are used, including excessive bone formation, adverse immune responses,
and increased risk in developing cancer (Carragee et al., 2011; Epstein, 2013). Therefore,
to avoid these complications, we decided to use a low-dose rhBMP-2 to determine
whether this would achieve a similar positive outcome in regards to new bone formation.
Our in vitro study showed that nHA/PU scaffold was able to bind well with both rhBMP2 and BSP. Both rhBMP-2 and BSP treated nHA/PU scaffold in cell culture appeared to
have elevated amount of mineral formation. In our calvarial in vivo system, the presence
of low dose rhBMP-2 was able to significantly enhance bone repair compared to the
scaffold-only control group. MicroCT analyses suggested that approximately 70% of the
defects were filled with bone by 6 weeks. This result was very promising since other
studies that utilized larger dose of rhBMP-2 were shown to achieve either a lower or
similar amount of new bone formation by 6-8 weeks post-op (Luvizuto et al., 2011;
Sawyer et al., 2009; Schwarz et al., 2009). Unfortunately, BSP-treated nHA/PU scaffold
group was not able to significantly enhance in vivo bone repair even after 12 weeks. In
the BSP-treated group, moderate island-like bone formation were found in the defect sites
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on occasion; however, most of the time only minimal bone formation was observed in the
defect sites. Similar observations were also found in the scaffold-only control group.
In summary, this study showed that nHA/PU scaffold is able to bind both rhBMP-2 and
BSP. Even though on its own, BSP is not effective as a promoter of bone repair in our
model, various mineralized tissue phenotypes observed in the Bsp-/- mice provide strong
support that BSP is still important for mineralized tissue development.

6.2

FUTURE DIRECTION

Role of BSP in mineralized tissue development
To further understand which part of the functional regions of BSP is important for
cementum development, a preliminary study was done by injecting BSP into Bsp-/- mice
in order to determine whether the acellular cementum phenotype could be rescued.
Subcutaneous injections (daily for the first 3 time points, every 2 days for the next 4 time
points, and every three days for the last 3 time points) of native and recombinant rat BSP
were done beginning with 5 day old Bsp-/- mice. At 6 weeks, microCT images revealed a
slight delay in periodontal breakdown (data not shown). However, no significant
conclusions could be derived using this method possibly due to the limited amounts of
BSP that could be injected (10 µl or less; using a 1mg/ml BSP-PBS solution) into the
young pups. In addition, it is likely that only a small percentage of the injected BSP
would be carried by the circulatory system to the periodontium. Future studies should
utilize an adeno-associated virus (AAV) linked to the Bsp gene (wild type full length, or
full length with altered functional domains) to rescue the acellular cementum deficiency
in the Bsp-/- mice. This method should be a more effective way to determine the potential
use of BSP to repair or rescue the structural defects seen in cementum-PDL interface of
Bsp-/- mice. In addition, the use of functional mutants may provide critical new
information on the roles of these domains in vivo, and insight into the mechanism of BSP
action. Of relevance, other studies have also used AAV-mediated systemic gene therapy
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method in order to effectively treat a transgenic mouse model. The authors demonstrated
that AAV-mediated gene therapy was able to successfully rescue the severe bone
phenotype seen in hypophosphatasia mice (Matsumoto et al., 2011).
As part of the Goldberg's group objective, as a side project, we also investigated the
potential role of BSP in other mineralized tissue development. Other than bone and
dentition, mineralized tissues are also found within the enthesis, which is composed of
four transitional zones, including tendon connective tissue, un-calcified fibrocartilage,
calcified fibrocartilage (CF), and bone, that connects tendon to bone. Using an anti-BSP
antibody, our preliminary study demonstrated for the first time that BSP is present in the
CF zone of the enthesis, which is found adjacent to the bone. Therefore, it is postulated
that BSP also plays an important role in the enthesis development and fibrocartilage
mineralization. All of the mice used for this study were fed with SD to reduce
malocclusion and prevent malnourishment. Initial mechanical tensile tests indicated that
the Bsp-/- mouse patellar tendon appeared to fail at a lower mechanical load compared to
that of WT mice. Based on these results, a more complete analysis of the quadriceps
tendon (QCT) and supraspinatus tendon (SST) entheses of 15-week old Bsp-/- mice were
performed (Marinovich, Soenjaya et al., 2016). In the QCT enthesis, the CF zone of the
Bsp-/- mice was 28% greater in length compared to WT mice. This lengthening of the CF
appeared to increase as the Bsp-/- mice aged. By 14 months of age, the length of the CF
zone was determined to be 41% greater than that of WT mice. However, no apparent
difference in the lengths of CF zone were observed in the SST enthesis of Bsp-/- and WT
mice. Other studies have indicated that the CF zone helps to anchor the tendons or
ligaments to the bone and withstand tensile and shear loads under minimal movement
(Benjamin and McGonagle, 2001). The enthesis fibrocartilage is a dynamic tissue that
responds to mechanical load. Thus, the observed increased length of the CF zone is
likely a compensation to strengthen the CF-bone interface and also restrict movement of
the enthesis to prevent injury. Further analysis revealed that the cross sectional area of
Bsp-/- patellar tendon is 7.5% larger compared to WT mice. Both Bsp-/- and WT patellar
tendon failed at a similar load, which suggests that the increased cross sectional area of
the Bsp-/- patellar tendon likely act as a compensatory mechanism to allow for greater
dissipation of stress along the enthesis to prevent failure. In addition, the study also
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indicated that no significant difference in mineral distribution and collagen organization
were observed between Bsp-/- and WT mice (Marinovich, Soenjaya et al., 2016). As
previously mentioned, Bsp-/- mice fed with soft diet have normal bone phenotypes such as
bone length and bone mineral density. Other studies from our groups have also indicated
that all of the bone phenotype occurred at the early stage of development. For example,
recent studies have indicate that the absence of BSP delayed the mineralization of the
fetal long-bones (Holm et al., 2015) and craniofacial bones (Foster et al., 2015).
However, these bone phenotypes become less apparent as the Bsp-/- mice aged, which
suggest that the role of BSP is likely being compensated by other related mechanisms.
Thus, future studies should focus on the role of BSP in early enthesis development and
mineralization.

Potential use of BSP for bone regeneration therapy
In terms for future studies, one potential suggestion is that BSP may be more effective if
used in combination with a growth factor such as rhBMP-2. In order to confirm this
hypothesis, we performed a preliminary study (n=2) that used nHA/PU scaffold treated
with a combination of 0.25 µg of rhBMP-2 and 20 µg of BSP in a rat calvaria defect
model. The initial results showed that the BSP-rhBMP-2 treated group appeared to have
increased bone formation compared to 0.25µg rhBMP2 treated group. Furthermore, the
amount of bone formation in BSP-rhBMP-2 treated group appeared to be approaching of
that observed in nHA/PU scaffold group treated with 1 µg of rhBMP-2 (data not shown).
However, for the pilot study the animal sample size were too small for proper statistical
analyses. Therefore, a more complete study should be done to determine the best BSPrhBMP-2 cocktail concentration that will gives the optimal bone repair.
Another potential study is the concept of permanently immobilizing BSP to the nHA/PU
scaffold, which was a technique used by the Glimcher’s group to crosslink BSP to
collagen scaffold. It will be interesting to verify whether covalently cross-linked BSP to
nHA/PU scaffold can promote bone repair.
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As for in vitro studies, future directions, experiments with rhBMP-2 and BSP should be
done to confirm any up-regulation of osteoblastic differentiation markers such as alkaline
phosphatase, collagen I, osterix and osteocalcin. The results will confirm whether the
presence of rhBMP-2 or BSP in the nHA/PU scaffolds can promote osteogenic
differentiation. Another suggestion is to look at other markers related to bone repair such
as angiogenesis. It will also be interesting to verify whether the presence of BSP
(covalently cross-linked) or rhBMP-2 treated nHA/PU scaffold can enhanced
angiogenesis in our calvarial defect model.
PicoGreen DNA quantification assay has been demonstrated to be a useful technique to
determine total DNA from scaffolds cultured with cells (Ng et al., 2005). This assay can
potentially be used in our in vitro culture system to quantify the approximate amount of
cells in the nHA/PU scaffold in the presence of BSP or rhBMP-2. Previous studies have
shown that DNA binds tightly to HA; the bound DNA are found to be more resistant to
degradation compared to unbound DNA (Brundin et al., 2013). Thus, after the cell lysis,
an additional step would need to be considered for extraction of DNA from mineralized
tissue using decalcification step with EDTA as previously described in previous studies
(Malaver and Yunis, 2003).
In conclusion, these future studies will further demonstrate the importance of BSP in
mineralized tissue development and also verify BSP potential role in enhancing bone
repair.
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All animal experimentation was conducted in compliance with the animal use protocol
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Appendix B: Appendix B: Statement of permission to re-use Figure 1.2 from
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